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 EXPLORING EFFICACY OF AN ANTI-MALARIAL NANOMEDICINE IN 
NON-SMALL CELL LUNG CANCER TREATMENT 
Vineela Parvathaneni 
 
New drug and dosage form development faces significant challenges, especially in 
oncology, due to longer development cycle and associated scale-up complexities. 
Repurposing of existing drugs with potential anti-cancer activity into new therapeutic 
regimens provides a feasible alternative. In this project, amodiaquine (AQ), an anti-
malarial drug, has been explored for its anti-cancer efficacy through formulating inhalable 
nanoparticulate systems using high-pressure homogenization (HPH) with scale-up 
feasibility and high reproducibility. A 32 multifactorial design was employed to better 
understand critical processes and formulation parameters so as to ensure product quality 
with improved anticancer efficacy in non-small cell lung cancer (NSCLC). Optimized AQ 
loaded nanoparticles (AQ NP) were evaluated for physicochemical properties, stability 
profile, in-vitro aerosol deposition behavior, cytotoxic potential against NSCLC cells in-
vitro and in 3D simulated tumor spheroid model while the results confirming the 
significance of nanoparticle encapsulation for an enhanced anti-cancer efficacy. 
Furthermore, targeting potential of transferrin ligand conjugated AQ-loaded nanoparticles 
(Tf-AMQ NPs) was investigated, also evaluated for their physicochemical properties. Tf-
AMQ NP (liquid state) exhibited an aerodynamic diameter of 4.4±0.1 µm and fine particle 
fraction of 83.2±3.0%, indicating drug deposition in the respirable airways. Cytotoxicity 
studies in NSCLC cell line with overexpressed transferrin receptors revealed significant 




drug or non-targeted NPs, along with significant apoptosis induction (caspase assay) and 
reduced % colony growth in A549 and H1299 cells with Tf-AMQ NP. Moreover, 3D 
simulated spheroid studies (~ 7-fold reduction in spheroid volume compared to AMQ NPs) 
revealed efficacy of conjugated nanoparticles in penetration to tumor core, and growth 
inhibition. AQ’s autophagy inhibition ability significantly increased with nanoparticle 
encapsulation and transferrin conjugation. Further, another ligand folic acid has been 
explored for its ability to be conjugated to nanoparticles and to enhance anti-cancer efficacy 
and were found to exhibit superior anti-cancer efficacy in multiple cancer types such as 
breast cancer and cervical cancer. To conclude, amodiaquine can be a promising candidate 
for repurposing to treat NSCLC while delivering inhalable transferrin conjugated 
nanoparticles developed using a scalable HPH process to the target site, thus reducing the 
dose, side effects. 
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1. Combination of Drug Repurposing and Nanotechnology: Vital in Drug 
Discovery and Development 
1.1. Introduction  
For a new chemical entity or molecule to be approved as a drug, traditional de novo drug 
discovery process takes 10-15 years (1,2) which also requires huge investments. A 
successful drug discovery and development process should identify drugs which are both 
safe and efficacious to achieve  desirable toxicity-to-benefit ratio (3). Majority of the lead 
candidates identified during traditional de novo drug discovery process fails to demonstrate 
safety and efficacy in the succeeding phases of clinical trials, presenting higher attrition 
rates during the new drugs’ discovery and development. As the probability of success rate 
is very less; possibility of lead molecules’ marketing approval is minimal as well (4). 
Therefore, pharmaceutical companies investing on the discovery and development of new 
drugs might not achieve great profits Overall, it delays investigations to address the unmet 
clinical needs for treating several indications (5). Thus, there raised a great demand to 
accelerate the drug discovery process. In this context, drug repurposing as an alternative 
approach offering an expedited drug discovery process.  
Drug repurposing (also called drug repositioning or reprofiling) is the identification of 
new therapeutic indications for known drugs (4). As repurposing builds upon available 
research efforts, through this strategy FDA review and approvals are speeding up (6). 
Drugs approved by regulatory agencies such as FDA, European Medicines Agency (EMA), 
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Medicines and Healthcare Products Regulatory agency (MHRA) are generally used in 
repurposing (2).  
Several approaches that aid in the implementation of organized, systematic, data-driven 
drug repurposing approaches, majorly through integrating computational assistance (7). 
Evaluation of a series of compounds in an array of independent models with the aim of 
identifying a new activity in one or more of the tested models illustrates the vital 
prerequisites needed for an efficient drug repurposing (8). Proper selection of an optimal 
repurposing approach is crucial for an effective drug development process. Shortened drug 
development cycles and availability of preclinical and clinical studies data; avoids large 
capital investments and also reduces risk of failure rates. Thus, many pharmaceutical 
companies are currently implementing this method to reprofile FDA approved drugs (2,5). 
However, in line with the recent developments, repurposed drugs are encountering several 
challenges such as requirement of rigorous clinical trials and regulatory approval. Other 
challenges include retention of their efficacy even after formulating into a dosage form. 
Furthermore, physicochemical properties of repurposed drugs might hinder their new 
clinical use or new route of administration. Hence, to fulfill the crucial aspects of drug 
repurposing, encountering challenges need to be overcome. Utilization of an optimal drug 
delivery system could assist in overcoming these challenges and to achieve a successful 
drug delivery. In this context, it is necessary to highlight the advantages of nanotechnology 
in delivering therapeutics.  
Nanotechnology‐based delivery systems have been widely explored in broad range of 
fields in medicine ranging from diagnosing applications to diseases treatment. Generally 
speaking, these delivery systems overcome the drug delivery challenges through carrying 
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enabling higher drug loadings, facilitating site-specific targeting, reducing side effects 
remarkably. Greater applicability of nanocarriers systems can be attributed to their 
physicochemical properties, composition and flexibility for surface modifications. Hence, 
wide variety of drugs could be encapsulated into the nanocarrier systems (9). Due to their 
site-specific drug delivery, ability to modulate the drug release profiles, 
pharmacokinetics/in-vivo biodistribution of the drugs, nanocarriers have been recognized 
for their full potential to carry repurposed drugs (10). With recent advancements along with 
the collected information over the past decades, nanocarrier drug delivery have opened up 
a new avenue for repurposing drugs and demonstrated promising results in several medical 
applications (3). 
Altogether, combination of drug repurposing and nanocarrier system is of paramount 
importance to accomplish all the benefits of drug repurposing (10). Significance of drug 
repurposing, available repurposing strategies along with the challenges encountered by 
repurposed drugs have been discussed in this review. Importance of nanotechnology in 
drug repurposing has been discussed with recent research works along with key details 
against several disorders.  
 
1.2. Discussion on Drug Repurposing 
1.2.1. Significance 
For a new drug to enter the market, it needs to withstand stringent regulatory guidelines 
prior to approval. It requires to a larger investments and longer time to obtain a drug 
meeting all of these regulatory requirements (4,11). Repurposing has gained importance as 
it can be a less expensive and shorter approach to provide drugs to patients when compared 
with developing new drugs through traditional discovery and development processes 
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(4,11). Therefore, repurposing of already approved drugs can cut down on the time and 
money required to identify a new indication for a medication. Moreover, this approach will 
help overcome the climate of inflating costs for drug development and ultimately lower the 
cost for patients (12). Hence, pharmaceutical companies or academic organizations are  
embracing drug repurposing to quickly and efficiently explore approved drugs for a new 
therapeutic use (13).  
1.2.2. Available Resources 
To begin with drug repurposing, drugs to be repurposed can be chosen from any stage of 
their evolution are shortlisted through silico screening. Repurposed drugs could belong to 
or chosen from one of the following categories:  
a. Approved drug identified with a specific side effect (effective in new indication) 
serendipitously (4).  
b. If a drug exhibits a response through a particular mechanism of action which targets 
more than one disease, they are suitable for drug repurposing. Typically, drugs in 
clinical development fall under this category for drug repurposing. For example, 
the clinical development of duloxetine, a nonselective serotonin-reuptake inhibitor 
was simultaneously carried out for depression and stress urinary incontinence 
(4,14). 
c. Even without any safety concerns, drugs may fail to show efficacy in phase I and 
phase II trials. They are subsequently rescued and become available to the public 
where a new target site and corresponding new indication may be identified. This 
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also includes drugs which have been discontinued for commercial reasons, i.e., 
budgetary issues, duplicate projects, or change in portfolio strategy (4,14).  
d. Drugs that are not launched in large markets (i.e., U.S. and Europe), even though 
they have been developed and marketed in other emerging markets. This is known 
as geographic or transnational drug repurposing (14,15). 
e. Drugs developed in academic institutions and public sector laboratories can also be 
sources of drug repurposing. Due to the inadequacy of resources, expertise and 
collaboration, institutional policy change or a change in a scientist's focus, the drug 
development research is not taken to a logical conclusion. These candidates can 
often act as leads for further development (14).  
f. Drugs which failed to show efficacy for an approved indication provides a good 
start for its repurposing. They can then be rediscovered for a new indication and 
ultimately a patient will find a medication for which a drug is not currently available 
(14).  
1.2.3. Drug Repurposing Strategies 
Drug repurposing can be executed serendipitously or can be hypothesis-driven through 
rational approaches. Experimental and computational strategies constitute hypothesis-
driven strategies where experimental approaches include binding assays and phenotypic 
drug discovery methods. Binding assays can be used to identify binding interactions of 
ligands to assay components and phenotypic assays assist in identifying lead compounds 
from large compound libraries. Phenotypic screening approaches have gained importance 
due to their ability to identify bioactivity in cells or organisms, leading to hit identification. 
This approach is preferred as it typically is a more accurate portrayal of the underlying 
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system. Lead compounds identified through in vitro screening typically have opportunity 
higher probability of remaining active when utilized in animal models and ultimately 
clinical trials (16).  
Computational approaches are principally data-driven; involve merging different 
types of information on drug-diseases relationships and systematic analysis of data of any 
type (such as gene expression, chemical structure, genotype or proteomic data or electronic 
health records (EHRs)) (11,17). They exploit known targets, drugs, disease biomarkers or 
pathways to establish novel methods and further accelerate the process of clinical trials 
(11). Knowledge based repurposing approach utilizes the data related to drug targets, 
clinical and biochemical details with a proper experimental design and incorporation of 
different biological, chemical, and clinical data, results in identification of novel and 
previously unknown relationships for a particular drug (11,18). Discovery of a drug for a 
new indication can also be determined through studying its drug-receptor interactions and 
“off-target” hits, drug centric repurposing approach (18,19). Target-based approaches are 
utilized to predict the activity against a specific target. The pharmacological effects of these 
repositioning candidates can be consistently evaluated in molecular, cellular, network 
backgrounds as well as computational tools such as cheminformatics and bioinformatics 
(4,11,20). Signature-based approaches emphasize on recognizing gene expression profiles, 
transcription factors involved in the disease pathogenies (4,11,20). The convenience of 
signature-based methods is that they reveal underlying molecular mechanisms of disease 
pathogenesis. Hence, it opens the doors to unravel the unknown mechanisms of the drug 
and target (4). Signature-based methods utilize mechanistic data at the molecular level, 
such as an altered gene and subsequent protein expression (21). The efficacy of a drug 
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depends on individual gene signatures, therefore, a gene signature data base is very helpful 
in the repurposing of a drug through computational methods (22). Computational tools 
available to explore the genetic messengers include Connectivity Map (CMap), GWAS, 
Library of Integrated Network-based Cellular Signatures (LINCS), Sequence Read 
Archive (SRA), NCBI-GEO (http://www.ncbi.nlm.nih.gov/geo/) and Cancer Cell Line 
Encyclopedia (CCLE) (2,4).  
The ability of a drug to proceed with drug repurposing requires a case by case study 
while recognizing heterogeneous parameters. In case of rare disorders or diseases for which 
there is lack of the information about the targets and the disease pathways are unclear, 
phenotypic assays are paramount for establishing lead molecules (5,23). Repurposing 
approaches which use different computational tools and technologies have accelerated the 
research process. Comprehensive review on the significance and practical application of 
available repurposing strategies have been reviewed earlier by Pushpakom et al. (11), 
Talevi (24), Parvathaneni et al. (2) and Xue et al. (17).  
Numerous researchers are focusing on finding new uses of old drugs for several indications 
such as pulmonary hypertension, arthritis, chronic obstructive pulmonary disease etc. 
Especially, the current pandemic Coronavirus disease (COVID-19) have raised 
researchers’ attention in exploring already approved drugs as there is a high urgency to 
identify therapeutic treatment (25). A summary of key examples of repurposed drugs is 
included in Table 1 (2,26–28). 
Table 1. List of various repurposed drugs with details of new indications 
S. No. Drug name Original indication New indication 
1 Allopurinol Tumor lysis syndrome Gout 
2 Amphotericin B Fungal infections Leishmanaiasis 
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3 Aspirin Inflammation and pain Heart attack and stroke 
4 Celebrex Osteoarthritis Reduce the risk of additional polyp formation in colon cancer 
5 Cymbalta Antidepressant Fibromyalgia 
6 Doxepin antidepressant Antipruritic 
7 Finasteride Benign prostate hyperplasia Male alopecia 
8 Fluoxetin Antidepressant Premenstrual dysphoric disorders 
9 Gemcitabine Viral infections Cancer 
10 Glycopyrronium Gastrointestinal disorder Chronic obstructive pulmonary disease 
11 Hydroxychloroquine Antiparasitic Arthritis 
12 Ibuprofen Rheumatoid arthritis Parkinson's disease 
13 Lomitapide Hypercholesterolemia Homozygous familial hypercholesterolemia 
14 Mifepristone Pregnancy termination Cushing's syndrome 
15 Minoxidil Anti-hypertensive Hair loss 
16 Pentostatin Chemotherapy for specific types of leukemia T-cell-related B-cell-related, called hairy cell leukemia 
17 Raloxifene Breast cancer Osteoporosis 
18 Rapamycin Prevents organ transplant rejection 
Autoimmune lymphoproliferative 
syndrome (ALPS) 
19 Sildenafil Angina pectoris Erectile dysfunction 
20 Tamoxifen Metastatic breast cancer Bipolar disorder 
1.3.  Challenges in Utilization of Repurposed drugs 
Drug repurposing enables identification of new uses of old drugs while overcoming the 
limitations of the traditional drug discovery process. Numerous repurposing approaches 
with recent advancements involve data integration with repurposing approach. Even 
though, an accelerated drug development is possible, repurposed drugs are encountering 
major hindrances for their further application. To achieve clinical utility of repurposed 
drugs, issues related to dosage and delivery capability needs to be resolved. Identified new 
use of repurposed drugs is required to be within the approved therapeutic window margin 
of that drug against original indication. Moreover, new indication might demand a different 
route of administration. In this context of higher dose requirement and change in route of 
administration, it is prerequisite to conduct safety and efficacy studies to attain marketing 
approval (29). It is also important to achieve anticipated in-vivo drug release profiles to 
assure the desired pharmacokinetic and biodistribution parameters. If not, release profiles 
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of repurposed drugs are required to be modulated to establish an effective therapeutic 
activity. Accordingly, it might require additional efforts to make use of identified 
repurposed drugs against new indication (10).  
Repurposed drugs might also have issues related to solubility, pharmacokinetic, 
biodistribution behaviors and targeting potential. For an intended new indication, the 
physicochemical properties such as solubility, release patterns are not suitable. Sometimes, 
it is necessary to achieve targeted drug accumulation as in case of cancer studies. In certain 
cases, stability of drug may be another problem which requires to be protected in the 
biological environment. In addition, repurposed drugs as such are unable to exhibit 
efficient intestinal permeability, sustained/controlled release profiles, ability to cross 
blood-brain barrier and cellular penetration as per the respective desired applications 
towards new indication (10). Hence, following successful drug repurposing, benefits of 
repurposed drug could be achieved through utilization of suitable drug delivery systems 
through overcoming challenges. This implies that success in drug repurposing is relying 
not only on multiple basic and clinical disciplines, but formulation aspects are to be 
weighed in as well. Novel drug delivery systems such as nanotechnology it is possible to 
attain desired physicochemical properties (26).  
1.4. Potential Advantages of Nanotechnology in Drug Repurposing – Promising 
Emerging Carriers in Drug Delivery 
Due to the challenges encountered in the utilization of repurposed drugs, there raised a 
great necessity for suitable delivery systems. In this context, nanotechnology has been 
offering excellent carriers for drug delivery. Nanotechnology is one of the most intensive 
research areas, applied widely for the prevention, diagnosis as well as in treatment of 
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diseases. Nanotechnological approach has gained great popularity due to certain properties 
such as size, structure, flexibility in loading different classes of drugs etc. Nanotechnology 
comprises of different nanocarrier systems such as lipid-based nanoparticles such as 
liposomes, solid–lipid particles, micelles and niosomes; polymeric nanoparticles; 
dendrimers; inorganic nanoparticles such as carbon nanotubes, metal-based nanoparticles, 
quantum dots and silica nanoparticles (30). 
Several types of nanocarriers are extensively used in pharmaceutical applications 
due to their ability to carry higher amounts of drugs and promote controlled drug release, 
resulting in reduced dosing frequency. Other advantages of nanocarriers include reduced 
toxicity and side-effects due to their targeting potential to the specific site of action. 
Nanocarriers are also known for their capability to improve the stability. Altogether, 
nanotechnology is contributing for a greater safety, efficacy, patient compliance along with 
an improved stability profile of drug and ultimately reduced healthcare costs. Different 
types of nanocarriers exhibit unique physiochemical and biological properties as 
represented in Figure 1 (31). 
Exploiting nanotechnology for delivering repurposed drugs enable advantages of 
both drug repurposing and nanotechnology in drug delivery. For instance, these systems 
present safer therapeutics as the safety profile of drugs is well-known while nanocarriers 
enable specific drug delivery. Nanocarrier encapsulation would reduce the required drug 
doses due to their targeting potential. Especially, flexibility in modification of targeting 
functionalities of nanocarriers establishes applicability across multiple areas of research. 
While drug repurposing fosters the drug discovery and development process through 
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skipping initial phases of clinical trials, application of nanotechnology in drug delivery 
would ultimately yield significant clinical benefits. Overall, with growing knowledge and  
interest over the past decades, combination of nanotechnology and drug repurposing have 
opened up a new avenue in drug delivery and demonstrating promising results in broad-
range of pharmaceutical applications.  
1.5.  Applications of Nanotechnology in Drug Repurposing 
To accomplish successful drug repurposing, an identified repurposed drug should be made 
available to the desired site action with more interactions with the new target while 
overcoming the challenges encountered in their delivery. Drug delivery refers to the use of 
a delivery tool or vehicle to carry a therapeutic agent and release it at a specific rate at a 
particular location. Drug delivery systems have also been used to stabilize components and 




increase therapeutic activity. Proper selection of drug delivery systems assists in 
overcoming the challenges encountered by repurposed drugs. 
Nanocarriers enable to adopt a route of administration that is different from the 
original mode of application of the drug. Modification of the route of administration has 
been required by several drugs to improve bioavailability or to modify the concentration 
of drugs at the new site of action, while avoiding the original target effects (32–36). 
Overall, benefits of changing the route of drug administration, drug targeting, and/or drug 
modification to ensure proper delivery to the new target are possible through utilization of 
nanotechnology approach. Nanocarriers can be fabricated according to the desire 
application due to feasibility of using broad range of materials and to make physical and 
chemical modifications to obtain unique, adaptable, and/or responsive release profiles (10). 
 Incorporating repurposed drug into a nanoparticulate system will potentially reduce 
the required dose to exhibit efficacy. Nanoparticulate drug delivery systems such as 
polymeric nanoparticle carrier systems can enhance specificity, tolerability and drug 
efficacy (37). These polymeric nanoparticulate drug delivery systems have been reported 
for their capability to encapsulate higher amounts of drugs and to provide selective 
therapeutic activity with less side-effects (38,39). Moreover, biodegradable polymeric 
nanoparticles have been used regularly due to their versatility and biocompatibility in 
encapsulation of both hydrophilic and hydrophobic drugs (40). Nanoparticles act as 
efficient carriers for delivering drug to the tumor while demonstrating higher cellular 
uptake and tissue penetration; thus exhibiting tumor targeting potential (35,41). In addition, 
nanoparticles facilitate accumulation of drugs in the desired tissues as in case of tumor 
treatment, simultaneously reducing the required doses to exert efficacy. For example, 
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nelfinavir (FDA approved antiretroviral drug) has been reported for its repurposing 
potential against lung cancer. However, higher dose requirements leading to toxicity are 
limiting its clinical translation. Parvathaneni et al have employed nanotechnology based 
drug repurposing and reported a potential dose reduction and enhanced anti-cancer 
efficacy, thus, harnessing the potential clinical use of nelfinavir against non-small cell lung 
cancer (NSCLC) (42). Polymeric nanoparticles allow introduction of targeting moieties 
(such as monoclonal antibodies, peptides and proteins) onto the surfaces of delivery 
systems. These systems can be employed to target the therapeutic agents to certain tissues, 
which will increase the selectivity of these nanocarriers and accumulation of the 
encapsulated product at the desired site, which will enhance its efficacy. Capability of 
nanoparticulate systems in delivering therapeutics through non-invasive pulmonary route 
of delivery facilitates local drug delivery in case of treating several lung disorders 
(43).Vaidya et al. have used cationic bovine serum albumin nanoparticles to encapsulate 
quinacrine (anti-malarial drug) and the formulation have demonstrated to have significant 
anti-cancer efficacy against non-small cell lung cancer with excellent inhalable properties 
(39). Nanoparticle encapsulated disulfiram, an FDA approved drug to treat alcoholism have 
reported its repurposing potential in inhibiting tumor growth in ovarian cancer model by 
He et al. Lu et al. have developed pH sensitive size shrinkable nanoparticles of metformin 
in combination with doxorubicin and reported their targeting potential towards tumors. 
Ebselen (anti-inflammatory) have demonstrated repurposing potential but utility of this 
drug is hindered by its poor aqueous solubility which requires a nanoparticulate delivery 
system for topical application for promising, safe and corresponding alternative to the 
treatment of cutaneous candidiasis (34). Recently, challenges involved in niclosamide  
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(anthelminthic drug) repurposing for cancer diseases has been reviewed by Barbosa et al. 
They have highlighted the therapeutic benefits of encapsulating niclosamide in different 
nanoparticulate systems (44). Figure 2 (44) summarizes the challenges encountered by 
niclosamide and also the benefits of nanotechnology in drug repurposing. 
 Liposomal drug delivery systems are one of the most promising non-toxic carriers of 
both lipophilic and hydrophobic drugs (45,46). These systems enhance the therapeutic 
index of drugs by increasing drug uptake, resulting in increased concentration in tumor 
cells (47). Parvathaneni et al. have formulated liposomal delivery system of pirfenidone 
(anti-fibrotic drug) to increase its therapeutic activity against non-small cell lung cancer 
(20). They found that the liposomal encapsulation of metformin has resulted in significant 
dose reduction compared to plain drug to exert anti-cancer efficacy (33). Shukla et al. used 
liposomal delivery system to increase therapeutic activity of metformin against breast 
cancer. They found that the liposomal encapsulation of metformin has resulted in 
significant dose reduction compared to plain drug to exert anti-cancer efficacy (33). 
Figure 2. Summary of challenges encountered by niclosamide and importance of 
nanotechnology in drug repurposing to treating various cancers 
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Celecoxib (anti-inflammatory drug) entrapped liposomes were prepared to overcome its 
drawbacks such as low water solubility and rapid plasma clearance and to allow a systemic 
administration and increase tumor accumulation of drug based on the enhanced 
permeability and retention mechanism by Matbou Riahi et al. (48). 
1.6. Exploitation of Nanotechnology in the Treatment of Several Indications 
Nanotechnology has been widely exploited in recent years in various applications. 
Recently, there has been a substantial rise in the use of nanocarriers to deliver therapeutic 
agents for treating various diseases with many successful outcomes (9). An overview on  
the significance of nanotechnology in drug repurposing against various disorders has been 
presented in Figure 3. (Image of Nanostructures was adapted from (49)). 
The utilization of different nanocarrier systems in delivering repurposed drug is 
discussed below by disease type. To exemplify the breath of nanoparticle drug delivery 
Figure 3. Illustration of significance of combination of drug repurposing and 
nanotechnology in treating various indications.  
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systems and/or drug repurposing, several disorders along with few case studies have been 
discussed below along with illustration of few examples in Table 2 (26,27). 
Table 2. List of the Application of Nanocarrier Systems in Drug Repurposing to Treat 
Different Disorders 
 
Drug Drug delivery system 
Original 










Niclosamide Nanocrystals Anthelmintic 
Anti-viral against 
lung infections in 
cystic fibrosis 
(51) 
Etanercept - Rheumatoid arthritis Asthma (52) 










Anti-cancer Coronary allograft vasculopathy (55) 
Lidocaine - Local anesthetic Arrhythmia (56) 







Ovarian, cervical and 






Metformin Chitosomes Anti-diabetic Malignant pleural mesothelioma 
(59) 





Nano lipid carriers 
 
Anti-diabetic Alzheimer's disease (61) 
Melatonin Polymeric nanoparticles Insomnia Glioblastoma (62) 







1.6.1. Lung diseases 
Pulmonary disorders of the airways and lungs include chronic obstructive pulmonary 
disease, asthma, cystic fibrosis, inflammatory disorders, pulmonary vascular diseases, 
interstitial lung diseases (pulmonary fibrosis), sarcoidosis and infectious diseases like 
pneumonia, tuberculosis (64,65). In spite of availability of advanced treatments, still there 
exists a need to emphasize on delivering therapeutics efficiently to lungs with an 
application of drug repurposing and nanocarrier drug delivery system. Efficiency of this 
combination in treating lung disorders has been proved in several studies. Literature 
comprehends several examples of therapies that have been effectively demonstrated for the 
treatment of allergic, genetic, and infectious diseases of the respiratory system.  
Pulmonary arterial hypertension (PAH) is caused by several pathological changes 
in the pulmonary vasculature. Majority of the approved PAH medications modulate the 
endothelin, nitric oxide, and prostacyclin pathways, addressing only the vasoconstrictive 
phenotype of PAH. Therefore, there is a pressing need to develop novel, effective therapies 
that target additional molecular pathways that drive the pathogenesis of PAH to enhance 
current treatment options and accelerate progress in the direction of a PAH treatment (66). 
Metformin (antidiabetic drug) have been demonstrated to promote pulmonary 
vasodilation by increasing endothelial nitric oxide synthase in preclinical models and 
mitigated pulmonary artery smooth muscle cell proliferation (67). Rosiglitazone (type 2 
diabetes) was reported to play a crucial role of peroxisome proliferator-activated 
receptor gamma (PPAR-γ) in PAH pathogenesis and it has been reported to deliberate 
PASMC proliferation by modulating cell growth and apoptosis. Advantages of 
rosiglitazone over other PAH treatments include its direct effects on vascular remodeling 
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in PAH. Thus, presenting rosiglitazone as a potential candidate for repurposing against 
PAH. In another study, Rashid et al have developed PLGA particles of rosiglitazone and 
evaluated the formulation in Sugen/Hypoxia induced PAH rats. Authors have reported that 
repurposing potential of rosiglitazone as an anti-PAH drug. In addition, inhaled PLGA 
particles of rosiglitazone were reported to be more potent compared to than plain 
intratracheal or oral rosiglitazone, even at much-reduced doses (68). 
Niclosamide (anti-helminthic), multiple pathway inhibitor has demonstrated to play 
a central role in ameliorating Transforming growth factor beta 1 (TGF-β1) induced 
profibrotic effects in fibrotic diseases. Computational biological studies predicted 
niclosamide to exhibit strong antifibrotic effects in attenuating pulmonary fibrosis (69). 
Recently, a new formulation of trimetazidine (in Europe and other countries for the 
treatment of angina pectoris): Livantra has been approved by US FDA for the treatment 
of pulmonary arterial hypertension (PAH). (70) Fasudil (approved for cerebral vasospasm 
induced by subarachnoid hemorrhage) have been investigated for its anti-PAH efficacy. It 
has been found to demonstrate pulmonary vasodilation in both animal model and human 
PAH. As intravenous fasudil is not selective for the pulmonary circulation and has a short 
half-life of ~45 minutes, Gupta et al have investigated capability of inhalable liposomal 
systems to deliver fasudil producing prolonged pulmonary selective vasodilation in PAH. 
Authors have reported the ability of developed fasudil liposomes to produce sustained and 
selective pulmonary vasodilation while reducing the required doses (36). In another study, 
inhalable polymeric particles of sildenafil (phosphodiesterase type 5 inhibitor (PDE5), 
original indication: erectile dysfunction) have been reported to prolong the drug release 
while producing selective pulmonary vasodilation. Thus, resulting in reduced the systemic 
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exposure of the drug which highlights the importance of nanotechnology in delivering 
sildenafil for PAH treatment (71). Tadalafil, PDE5 inhibitor was originally developed for 
treating erectile dysfunction and later repurposed for PAH. Recently, Teymouri Rad et al 
reported an increased efficacy of tadalafil nanocomposites administered as intratracheal 
insufflation compared to oral version of tadalafil and concluded that inhalable tadalafil 
nanocomposites as an alternative strategy for an oral version of tadalafil in PAH treatment 
(72). Several other repurposed drugs such as pazopanib, imatinib, tofacitinib for treating 
allergy and asthma have been summarized by Kruse and Vanijcharoenkarn et al (73). 
In case of treating respiratory infections, emergence of new and resistant strains 
alarms the researchers about necessity to develop new therapies for combating several viral 
or bacterial infections. While there are several approved drugs under investigation to 
repurpose against COVID-19, still there is no approved treatment for that. Many 
researchers have been exploring nanotechnology to achieve better outcomes of repurposed 
drugs. Nanomedicine formulations have been investigated for their ability to deliver 
dexamethasone to inflammation-initiating and -propagating phagocytic cells in the lung, 
assists controlling cytokine storm. Dexamethasone nanoformulation can increase drug 
availability and drug activity in the inflamed parts of the lung while exerting anti-fibrotic 
effects. Thus, dexamethasone nanomedicine have been shown to be useful for preventing 
fibrosis, key complication in the long-term follow-up management of COVID-19 (74). 
1.6.2. Cardiovascular diseases 
Cardiovascular and circulatory diseases namely ischemic heart disease, cardiomyopathy, 
rheumatic disease, endocarditis, peripheral vascular disease etc. are now recognized as the 
leading causes of death in the world (75). Currently, there is a major current health concern 
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demanding acceleration of drug development process for cardiovascular disease which 
have become quiet. In the advent of target deconvolution, reconsideration of previously 
approved drugs has become significant (76). Recent studies suggest minocycline’s 
(antibacterial drug) protective role in cardiovascular pathology and reported its activity 
against myocardial ischemia-reperfusion injury (77). In addition, emerging evidence 
supports the potential repurposing of the disease-modifying antirheumatic drug (DMARD) 
methotrexate for the management of patients with atherosclerotic cardiovascular disease 
and residual cardiovascular risks (57). Recent studies have highlighted the beneficial 
effects of currently marketed anti-inflammatory drugs, such as colchicine and 
hydroxychloroquine, in reducing cardiovascular events in patients with stable coronary 
artery disease (78–81). Despite of a large number of therapeutic options being developed 
for the management of cardiovascular diseases, they are insufficient to stop or significantly 
reduce the progression of these diseases and may produce unwanted effects. In this context, 
important advances in the area of nanotechnology and the controlled release of drugs intend 
to avoid limitations of conventional therapies for the treatment of several CVDs (82). 
Matoba et al. have highlighted the capability of several nanocarrier systems in providing 
enhanced drug delivery for treating unstable coronary atherosclerosis and their other 
possible applications against myocardial ischemia-reperfusion injury and pulmonary 
hypertension. Moreover, it was reported that nanotechnology based drug delivery systems 
(polymeric nanoparticles) of several drugs have been under clinical trials to investigate 





Malignant mesothelioma (MM), aggressive type of cancer arising from mesothelial cells 
lining the pleural, peritoneal, and pericardial cavities (84,85). It is characterized by a dismal 
prognosis and inherent resistance to chemotherapeutics, thus demanding development of 
therapeutic approaches (85). Despite availability of several standard therapies (cisplatin + 
pemetrexed), patients’ median survival is not improved significantly. Patient survival still 
needs to be drastically improved with new therapeutic approaches by means of unique 
mechanisms of action against the MM malignant phenotype (85). Moreover, mesothelioma 
cells are resistant to traditional chemotherapeutic agents, prompting the need for new drug 
development (59). As discovery of new molecules with superior therapeutic efficacy is 
expensive and time-consuming, several researchers have been exploring repurposing 
potential of old drugs for a better MM prognosis. Recently, anti‐tumor activity of 
pyrvinium pamoate (anti‐helminthic) drug has been demonstrated in MM. Moreover, 
pyrvinium pamoate significantly impaired MM cell proliferation, colony formation, 
migration, and tumor spheroid formation (86). Szymiczek et al immunosuppressant 
FTY720, approved for multiple sclerosis treatment, has been investigated for its anti-cancer 
efficacy in MM. However, to alleviate the side effects of repurposing drugs (Eg. FTY720), 
development of optimal nanoparticle drug delivery system is essential (85). In a recent 
study, our research group have reported the research findings demonstrating the efficacy 
of quinacrine (FDA approved anti-malarial) (60). Besides highlighting the importance of 
drug repurposing, researchers have realized the necessity of delivery systems towards 
better performance. They have evaluated the effects of quinacrine on cell viability of 
normal cells (human embryonic kidney cells, HEK-293). Quinacrine was reported to 
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exhibit toxicity on normal cells along with cancer cells in this study. Thus, it is highlighting 
the importance of a delivery system to reduce exposure to normal tissues. There are several 
studies reporting the repurposing potential of metformin against MPM (87,88). However, 
metformin upon intrapleural administration suffers from rapid elimination thus requiring 
higher doses with frequent dosing. In another study, Shukla et al have demonstrated the 
improved cytotoxic efficacy of metformin loaded into chitosomes which prolonged 
retention and drug release of metformin (59). 
1.6.4. Brain disorders 
Most commonly occurring brain disorders are brain seizure (89), multiple sclerosis (90); 
neurodegenerative diseases like parkinson’s disease (PD), alzheimer’s disease (AD) (91), 
glioblastoma and dementia (92,93); infectious diseases like meningitis and encephalitis 
(94), vascular diseases like stroke, aneurysm, and hematoma (95,96). Major factors 
contributing to the limitations of brain delivery are the blood-brain barrier (BBB) and the 
blood-cerebrospinal fluid barrier (BCSFB) (97,98). Disulfiram (inhibitor of acetaldehyde 
dehydrogenase) used to treat chronic alcoholism has been investigated for its efficacy 
against glioblastoma (99). Recently, nanoparticles have withdrawn great attention due to 
their ability to carry drugs across the BBB. Furthermore, these systems offer controlled 
drug release, which potentially allow for a decrease in the frequency of administrations. 
Moreover, nanoparticles are expected to improve the drug physicochemical stability and 
increase the biological availability (62). Da Silveira et al. investigated and reported the 
antitumoral effect of ketoprofen-loaded nanocapsules in treating glioblastoma (100). Zhou 
et al. have developed brain penetrating PLGA nanoparticles loaded with agents identified 
(library screening approach) as active against brain cancer stem cells. They have reported 
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the significance of a combination of drug repurposing and nanoparticle-based drug delivery 
in treating glioblastoma (101). In another study, epilepsy have benefitted from repurposing 
drugs with the use of liposomal systems loaded with curcumin (anti-inflammatory) in 
treating seizures (102). 
1.6.5. Cancer 
Cancer is one of major health issues worldwide, even though there are several current 
therapies available. Limited success with new drug developments which have required 
huge investments is alarming the researchers to choose an alternative strategy. Moreover, 
for approved oncology drugs, prices have raised steeply in recent years; increasing the 
economic burden on the public. Hence, there is a growing interest for drug repurposing, 
i.e. using already approved drugs for treating new indications (cancer) to improve success 
rates, shorten time frames for drug development while reducing the overall costs.  
 Several recent studies have reported the repurposing potential of FDA approved 
drugs against cancer both in its prevention and therapy. In addition, advantages of different 
types of nanocarrier systems in overcoming the challenges encountered by repurposed 
drugs have been discussed here along with respective examples. Generally speaking, two 
major prerequisites for an optimal cancer drug delivery therapy include avoiding pre-
release of drug and resulting in desirable drug release profile at site of action (3). Thus, 
several researchers are utilizing different types of nanocarriers to fulfill the crucial aspects 
in drug repurposing and delivery. Major aspects include drug efficacy enhancement 
through modified bio-distribution profile, minimizing side effects; prolonging the drug 
release; resolving the solubility,  bioavailability issues and facilitating a targeted or 
localized tumor therapy (10). 
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El-Moslemany et al. have investigated the repurposing potential of miltefosine, an 
alkylphosphocholine initially developed as an anticancer drug, to use leishmaniasis 
treatment as a antischistosomal agent. They have reported the capability of respective 
nanocarrier system (lipid nanocapsules) in dose reduction from the in-vivo studies (103). 
In another study, Alhakamy et al. have reported the efficacy of Itraconazole, a broad-
spectrum antifungal drug in NSCLC treatment. They have loaded the drug into chitosan-
coated polymeric nanoparticles to overcome issue of poor water solubility the drug which 
hinders its use as a therapeutic agent. (104). Recently, our research group have reported 
repurposing potential of various classes of drugs such as anti-fibrotic and an anti-viral 
category. While these drugs have demonstrated anti-cancer efficacy, to enhance the 
efficacy further and to achieve a safe delivery of the therapeutics, different types of delivery 
systems have been investigated. Anti-malarial drug, amodiaquine have also been under 
investigation to explore its anti-cancer efficacy in melanoma and its repurposing potential 
has been reported by Salentin et al (105). There are several reports stating the presence of 
redox imbalance in cancer environment. Amodiaquine is a mannich base 4-
aminoquinoline. Cationic complexes of amodiaquine base with Rhodium have been 
reported for their anti-tumor activity (106). In addition, several other properties of 
amodiaquine such as ability to inhibit ribosome function, autophagy inhibition were also 
reported. Furthermore, loading amodiaquine into a polymeric nanoparticulate system could 
enhance the anti-cancer efficacy of drug against non-small cell lung cancer (NSCLC). 
Utilization of targeting approach facilitates targeted drug delivery to the specific cancer 
cells. Overexpression of transferrin receptors in several NSCLC cells has been reported, 
thus targeting them directs therapeutics towards cancer cells with overexpression of 
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transferrin receptors (107). TFR1 and TFR2 are two subtypes of TFRs those bind with iron-
transferrin complex to facilitate iron into cells. TFR1 is ubiquitously expressed on the 
surfaces of generic cells, whereas TFR2 is specially expressed in liver cells. Recently 
reports showed that TFR1 is abnormally expressed in various cancers. Hence, targeting 
TFR1 through respective drugs or drug delivery systems demonstrated strong anti-tumor 
effects, herein TFR1 probably became a potential molecular target for treatment for cancers 
(108). 
Parvathaneni et al have successfully encapsulate pirfenidone (anti-fibrotic) into 
liposomes and reported their superior anti-cancer efficacy against NSCLC. Other example 
includes zoledronate–calcium NPs (zoledronate: approved for osteoporosis) has been 
loaded into PLGA NPs which were further functionalized with octadecanoic acid‐
hydrazine‐polyethylene glycol by Li et al. This delivery system has minimized the burst 
release of zoledronate and enhanced toxicity in cancer cells as well as macrophages. 
Moreover, results from in-vivo experiments have revealed that developed nanoparticulate 
formulation has reduced drug accumulation in bone and demonstrate better extra skeletal 
tumor-targeting efficacy compared to plain drug (109). Curcumin has demonstrated anti-
cancer activities through several different signaling pathways (110), yet it requires a 
delivery system to overcome the challenges pertaining to its poor water solubility and low 
bioavailability. Laha et al. have developed folic acid‐conjugated curcumin‐loaded metal-
organic nanoparticles for treating triple‐negative breast cancer which exerted an effective 
tumor growth inhibition in mice (111). Repurposing of anti-inflammatory drugs such as 
ibuprofen, ketoprofen, and celecoxib as anti-cancer agents against gastric, brain, breast, 
and colon cancers is relied on utilization of nanoparticulate systems to ensure tumor-
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targeted delivery (10). To elaborate, even though celecoxib demonstrated anticancer 
activity against many cancer types, serious side effects of it are hindering its successful 
repurposing. Thus, Venkatesan et al have developed chitosan modified hydroxyapatite 
nanocarriers-mediated celecoxib to resolve these issues (112). 
1.7. Conclusion 
Even though discovering a new drug is better, time, cost and success rate in the discovery 
are making researchers to look towards alternative strategies. Thus, drug repurposing is 
becoming an attractive avenue in drug discovery and development. Hence, existing drugs 
could be explored for their new use with lower investments and higher success rates in 
shorter timeframes. However, utilization of repurposed drugs is encountering several 
challenges such as higher dose requirement compared to that for original indication etc. 
Hence, considering delivery of repurposed drugs using nanotechnology could be an 
interesting opportunity to achieve the whole benefits of drug repurposing. Several 
nanocarriers have been proven to deliver repurposed drugs to exert desired therapeutic 
effect while overcoming the respective challenges confronted by majority of repurposed 
drugs. 
1.8. Expert Opinion 
Due to the advent of drug repurposing approach, drug discovery and development process 
has been accelerated to combat the shortage of drugs. Exploration of new uses of old drugs 
cuts down the time and costs invested in lengthy, expensive de novo drug discovery. 
Multiple resources of approved drug library or of other categories are available for drug 
repurposing. Known approved drugs or clinically failed drugs could be repurposed against 
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new diseases of interest. Several repurposing strategies are available ranging from 
phenotypical screening to complex computational methods with data integration to employ 
drug repurposing. Through phenotypic screening approaches, lead molecules can be 
identified based on their bioactivity in cells or organisms. Target-based approaches are 
utilized to predict the activity against a specific target. Moreover, pharmacological effects 
of repositioning candidates can be consistently evaluated in molecular, cellular, network 
backgrounds as well as computational tools such as cheminformatics and bioinformatics 
can be applied. The ability of a drug to proceed with drug repurposing requires a case by 
case study while recognizing heterogeneous parameters. However, even after identification 
a repurposed drug, there are certain hurdles hindering their successful utilization. 
Challenges encountered by repurposed drugs generally include requirement of higher doses 
(than approved doses for original indication) of these drugs to exert activity against new 
indication, possibility to administer via different route and feasibility of their 
physicochemical properties. Hence, there arises a need of drug delivery system to deliver 
these repurposed drugs. Moreover, nanotechnology (nanocarriers systems) has now been 
an attractive strategy to deliver therapeutics to desired site with optimal release profiles. 
These systems are becoming critical tools in addressing the limitations of repurposed drugs. 
Majority of research studies have investigated several FDA approved drugs for their 
repurposing potential and evaluated their efficacy through their encapsulation in various 
nanocarriers. Thus, a combination of drug repurposing and nanotechnology could open a 






2. Hypothesis & Study Objectives 
2.1. Hypothesis 
We hypothesize that scalable, targeted nanoparticulate delivery systems of amodiaquine 
are capable of delivering drug into the deep lungs, thus reducing the dose and off-target 
effects. 
2.2. Objectives 
2.2.1. Development of Pharmaceutically Scalable Inhaled Anti-cancer Nanotherapy 
– Repurposing Amodiaquine for Non-Small Cell Lung Cancer (NSCLC) 
2.2.1.1. Exploration of Anti-cancer efficacy of amodiaquine against NSCLC 
Amodiaquine is an anti-malarial drug and no studies were reported on its anti-cancer 
efficacy in non-small cell lung cancer. Hence, our objective is to screen different NSCLC 
cell lines to study cytotoxicity effect of AQ. 
2.2.1.2. Formulation and Characterization of AQ-loaded Nanoparticles 
A scalable approach, high-pressure homogenization has been chosen for the formulation 
of NPs in the current study. However, for obtaining an optimal product, variables 
pertaining to process and formulation composition needs to be considered. A systematic 
experimental design assists in identifying the critical process and product parameters. 
Assessment of physicochemical properties of the developed AQ NPs would provide details 





2.2.1.3. Determination of Anti-cancer Efficacy of AQ and AQ-loaded NPs 
Developed formulations are required to be evaluated for their anti-cancer efficacy and to 
compare with that of plain AQ, if nanoparticulate encapsulation have enhanced the 
therapeutic efficacy of AQ or not. In brief, several in-vitro cell culture studies such as 
cytotoxicity studies, scratch assay, clonogenic assay and ex-vivo studies (3D spheroid 
studies) help in assessing the efficacy of NPs.  
2.2.2. Development and Characterization of Transferrin Functionalized 
Amodiaquine Loaded Nanoparticles-Efficacy in Non-Small Cell Lung Cancer 
(NSCLC) Treatment   
2.2.2.1. Conjugation of PLGA polymer with Transferrin and its Characterization 
Conjugation of Trasferrin onto PLGA polymer will be carried out using EDC/NHS 
chemistry. 
2.2.2.2. Formulation and Characterization of Tf-AQ-loaded Nanoparticles 
To impart targeting potential to the NPs, non-conjugated and ligand (transferrin) 
conjugated polymer has been chosen to use at ratio of 5:1.  
2.2.2.3. Determination of Inhalable properties of NPs 
In-vitro lung deposition test using Next Generation Impactor (NGI) determines the 




2.2.2.4. Comparing efficacy of non-targeted and transferrin receptor Targeted 
AQ-loaded Nanoparticles 
To determine the superior anti-cancer efficacy of targeted AMQ NPs compared to both 
plain AQ and non-targeted AMQ NPs, several cell culture studies will be carried out which 
include both two-dimensional and three-dimensional models. These studies include 
different NSCLC cell lines with varied expression levels of transferrin receptors. 
2.2.3. Development and Characterization of Folic acid Conjugated Amodiaquine 
Loaded Nanoparticles-Efficacy in Cancer Treatment 
2.2.3.1. Conjugation of PLGA polymer with Folic acid 
PLGA needs to be conjugated with folic acid (FA) via set of reactions utilizing EDC/NHS 
chemistry and PEG-bis-amine for the formation of PLGA-PEG-FA conjugate. 
2.2.3.2. Formulation and Characterization of FA decorated AQ-loaded 
Nanoparticles 
To impart targeting potential to the NPs, non-conjugated and ligand (folic acid) conjugated 
polymer has been chosen to use at ratio of 5:1.  
2.2.3.3. Comparing the efficacy of non-targeted and transferrin receptor Targeted 
AQ-loaded Nanoparticles 
To determine the superior anti-cancer efficacy of targeted AMQ NPs compared to both 
plain AQ and non-targeted AMQ NPs, several cell culture studies will be carried out which 
include both two-dimensional and three-dimensional models. These studies utilize multiple 





Lung cancer is the leading cause of cancer deaths worldwide in both men and 
women with non-small cell lung cancer (NSCLC) accounting for approximately 85% of 
lung cancer cases (113). Even though there are major advancements in the field of 
discovery and development of novel drugs and delivery systems, it still remains a 
challenging task to treat NSCLC. Moreover, there is growing evidence that cancer cells 
develop resistance to chemotherapeutic agents upon chronic use, which makes it 
imperative to identify newer drugs with exceptional anticancer activity. As it takes 12-15 
years for developing a new drug in the traditional drug discovery process, drug 
repositioning (repurposing) has been drawing significant attention because of its ability to 
identify new use of already FDA approved molecules and hence accelerate the 
development process at lower costs (114). Altogether, to harness the potential clinical use 
of different class of drug as an anticancer agent, a suitable drug delivery system facilitating 
enhanced efficacy and dose reduction is required. Especially, nanoparticulate drug delivery 
systems have been reported for their capability to encapsulate higher amounts of drugs and 
to provide selective therapeutic activity with less side-effects (38,39). 
3. Development of Pharmaceutically Scalable Inhaled Anti-cancer Nanotherapy – 
Repurposing Amodiaquine for Non-Small Cell Lung Cancer (NSCLC) 
3.1. Introduction 
Nanoparticles (NPs) have attained considerable attention in delivering therapeutics due to 
their unique characteristics related to size, surface, payload capacity and flexibility in 
surface modifications to exert targeting potential (115). Available marketed products of 
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NP systems include Cimzia®, Eligard®, Pegasys®, Renagel® etc. (116). NPs have 
demonstrated reproducible results on small laboratory scale production batches, however, 
a major hindrance exists in the translation from laboratory scale to commercial production 
due to manufacturability challenges (117,118). Manufacturing challenges such as 
feasibility of scale-up, product quality and process repeatability are to be considered during 
the development of NPs (119). Moreover, lack of sufficient information and knowledge on 
the scale-up technologies makes it difficult to introduce NPs into the market at the same 
pace of their development (115,119). Further, scale-up is known to affect the characteristics 
of NPs and necessitates further optimizations at industrial scale. A better strategy would 
be to develop NPs using commercially scalable approaches at the laboratory scale, and 
researchers should pay more attention to formulation scale-up in addition to the 
development of complex delivery systems (119). Among several existing methods of NPs 
production, high pressure homogenization (HPH) has gained much importance due to its 
scale-up feasibility and efficiency in providing reproducible results (120). HPH allows for 
seamless translation from academic/small scale research labs to commercial scale 
production in cGMP facilities, and facilitates manufacturing of various formulations such 
as emulsions, suspensions and NPs in larger quantities (118,120,121). During the HPH 
process, formulations are subjected to both mechanical forces such as cavitation, impact, 
shear, turbulence and high pressure (122) which aid in accomplishing NPs with optimal 
characteristics such as minimal particle size and maximum drug loadings as reported by 
Hoyer et al (120). Shi et al have reported that optimal homogenization pressure and number 
of homogenization cycles have resulted in small sized NPs with uniform size distribution 
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(123). In another study, high HPH was used to achieve NPs of minimal particle size and 
good stability (124).  
While effective, there are multiple variable parameters in HPH process, which need 
to be optimized and fine-tuned to reproducibly develop a stable and effective delivery 
system. Due to the involvement of several critical processes and formulation parameters, 
it is imperative to utilize statistical design of experiment (DoE) approach to assist in 
optimizing formulation while improving the knowledge of several parameters (118). For 
instance, Petersen and Steckel have investigated various parameters such as 
homogenization pressure, pre-emulsion quality and formulation variables using DoE to 
identify the critical parameters and developed an optimized emulsion (125). The 
importance of DoE can be understood from several recent works where application of 
systematic DoE approach has assisted in developing solid lipid nanoparticles of Efavirenz, 
poorly soluble drug (118) and inhalable microparticles of highly lipophilic drug (126). 
One therapeutic area where particle characteristics play a vital role in particle 
accumulation and performance, is localized delivery to the lungs for respiratory diseases. 
Accumulation into the deep lungs is imperative for treatment of majority of respiratory 
diseases including pulmonary hypertension, pulmonary fibrosis, and non-small cell lung 
cancer (NSCLC) (127,128). Accumulation of drug-loaded nanocarriers in the lungs after 
pulmonary delivery has been studied by several researchers, and improved efficacy of 
inhalable carriers in NSCLC has been reported earlier (129). For instance, gemcitabine-
loaded gelatin nanocarriers (130), paclitaxel-loaded nanocomposite microparticles (131), 
quinacrine-loaded bovine serum albumin modified cationic nanoparticles (129), 
pirfenidone-loaded liposomes (20) and lactoferrin/chondroitin-functionalized monoolein 
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nanocomposites (132) etc. have been reported for their capability as inhaled nanocarriers 
in providing localized drug delivery in NSCLC treatment. In addition, Abdelaziz et al 
(127), Mangal et al (133), Ahmed et al (134) and Anderson et al (135) have also 
highlighted the significance of nanocarriers in pulmonary delivery along with details of 
further investigations being carried out. Particle size, surface morphology and mass median 
aerodynamic diameter (MMAD) of inhaled therapeutics determines their fate and the site 
of deposition in deep lungs (136). MMAD within the range of 2-5µm is essential for deep 
lung accumulation of particulate therapeutics, which is otherwise difficult to maintain due 
to inherent differences in particles’ physicochemical properties. Variability in 
physicochemical properties brings immense variability in therapeutic performance, thus 
making scalability a major challenge (137,138). 
In this study, we aim to investigate the utility of DoE based nanoparticle 
development using HPH and test the efficacy of optimized formulations in a relevant 
respiratory disease model. Here, we chose amodiaquine, 4-[(7-chloroquinolin-4-yl) 
amino]-2- [(diethylamino) methyl] phenol (AQ), an FDA approved anti-malarial 
compound (Basoquin), to formulate biodegradable polymer (PLGA)-based NPs using HPH 
and to evaluate their efficacy against NSCLC. While AQ has been approved as an anti-
malarial therapeutic, it is also a potent autophagy inhibitor with an ability to induce 
apoptosis in-vitro (139,140). Qiao et al for the first time reported AQ’s ability to cause 
autophagic-lysosomal and proliferative blockade in melanoma cells (139). Another recent 
report has also highlighted AQ for its drug repurposing efficiency through a structure-based 
screening approach (105). Non-small cell lung cancer (NSCLC) is also characterized by 
autophagy induction and deficits in apoptotic mechanisms for its pathogenesis (141), hence 
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targeting these processes using AQ is of considerable interest. AQ makes an interesting 
model drug as (i) its long-term safety is well documented being a FDA approved molecule; 
(ii) there is no AQ nanoparticulate delivery system developed so far thus making it feasible 
to understand the effects of its physicochemical properties on formulation development 
and characterization. As discussed earlier, NSCLC is a disease of the deep lungs, and 
inhalation therapy is gaining importance in recent years due to successful local delivery of 
therapeutics to cancer cells in treating NSCLC, where NPs act as potential carriers (127). 
Combination of drug repurposing and nanotechnology have been reported for its efficacy 
in treating NSCLC by several researchers recently (32,42). 
In this project, a 32 multifactorial design has been applied for better understanding 
of critical processes and formulation factors to ensure product quality with accepted 
Quality Target Product Profile (QTPP) for improved anticancer efficacy. The objective of 
this project is to formulate scalable, inhalable AQ-loaded PLGA NPs using HPH approach 
and to explore their efficacy in NSCLC.  
3.2. Materials and Methods 
3.2.1. Materials 
Poly (lactic-co-glycolic) (PLGA 50:50, 25–35 kDa, acid terminated), 
polyethyleneimine (PEI), poly vinyl alcohol (PVA), and amodiaquine (AQ) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). A549, H4006, H358, H2122, H460 
and H157 NSCLC cell lines were obtained from ATCC and maintained in RPMI medium 
(Corning) supplemented with 10% FBS (Atlanta Biologicals), sodium pyruvate, penicillin-
streptomycin (Corning) at 5% CO2/37°C. Human embryonic kidney cell line (HEK-293) 
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was obtained from ATCC and maintained in DMEM medium (Corning) supplemented 
with 10% FBS (Atlanta Biologicals) and penicillin-streptomycin (Corning, NY, USA) at 
5% CO2/37°C. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
dichloromethane (DCM), dimethyl sulfoxide, coumarin-6, crystal violet dye, 16% 
paraformaldehyde (PFA) solution, HPLC grade methanol, acetonitrile (ACN) and water 
were purchased from Fisher Scientific (Hampton, NH, USA). Molecular biology kits, 
supplies, and antibodies were purchased from other commercial vendors which are listed 
at appropriate places throughout the manuscript. 
3.2.2. UPLC Method Development for Amodiaquine (AQ) 
A reverse-phase liquid chromatography method was developed for quantifying AQ using 
Waters series Acquity UPLC (Waters, USA). The column used was XselectTM HSS T3 (3.0 
× 100 mm; 2.5 μm particles). The mobile phase consisted of aqueous phase of 0.1% 
orthophosphoric acid in water, and organic phase of ACN at 50:50 at a flow rate of 0.5 
mL/min at 343 nm wavelength. Retention time was found to be 0.731 min with total run 
time of 1.5 min. Data were collected and analyzed using the Empower 3.0 software. 
3.2.3. Optimization of Process and Formulation variables using Design of 
Experiment (DoE) 
In this study, design of experiment (DoE) was used to develop nanoparticle formulations 
through which all potential factors were evaluated simultaneously, systematically, and 
quickly; using MINITAB statistical software (Minitab release 17, State College, PA, 
USA). Critical parameters such as probe homogenization speed and formulation variables 
involved in the formulation of nanoparticles were identified and were studied for their 
effect on drug loading which has been identified as a critical attribute while screening 
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through DoE approach. The aim was to establish Quality Target Product Profile (QTPP) 
for drug-loaded nanoparticles with optimal characteristics of (i) the highest drug loading 
(>3%), (ii) lower particle size (<250 nm), along with (iii) uniform size distribution 
(polydispersity index of <0.1). These specifications were established according to the 
intended route of administration i.e., inhalation route to ensure product safety and efficacy. 
A 32 randomized full factorial design, in which two factors (PEI concentration and 
homogenization speed) were studied at three levels (i) PEI concentrations – 0, 0.5 and 1% 
(w/v) (ii) homogenization speed– 6,000, 12,500 and 25,000 rpm. A design-space was 
estimated from these two factors (probe homogenization speed and PEI concentration), with a 
risk of failure limit of ±30 mV zeta potential and 600nm particle size. The levels were chosen 
based on the preliminary studies performed to formulate nanoparticles using high pressure 
homogenization. Homogenization pressure of 30,000psi, reverse flow pattern, and number 
of cycles of 7 to circulate the formulation was kept constant throughout the study. Reverse 
flow pattern refers to the configuration where inlet and outlet fluids flow in opposite 
direction resulting in maximum shear, cavitation and impact. This results in products of 
desired quality due to the efficient emulsification during each pass through the emulsifying 
cell (142). Experimental trials (n=3) were performed at all nine possible combinations; 
coded as A1-A9. From this set of experiments, an optimized formulation with the highest 
% drug loading (>3%) and lower particle size (<250nm) will be identified to establish the 
optimal parameters for further studies. Experimental trials of factorial design containing 
different combinations are shown in Table 1. The effect of different variables on three 
different responses [i.e. particle size (PS), zeta potential (ZP) and drug loading (%DL)] 
was investigated.  
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Optimized formulation, A6, with respect to predetermined particle size, zeta 
potential and entrapment efficiency, was subjected to further investigation to establish the 
optimal drug quantity to achieve QTPP as described earlier. Effect of different drug 
quantities (1, 2.5, 5 and 10 mg) on particle size, PDI, % entrapment efficiency (%EE) and 
% drug loading (%DL) is shown in Table 2. Formulations were coded as C1-C4. Other 
variables (including; formulation and operation parameters) were kept constant throughout 
the study. The association between dependent variables and responses was interpreted 
using response surface plots. 
 In brief, AQ NPs were formulated through high-pressure homogenization by 
modifying a method reported by Dong and Feng (143) with slight modifications. Briefly, 
coarse emulsion was prepared by homogenization of aqueous solution of AQ at 5mg/mL 
(Set I) or varying concentrations such as 2,5,10 and 20mg/mL (C1-C4) respectively and 
organic solution of PLGA RG-502H (20mg/ml of DCM) in aqueous 1% w/v PVA solution 
in 1X phosphate buffered saline (PBS; pH 7.4) with or without PEI at respective 
concentrations. Coarse emulsion was then processed through high-pressure homogenizer 
(Nano DeBee; BEE International, South Easton, MA, USA) at a pressure of 30,000psi for 
7 cycles. The obtained emulsion was subjected for overnight stirring to remove organic 
solvent. Next day, nanoparticles were washed twice using 1X PBS by centrifugation at 






3.2.4. Characterization of AQ NPs 
3.2.4.1.  Particle size, Poly Dispersity Index (PDI) and Zeta potential 
Particle size, PDI and zeta potential were measured by dynamic light scattering (DLS) 
using Zeta Sizer (Malvern Instruments, Malvern, UK). Formulations were diluted 100-fold 
with milli-Q water to obtain samples for measurement of size and zeta potential. The 
respective samples were loaded into the zeta cells (DTS 1070) and analyzed. 
3.2.4.2.  Drug Content 
To determine encapsulated drug amount in nanoparticle formulation, a direct vesicle lysis 
approach was carried out. To 20μL of formulation, 1,980µL of ACN:Water:DCM – 
98:1.5:0.5 was added followed by centrifugation for 45 min at 4°C at 21,000 RCF to lyse 
nanoparticles. Clear supernatant was collected, analyzed for the drug content using UPLC 
as described earlier and % EE/%DL was calculated. 
% 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%𝐸𝐸) = [
𝐷𝑟𝑢𝑔 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦
] × 100 
% 𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%𝐷𝐿) = [
𝐷𝑟𝑢𝑔 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 + 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑
] × 100 
3.2.4.3.   In-vitro Release Studies 
In-vitro release studies were performed for determining the drug release pattern from 
optimized AQ NPs using dialysis method as reported previously (53). Briefly, 10,000 
MWCO dialysis cassettes (Slide-A-Lyzer, 10,000 MWCO, 0.1–0.5 mL were 
preconditioned in PBS buffer (pH 7.4) for 10 min to allow them to get hydrated. Then, 
using syringe with 19G11/2 TW BD filter needle, 500µL of formulation was loaded into the 
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cassettes membrane though one of the ports. The cassettes were immersed in a beaker with 
150 mL of PBS buffer with 1% polysorbate 80 (pH 7.4; 37ºC) using a floater while stirring 
at a speed of 200 rpm. At regular time points of 0.5, 1, 2, 4, 8, 12 and 24 hours, samples 
were withdrawn with replenishing the dissolution medium with fresh PBS with 1% 
polysorbate 80. The amount of drug released was estimated using UPLC as discussed 
above. 
3.2.4.4.  Morphological Analysis using Scanning Transmission Electron Microscopy 
(STEM): 
Morphology of nanoparticles was studied by Scanning Transmission Electron Microscope 
(STEM) using FEI Talos F200x Transmission/Scanning Transmission Electron 
Microscope (S/TEM) equipped with A-Twin objective lens operating in STEM mode. The 
samples were prepared by placing 10µL of the sample solution carefully on a lacey carbon-
coated copper grids (300 mesh, Ted Pella Inc., Redding, CA, USA). The sample was 
allowed to adhere to the grid by subjecting it to air drying. The grids were then imaged 
using Smartcam digital search and view camera. 
3.2.4.5.  Solid State Characterization Studies: 
Powder X-ray Diffraction (PXRD) Studies: X-ray diffraction spectroscopy was carried 
out using XRD-6000 (Shimadzu, Kyoto, Japan). The diffractometry was performed by 
using a graphite monochromator consisting of copper-Kα1 radiation of wavelength 1.5418 
Å operating at 40 kV, 30 mA. The samples were spread uniformly on a glass micro sample 
holder and were analyzed in the range of 5 to 60° at the scanning speed of 2° (2θ)/minute. 
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Differential Scanning Calorimetry (DSC) Studies: The thermograms for AQ, AQ NP, 
blank NP and physical mixture of AQ and blank NP were generated using a DSC 6000 
(PerkinElmer, Inc; CT, USA) equipped with an intra-cooler accessory. An accurately 
weighed sample (1-5 mg) was sealed in an aluminum pan and analyzed over a temperature 
range of 30°C to 210°C and compared to a sealed empty aluminum pan maintained as 
reference. The heating rate was maintained at 10°C/min under a nitrogen purge having flow 
rate of 50 mL/min. 
3.2.4.6. In-vitro Aerosol Performance Lung Deposition Test: 
In-vitro lung deposition behavior of AQ NPs was evaluated using a M170 Next Generation 
Impactor™ (NGI: MSP Corporation Shoreview, MN, USA) in accordance with earlier 
published studies (144). The NGI was equipped with a stainless-steel induction port (USP 
throat adaptor) attachment and specialized stainless steel NGI™ gravimetric insert cups 
(NGI Model 170, MSP Corporation, Shoreview, MN, USA). AQ NP formulation (2 mL) 
was placed into a PARI LC PLUS® nebulizer cup of Pari FAST-NEB compressor system. 
(Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT, USA), which was attached 
to a customized rubber mouth piece connected to the NGI™. A Copley HCP5 vacuum 
pump (Copley Scientific, UK) was used to produce a flow rate of 15 L/min. Using a Copley 
DFM 2000 flow meter (Copley Scientific, UK), flow rate was adjusted before each 
experiment. In brief, 2 mL of formulation was nebulized with PARI LC PLUS® nebulizer 
which passed through induction port into the NGI using pump at a flow rate of 15 L/min 
for 4 min. Prior to running the NGI, the plates were refrigerated at 4°C for 90 minutes to 
cool the NGI plates. Samples were collected from each stage i.e. Stages 1-8 including throat 
and induction port as well which is important in determining emitted dose through rinsing 
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with ACN:water (75:25) and analyzed with established UPLC method for drug content and 
effective deposition at each stage. All experiments were performed in triplicate (n=3). Fine 
particle fraction (FPF, %) was determined as the fraction of emitted dose deposited in the 
NGI with dae< 5.39µm. Mass median aerodynamic diameter (MMAD, dae< 5.00µm) and 
geometric standard deviation (GSD) are the critical parameters for inhalation testing, and 
were calculated by quantifying the nanoparticle deposition at each stage in the NGI using 
log probability analysis (n=3) (144,145).  
3.2.5. Stability Studies 
Stability of the optimized AQ NP (C3) was evaluated while storing the samples at 
temperatures of 4ºC, 25ºC and 37ºC for four weeks as reported previously (53). Samples 
were withdrawn after week 1, 2, 3 and 4; diluted with water (100-fold) and analyzed for 
particle size, PDI and zeta potential using Malvern Zeta Sizer. Entrapment efficiency was 
determined by lysing the samples as described above using UPLC. All experiments were 
performed in triplicate. 
3.2.6. Cellular Uptake Studies 
Cellular uptake studies were performed using a protocol reported earlier (146). NPs for 
cellular uptake were formulated by replacing AQ with coumarin-6, a fluorescent dye, for 
easier tracking. In brief, A549 cells were plated in tissue culture treated cell imaging 8 
chambered cover glass (Eppendorf, Hauppauge, NY, USA) at a seeding density of 10,000 
cells/chamber followed by overnight incubation. Next day, cells were incubated with 
coumarin-6, coumarin-6 loaded nanoparticles at 1µg/mL concentration for 1 and 3 hours. 
After each interval, cells were washed with ice cold PBS twice and fixed with 4% PFA for 
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10 min. Fixed cells were washed again with ice cold PBS twice. Then, the chamber was 
removed and 20µL of vectashield hardset mount with DAPI nuclear stain (H1500, Vector 
laboratories, Burlingame, CA, UAS) was placed on a glass slide dropwise followed by 
placing a cover glass. After hardening of mounting medium through overnight at 4°C, slide 
was imaged using EVOS-FL microscope (Thermo Scientific, Waltham, MA, USA).  
3.2.7. Cytotoxicity Studies 
AQ NPs along with plain AQ were evaluated for their cytotoxicity in six different non-
small cell lung cancer (NSCLC) cell lines: A549, H157, H358, H2122, H460 and H4006 
as reported earlier with slight modifications (146,147). Briefly, cells were grown in FBS 
supplemented RPMI-1640 media as described in Materials section, and were seeded in TC 
treated 96-well plates (Eppendorf, Hauppauge, NY, USA) at a seeding density of 2,500 
cells/well (7,500 cells/cm2), incubated overnight for adherence at 37ºC/5% CO2, and 
treatments were added next day at different AQ concentrations ranging from 0.39-100µM. 
Corresponding volumes of AQ NPs were calculated based on the drug entrapment 
efficiency. Blank culture media was added as control. After 72 hours of incubation, % cell 
viability was determined by performing MTT assay as described earlier (147), by reading 
the absorbance of dissolved formazan crystals at 570nm (Tecan Spark 10M; Tecan, 
Männedorf, Switzerland). AQ and AQ NP were also tested for their cytotoxicity efficacy 
against A549 cells with different incubation periods of 6 and 12 hours. The safety of AQ 
NP formulations was determined by evaluating the cytotoxicity of Blank-NPs on human 
embryonic kidney (HEK-293) cell line. Briefly, cells were seeded into 96-well plates as 
described earlier and were incubated overnight followed by treatment with equivalent 
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amounts of Blank-NP corresponding to 10µM of AQ NP for 72 hours. % cell viabilities 
were determined through MTT assay as described earlier. 
3.2.8. Scratch Assay 
In-vitro scratch assay was used to study the cell migration. Briefly, scratches were created 
on a confluent cell monolayer. The cells on the edge of the scratch will migrate toward the 
center to close the scratch, thus establishing new cell-cell contacts. The assay was 
performed as previously reported (148). Briefly, A549 or H460 cells were plated in 24 well 
cell culture plates at a seeding density of 1 x 105 cells/well followed by overnight 
incubation. Next morning, scratches were made along the center of all wells with the help 
of a sterile p200 (200µL) pipette tip. All the wells were washed with PBS twice and 
reference markings were drawn near the scratch area from the bottom side of the plate with 
a fine tip marker. Then scratch images were captured within the marked area using inverted 
microscope (Laxco, Inc., Mill Creek, WA, USA) with 10X magnification. Later treatments 
of control, AQ, AQ NP (10μM) were added to the respective wells and incubated followed 
by imaging after 24 and 48 hours (A549); 24 and 120 hours (H460). The images captured 
were analyzed quantitatively to assess the inhibitory effect of nanoparticles on cell 
migration. Scratch width was measured from all wells using ImageJ software and % scratch 
closure was calculated further. 
3.2.9. Clonogenic Assay 
Clonogenic assay is an in-vitro cell survival assay which is based on the single cell’s 
capability to grow into a colony. Using this assay, the effectiveness of the AQ and AQ NPs 
toward colony inhibition was determined. The protocol reported previously (146,149) was 
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briefly modified and followed in this study. A549 or H4006 cells were seeded into 6-well 
cell culture plates at seeding density of 500 cells per well for each cell line. Plates were 
kept for overnight incubation to allow time for cells to adhere. Next day, media was 
replaced, and cells were treated with AQ or AQ NPs (10µM), or control for 48 hours after 
which media was replaced with fresh culture medium on alternative days for 7 days. On 
7th day, the colonies were stained with crystal violet. Briefly, the contents of the well were 
removed and washed with ice-cold PBS buffer twice followed by fixation with 4% PFA 
solution (in ice-cold PBS) for 10 min. Fixed cells were again washed with ice-cold PBS 
twice followed by staining with 0.01% (w/v) crystal violet solution with 1-hour incubation. 
After staining cells were washed with distilled water and images were captured using 
digital camera. Cell colonies were counted by colony counter software Open CFU (150).  
3.2.10. 3D Spheroid Study 
An effective NSCLC therapy is not only determined by enhanced cellular uptake or 
cytotoxic potential, but also improved penetrability of nanoparticles into solid tumors. 3D 
spheroid cell culture studies are capable of mimicking the in-vivo features of tumors as 
reported in our previous studies (147). Briefly, 2,000 cells per well were seeded in Nunclon 
Sphera 96-well U bottom plates, and were allowed to grow into solid tumor mass due to 
the shape of these ultra-low attachment cell culture plates. This in-vitro spheroid study was 
conducted through two kinds of models i.e. prophylactic and therapeutic models, differing 
in tumor growth and treatment strategies.  
In prophylactic study, 2,000 cells (A549) were seeded into each well of Nunclon 
Sphera 96 well ultra-low attachment treated spheroid microplates (Thermo Fisher 
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Scientific, Waltham, MA, USA) and incubated overnight under standard conditions of 
37°C/5% CO2. Next day, media was replaced with either fresh media (control) or respective 
treatment solutions of AQ or AQ NP to achieve 10 and 25 μM in the wells. On day 1, all 
the wells were observed for spheroid formation with a rigid margin. Images were captured 
using inverted microscope (Laxco, Mill Creek, WA, USA) on day 3, 5, 7 10 and 12. NIH 
ImageJ software was used to measure diameter of all the spheroids. Spheroids were treated 
on respective days by replacing half of the medium (100µL) from every well with 
respective treatments in a gentle manner to avoid the bubble formation and the aspiration 
of spheroid itself. 
In therapeutic 3D model, A549 cells were seeded into Nunclon Sphera plate at density 
of 500 cells/well and were incubated at 37°C/5% CO2. Then, all wells were observed for 
spheroid growth and images were captured on day 1, 3, 5 and 7. On day 7, spheroids were 
subjected to two kinds of dosing treatments i.e. a single dose and a multiple dose treatment. 
Briefly, both single and multiple dosing spheroids were treated with 20μM and 50μM 
concentrations of AQ and AQ NP (to maintain original concentrations of 10 and 25μM 
employed in the beginning), and images were captured. For single dosing, 100µL of media 
was replaced with fresh media on further days of imaging. For multiple dosing, wells were 
replenished with 10 and 25μM concentrations of AQ, AQ NP or fresh media (control). 
Images were captured on day 3, 7 and 10 and 15 days following treatment.  
3.2.11. Live-Dead cell assay 
Live-dead cell assay was performed on spheroids on day 15 of single and multiple dosing 
in therapeutic model according to manufacturer’s protocol. Briefly, 100 µL of 2µM calcein 
AM/4µM Ethidium homodimer III (EthD-III) staining solution was added to spheroids 
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after complete removal of media from the respective wells. The plate was incubated for 45 
min at room temperature. This provides green/red fluorescent staining of viable and dead 
cells, respectively. Images were captured using (EVOS-FL, Thermo Fisher Scientific) and 
mean green fluorescence intensity/mm2 of spheroid was quantified using ImageJ software 
which signifies the presence of live cells in spheroid mass. 
3.3. Mechanism of Action 
3.3.1. Autophagy Inhibition Microplate Assay 
Autophagy enables cancer cells to survive under micro-environmental stress conditions 
and promotes tumorigenesis (151). While AQ is a known autophagy inhibitor, it is crucial 
to determine the capability of AQ NPs to inhibit autophagy. Autophagy inhibition 
microplate assay was performed using CYTO-ID® Autophagy Detection Kit (Enzo Life 
Sciences, Farmingdale, NY, USA). In brief, A549 cells were plated at density of 2.5 x 
104 cells/well in 96 well plate (Fisher scientific, Hampton, NH, USA), and starved for 24 
hours in serum free media, and were later incubated with AQ 10µM, AQ NP 10µM or 
drug-free control for 18 hours. Treatments were replaced with 100µL of 1X assay buffer 
followed by addition of 100µL of dual color detection reagent (CYTO-ID® Green 
Detection Reagent + Hoechst 33342 nuclear stain in cell culture medium without phenol 
red indicator supplemented with 5% FBS). Plates were protected from light and incubated 
for 30 min at 37°C. Later, cells were washed with 200 µL of 1X assay buffer to remove 
excess dye. Then 100µL of 1X assay buffer was added to each well, and plates were read 
with a FITC filter (Ex ~480nm, Em ~530; green detection reagent), and with a DAPI filter 
set (Ex ~340nm, Em ~480nm; Hoechst 33342 Nuclear Stain). Here, CYTO-ID® Green 
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Detection Reagent serves as a bright fluorescent probe in vesicles produced during 
autophagy (152). 
3.3.2. Apoptosis: Caspase 3/7 Assay 
Apoptosis, or programmed cell death, plays a critical role in assessing the potency of drug 
delivery systems. Caspase-3 is one of the major markers of apoptotic cell death, which can 
be activated in apoptotic cells both by extrinsic and intrinsic pathways (153). AQ and AQ 
NP were tested for their cytotoxicity efficacy against A549 cells with different incubation 
periods as well. Representative graph related to their cytotoxicity after 6 and 12 hours can 
be found in Figure 17A. After 6 hours of incubation, no significant difference was 
observed between AQ and AQ NP in their cytotoxicity potential.  Hence, incubation period 
of 6 hour and treatment concentration of 10µM were chosen in performing the present 
assay. Caspase-3 activity was measured using EnzChek™ Caspase-3 Assay Kit 
(Molecular Probes, Eugene, OR, USA) and assay was performed as per manufacturer’s 
specifications. Briefly, A549 cells were seeded at a density of 1x106 cells per tissue 
culture dish (100 mm diameter) (Thermo Scientific, Rochester, NY, USA) and treated 
with AQ, AQ NP (10µM) or control for 6 hours followed by harvesting and washing of 
cell pellets. Cell lysis was carried out using 1X cell lysis buffer while subjecting to 
freeze-thaw cycle, followed by centrifugation at 3,000 RCF for 5 minutes. Supernatants 
obtained were transferred to 96 well plate to which 50µL of 2X substrate working 
solution (10mM Z-DEVD-AMC substrate + 2X reaction buffer) was added and 




3.3.3. In-vitro Angiogenesis study 
Angiogenesis or formation of new blood vessels from preexisting vasculature is a key 
process in some physiological conditions including cancer pathogenesis. Angiogenesis 
have a pivotal role in pathogenesis of NSCLC among other cancer kinds in the form of 
over-proliferation of blood vessels (155). To understand AQ loaded nanoparticles’ anti-
angiogenic ability, angiogenesis assay was performed as per manufacturer’s instructions 
(3470–096-K; R&D Systems, Minneapolis, MN, USA). Briefly, human umbilical vein 
endothelial cells (HUVEC: LONZA, Basel, Switzerland) cells were seeded into a T-25 
flask prior to performing angiogenesis assay. Next day, 50 μL of Cultrex® RGF BME 
was aliquoted into each well of a 96 well plate and incubated at 37 °C for 60 minutes to 
allow the BME to gel. HUVEC cells were then labeled with 2μM calcein AM; seeded at 
1.3x 104 cells/well on BME coated 96-well plates after preparing dilutions of AQ and 
AQ NP (10μM). Cells were incubated for 6 hours at 5% CO2/37 °C. Images were taken 
using fluorescence microscope (EVOS-FL, Thermo Fisher Scientific, Waltham , MA, 
USA) and tube formation was evaluated and quantified using NIH ImageJ software with 
the angiogenesis analyzer plug-in (156). 
Statistical Analysis: 
All data were addressed as mean ± SD or SEM, with n=3 unless otherwise mentions. Three 
trials of cytotoxicity studies were performed for each control or treatment with n=6 for 
each trial.  data Unpaired student’s t-test was used to compare two groups and one-way 
ANOVA followed by Tukey’s multiple comparisons test was used to compare more than 
two groups using GraphPad Prism software (Version 7.04 for Windows, GraphPad 
Software, San Diego, California USA). A p value of <0.05 was considered statistically 
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significant and was presented in data figures as a single asterisk (*). However, some studies 
have demonstrated a smaller p-value of 0.01 or less, which is included at respectively 
places. 
3.4. Results 
3.4.1. UPLC Method Development for Amodiaquine 
A rapid, UPLC method was developed for determination of AQ. Retention time was found 
to be 0.731 min with run time of 1.5 min. Peak was eluted with good resolution. A 
representative chromatogram is presented in Figure 4A. The method provided excellent 
linearity between 0.05 to 6 µg/ml. 
Optimization of Process and Formulation Variables using Design of Experiments 
(DoE): 
As presented in Table 3, adopted Minitab® 18 software provided a numerical optimization 
technique to produce set of formulations with anticipated responses such as lower particle 
size, positive zeta potential with highest % drug loading. The developed model of 
experimental runs for three quality attributes supported the proposed design space. Accordingly, 
the acceptable region that fulfills those targeted features is achieved when 1% or <1% (w/v) PEI 
is used in nanoparticle preparation. Results revealed that PEI concentration had great impact 
on particle size, zeta potential and % DL; each studied at three levels. As for particle size, 
it was found that particle size increased with increasing PEI concentration, at same 
homogenization speed, while positive zeta potential was observed only at PEI 
concentration of ≥0.5% w/v. % DL was found to be higher in case of 0.5% and 1% w/v 
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PEI. Positive charge density of PEI enhances encapsulation of weakly basic drug molecules 
such as AQ (157).  
Table 3: Composition and Characteristics of Amodiaquine Loaded Nanoparticles in a 32 
Full Factorial Design 
 
Results showed that coarse homogenization speed could only affect particle size; while 
having negligible effect on zeta potential and drug entrapment. Coarse homogenization at 
6,000 rpm resulted in smaller particle size compared to 12,500 and 25,000 rpm; at all PEI 
concentrations. Largest particle size (645.8±92.0nm) was observed in formula (A9); 
containing 1% PEI and homogenized at 25,000 rpm. At 0.5% PEI concentration, increase 
in speed from 6,000 to 25,000 rpm rendered a concomitant increase in the breaking energy, 
resulting in smaller emulsion droplets (158). For future investigations on effect of initial 
drug amount on PS, ZP, %EE and %DL, an optimized formula was selected through 
relating constraints between independent variables and dependent responses. The criteria 
for optimized formulation was set to be demonstrating the highest % drug loading (>3%) 






Loading X1 X2 
A1 -1 -1 211.57±37.5 0.33±0.2 -18.7±5.1 22.0± 7.8 0.9±0.3 
A2 -1 0 202±3.6 0.23±0.1 -13.0±1.8 24.8±10.9 1.0±0.4 
A3 -1 +1 195±5.5 0.22±0.0 -13.5±6.4 31.8±1.5 1.3±0.1 
A4 0 -1 382±60.1 0.30±0.2 10.2±5.9 41.5±2.6 1.7±0.1 
A5 0 0 453.73±88.9 0.38±0.1 7.3±3.3 77.2±28.4 3.1±1.1 
A6 0 +1 214.66±2.9 0.31±0.0 11.8±3.4 70.8±11.3 2.8±0.5 
A7 +1 -1 235.5±45.0 0.23±0.1 15.2±5.3 61.5±20.7 2.5±0.8 
A8 +1 0 544.2±70.6 0.41±0.1 14.2±12.2 51.1±12.9 2.0±0.5 
A9 +1 +1 645.76±92.0 0.35±0.1 17.9±5.7 78.5±3.5 3.1±0.1 
Coded 
Values 
Actual Values  
Drug Quantity: 2.5mg 
Polymer: PLGA 502H 
EAP: PVA 1% (w/v) 
Probe Homogenization Time: 10min 
X1- Polyethyleneimine concentration (%w/v) in EAP, X2-Probe 
Homogenization speed (RPM), EAP-External Aqueous Phase, PDI-Poly 
Dispersity Index 
X1 X2 
-1 0 6000 
0 0.5 12500 
+1 1 25000 
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and lower particle size (<250nm). According to obtained results, formulation A6 (0.5% 
PEI, 25,000 rpm) was selected for further optimization. Even though, A7 had the highest 
entrapment and lower particle size, it was not chosen considering the presence of highest 
concentration of PEI, a cationic polymer, with potential of intracellular toxicity. While both 
A5 and A6 exhibited significantly higher % drug loading (>3%), only A6 resulted in 
optimal particle size (214.7±2.9nm). Hence, parameters pertaining to A6 were chosen for 
further experimental trials to optimize drug quantity.  
 Results describing effect of varying initially loaded drug amount on particle size, 
zeta potential and entrapment efficiency are demonstrated in Table 4. From results, it can 
be observed that increasing initial drug loading led to subsequent increase in %EE and 
Figure. 4. A. UPLC chromatogram of amodiaquine. B. Effect of drug quantity on % 
drug loadings of AQ NP of amodiaquine   
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%DL. The highest %DL was observed in formula C3 and C4, loaded with (5 and 10 mg) 
amodiaquine; 4.0% for C3 and 5.7% for C4 respectively (Figure 4B). Formula (C3; further 
denoted as AQ NP) containing 5 mg amodiaquine was chosen to be the best achieved 
formulation, as it showed higher %EE (52.3%) compared to C4 (39.8%), thus indicating 
significantly less wastage of starting raw material, as seen in Table 4.  
Moreover, C3 was found to exhibit a particle size of 229.4nm with a PDI of 0.058 
i.e. an almost monodispersed nanoparticle formulation. These studies revealed that C3 
(AQ-NP) was able to meet the specification set as per QTPP. Hence, further in-vitro studies 
were performed using C3 formulation which is denoted as AQ NP. 















C1 1 222.9 0.2 11.3 35.3 0.6 
C2 2.5 211.5 0.1 10.1 65.7 2.6 
C3 5 229.4 0.1 17.8 52.3 4.0 
C4 10 229.9 0.2 14.3 39.8 5.7 
 
3.4.2. Characterization of AQ NPs  
3.4.2.1. Particle Size, Polydispersity Index (PDI), Zeta Potential 
Nanoparticle formulation (C3) was found to have a particle size, PDI and zeta potential of 
250.3±43.0nm, 0.18±0.1 and 16.96±1.0mV respectively. Formulations were found to have 
a positive zeta potential due to the presence of PEI. A histogram representing particle size 
distribution of C3 can be found in Figure 5A representing uniform particle size distribution 
with single peak. 
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3.4.2.2.  Drug Content: 
As shown in Table 3, A6 was found to be an optimized formulation among A1-9 with 
lower particle size and highest % DL. It was found that C3 had the highest % EE of 52.3% 
along with high % DL (4.0 %) as seen in Table 4 and Figure 5D. C3 was chosen for further 
studies and denoted as AQ NP. 
3.4.2.3.  In-vitro release studies: 
In-vitro release studies were performed to determine the drug release pattern from AQ NP 
(C3) in phosphate buffered saline (PBS; pH 7.4, 37°C) to mimic physiological fluid 
Figure 5. Physicochemical characterization of nanoparticles.  
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environment. The AQ NP (C3) was found to exhibit a controlled release pattern with about 
80% (85.3±6.4%) drug being released after 4 hours as shown in Figure 5B. This reveals 
the ability of nanoparticles to release drug completely in 4-8 hours after reaching 
physiological environment. 
3.4.2.4. STEM studies: 
A representative STEM image presented in Figure 5C indicated that the nanoparticles had 
uniform spherical shape with a smooth surface. As anticipated based on zeta potential 
measurement, no aggregation of nanoparticles was observed during STEM analysis. This 
reveals the uniform dispersion of nanoparticles in the formulation. These results agree with 
DLS measurements. 
3.4.2.5.  Solid State Characterization: 
Powder X-ray Diffraction (PXRD): Due to its crystalline nature, AQ showed distinct 
peaks at 2θ values of 19.88 and 25.88 in XRD spectra whereas there were no AQ peaks 
present in AQ NP indicating encapsulation of drug inside the nanoparticles as shown in 
Figure 5D. Results were found to be consistent with earlier studies of artesunate-
amodiaquine microparticles (159). Physical mixture of Blank NP and AQ also exhibited 
peaks inferring the crystalline nature of drug.  
Differential Scanning Calorimetry (DSC): The DSC studies were performed to 
understand melting and crystallization behavior of AQ when present in different forms 
such as NP encapsulated AQ, physical mixture with blank NPs, as compared to control. As 
can be seen in Figure 5E, thermogram of AQ showed a sharp endothermic peak at 166.8°C 
due to its melting transition. The absence of a sharp peak in AQ NP indicated complete 
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drug encapsulation in the nanoparticle formulation core and suggested a consistent result 
with that of XRD as discussed above. Results found to be consistent with earlier studies 
(160). 
3.4.2.6.   In-vitro Aerosol Performance and Lung Deposition: 
Once nebulized, aerodynamic properties of particles govern their deposition profile in the 
airways and alveolar deep lung regions. Using a next generation cascade impactor (NGI), 
crucial parameters to determine respirability of the nanoparticles were determined. Mass 
median aerodynamic diameter (MMAD), which describes the aerodynamic particle size 
distribution of an aerosol by mass, and geometric standard deviation (GSD), which 
describes the spread of the aerodynamic particle distribution, were determined. The 
MMAD of AQ NP was 4.7±0.1µm suggests that majority of the emitted dose will be 
Figure 6. In-vitro deposition profile of AQ NPs. A. Aerosol dispersion 
performance as % deposited on each stage of the NGI™. B. Cumulative % 
deposition plot representing cumulative % of particles deposited at each stage. 
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delivered to respirable region of the lungs, while the GSD was 2.0±0.4µm. The % fine 
particle fraction (FPF), also called the respirable fraction, was 81.0±9.1% as shown in 
Table 5 which suggests good aerosolization performance. Aerosol dispersion profile at 
each stage of NGI, and a graph representing % cumulative deposition respective to each 
stage can be seen from Figures 6A & 6B respectively. Particle size distribution is one of 
the most important parameters in inhalational delivery which determines efficiency of the 
delivery system to deliver the particles deep enough to the alveolar region (161). These 
data suggest that the prepared formulations possess all the characteristics to render them 
inhalable with deep lung deposition.  
Table 5: In vitro Aerosol Deposition Profile of Amodiaquine Nanoparticles.  
Formulation MMAD (µm) Recovery (%) FPF (%) GSD (µm) 
C3 4.7±0.1 72.8±25.1 81.0±9.1 2.0±0.4 
 
3.4.3. Stability Studies 
Stability is a major concern while dealing with nanosized drug delivery systems due to 
emulsion instability and particle aggregation (53). As shown in Figure 7, stability analysis 
data reveal that AQ NP formulation was stable at 4⁰ and 25⁰C, with no significant changes 
in particle size or zeta potential (Figures 7A & 7B). Here, the positive zeta potential of the 
AQ NP prevents the particles from coalescing and aggregating. There was no detrimental 
effect of temperature and storage time on entrapment efficiency either. Hence, the 
formulations were found to retain their physicochemical properties during their storage at 
different temperatures of 4°C and 25°C over a period of 4 weeks. Formulations stored at 
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37°C to expose them for temperature excursions (162) and were found to exhibit increased 
particle size which could be due to coalescence. However, regular labeled storage 
conditions do not include 37°C. 
3.4.4. Cellular Uptake Studies 
Figure 8 represents intracellular uptake of nanoparticle formulations using A549 NSCLC 
cells. In this experiment, AQ was replaced with fluorescent coumarin to make it possible 
to visualize the uptake and accumulation. Fluorescent images taken following 1- and 3-
hour incubation with coumarin loaded nanoparticles clearly demonstrated significant 
internalization compared to plain coumarin in A549 cancer cells even after 1-hour 
incubation period. It can also be observed that there was higher accumulation of the 
Coumarin-NP around the nucleus (DAPI stained), the most evident location for 
nanoparticle disruption and drug release inside the cells (163). Presence of positive charge 
Figure 7. Influence of storage temperature and length of storage on (A) particle 
size and (B) zeta potential of amodiaquine nanoparticles.  
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on the Coumarin-NP enables interaction of nanoparticles with cell surfaces (negatively 
charged), thus further resulting in efficient cellular internalization. 
3.4.5. Cytotoxicity Studies 
Cell viability studies were performed using MTT assay to evaluate the cytotoxic potential 
of AQ-loaded NPs versus plain drug. From this study, it was revealed that AQ cytotoxicity 
against NSCLC cell lines was significantly enhanced by nanoparticle encapsulation. 
Similar trend was found in all six NSCLC cell lines: A549, H4006, H157, H358, H2122 
and H460. Figure 9 illustrates the cytotoxic effects of AQ and AQ NP in all six NSCLC 
cell lines. The IC50 values for plain AQ and AQ NP were found to be 21.8±8.3µM, and 
Figure 8. Representative in-vitro cellular uptake of coumarin-6 loaded nanoparticles by 
A549 cells at two different time points; 1 h and 3 h. Scale bar 100μm.  
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9.4±2.1µM in A549 cell line; 14.4±1.6µM, and 1.9±0.5µM in H2122 cell line; 
22.5±2.3µM, and 16.3±2.8µM in H157 cell line; 28.8±17.7µM, and 10.3±10.2µM in H460 
cell line; 28.8±9.7µM, and 13.5±5.3µM in H4006 cell line; 35.7±9.7µM, and 13.6±8.0µM 
in H358 cell line respectively (Table 6).  
Smaller and consistent particle size and positive surface charge of AQ NP facilitates 
efficient internalization of nanoparticles resulting in more accumulation of nanoparticles 
inside the cells, thus leading to higher cytotoxic potential at the same dose. From 6 and 12 
hours cytotoxicity study, it was observed that toxicity towards A459 was found at In-vitro 
Figure 9. Inhibitory effects on different NSCLC cells after treatments with amodiaquine (AQ), 
and amodiaquine nanoparticle (AQ NP).  
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studies to establish safety of optimized nanoformulation were performed on HEK-293 
human embryonic kidney cell line. When HEK cell line was treated with blank drug-free 
AQ-NP equivalent nanoformulation equivalent to 10µM AQ for 72 hours, cell viability of 
>80% (81.7±12.4%) suggested that optimized AQ-NP was not toxic to HEK cells, in 
absence of the drug. The tested concentration of 10µM was chosen based on the observed 
IC50 values from cytotoxicity studies in NSCLC cell lines. These observations were 
expected since polymer used to prepare nanoparticles have long been known to produce 
little or no cytotoxicity. The safety profile of nanoparticles has been presented in Figure 
17B. 
Table 6: Comparison of IC50 for AQ and AQ NP in Different NSCLC cell lines. Data 
represent mean±SD (n=6) for 3 independent trials. 
Cell Line IC50 (µM) 
AQ AQ NP 
A549 21.8±8.3 9.4±2.1a 
H2122 14.4±1.6 1.9±0.5b 
H157 22.5±2.3 16.3±2.8c 
H460 28.8±17.7 10.3±10.2d 
H4006 28.8±9.7 13.5±5.3e 
H358 35.7±9.7 13.6±8.0f 
 
a, b, c, e, f:  ****; d: ****  
***p (α < 0.001), ****p (α < 0.0001) 
3.4.6. Scratch Assay 
Scratch assay is a well-established method to access cell-cell interaction, and cellular 
migration (148). For these experiments, a scratch was made as described earlier, cells were 
treated with AQ or AQ NP or fresh media (control), and images of scratched area were 
taken at respective time points.  
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Figure 10A represents images at 0, 24 and 48 hours following treatment in A549 
cells. After 48 hours, % scratch closure was found to be 97.2±0.1, 91.7 % ± 2.3 and 31.4% 
± 6.8 for control, AQ 10μM and NP 10μM respectively in case of A549 (AQ 10μM vs NP 
10μM; p<0.0001). From Figure 10A & 10B, it can be understood that scratches treated 
with control and AQ show migration of cells and those treated with AQ NP didn’t exhibit 
any significant cell migration or scratch closure. Similarly, AQ NP also inhibited scratch 
closure in case of H460 cell line as well, imaged at 0, 24 and 120hrs (not shown); respective 
Figure 10. In-vitro scratch wound healing assay with A549 cells treated with AQ and 
AQ NP with no treatment as a control. A. Shows representative images for indicated 
treatments. B. The graph shows % area closure of scratch after 24 and 48hrs. Scale Bar 
500μm. Images were taken at 10X magnification. 
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graph can be found in Fig 11. This indicates the efficacy of AQ NP with enhanced anti-
migratory effects, thus reducing the tumor metastasis probability. 
3.4.7. Clonogenic Assay 
Clonogenic assay is an in-vitro cell survival assay used to determine the colony formation 
capability of single cancer cells (164). AQ and AQ NP were evaluated for their long-term 
efficacy using clonogenic assay in two different NSCLC cell lines, A549 and H4006. From 
Figure 12A, it can be illustrated that colony growth was significantly inhibited by AQ NP 
compared to AQ, in both A549 and H4006 cell lines. After 48-hour treatment period and 
7-day incubation, % of colonies survived after treatment with 10µM AQ or AQ NP were 
94.5±15.5%, 27±3.0% (A549; Figure  12B, p<0.001); and 49.3±6.2%, 13.7±3.0% 
(H4006; Figure  12C, p<0.0001) respectively, considering number of colonies to be 100% 
in drug free treatment control wells (Figure  12B & C). The data suggest an approximately 
4-fold higher efficacy against cancer colony formation with AQ-loaded NPs as compared 
to plain AQ. This data may be considered a representative of AQ NP’s efficacy in 
Figure 11. A. In-vitro scratch wound healing assay with H460 cells treated 
with AQ and AQ NP with no treatment as a control. B. Prophylactic single 
dose spheroid study images. C (Single Dose), D (multiple Dose). 
Therapeutic spheroid study on 15th day of Post treatment 
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eliminating the possibility of tumor relapse, from single cancer cells left behind following 
chemotherapy and surgical intervention; and can well be linked to enhanced intracellular 
(and intratumoral) drug accumulation with nanoparticles formulation.  
3.4.8. 3D Spheroid Cell Culture Study 
A549 cell line was able to form spheroid masses from day 1 during culture, which indicated 
strong cell-cell communications. While preventive or prophylactic treatment assists in 
determining the treatment’s potential in inhibiting tumor growth, and may mimic therapy 
Figure. 12. A. Clonogenic assay images of A549 and H4006 cells B, C. Quantitative 
representation of clonogenic assay as % colony growth with AQ or AQ NP treatment 
as compared to control (B: A549, C. H4006). 
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following early diagnosis; therapeutic model represents traditional cancer therapy focused 
on reducing an already established tumor mass.  
Preventive (prophylactic) model involves plating of cells followed by overnight 
incubation and treatment on next day as soon as the cells accumulate to take shape of a 
conglomerated mass. Representative images for A549 cell line can be seen in Figure 11B 
(Day 0), where cells are seen to be loosely associated in the form of a mass. % Spheroid 
volumes 12 days after a single treatment with AQ & AQ NP (10 or 25μM) are shown in 
Figure 13A. As can be seen, on day 12 spheroid volumes for AQ NP treated groups were 
Figure. 13. A. 3D Prophylactic spheroid study on A549 cell line. B. Therapeutic Study 
Spheroid images of A549. C, D. Spheroid volume vs time (days) plot for single (C) and 
multiple dose (D) study. Scale bar for the images represents 400μM. 
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found to be significantly smaller than control volumes. Spheroid diameters (μm) and 
volumes (mm3) on day 12 after respective treatments were as follows respectively: Control: 
1,850.0±77.9μm, 3.3±0.4 mm3; AQ 10μM: 1,818.8±58.9μm, 3.2±0.3mm3; AQ NP 10μM: 
1,704.5±226.2μm, 2.7±0.9mm3. With time, spheroid volumes increased significantly in 
control groups. However, AQ-loaded NP inhibited spheroid growth significantly compared 
to plain AQ (p<0.001). Results revealed that nanoparticle formulation was able to inhibit 
the spheroid growth in NSCLC cell line (A549). 
In therapeutic spheroid model, cells were allowed to form tight cellular masses for 
a period of 7 days, as would be the case with late diagnosis of a well-established tumor. 
After tumor formation, spheroids were treated by either a single dose (one dose in the 
beginning) or a multiple dose (dosing every 3rd day, mimicking chemotherapy treatments).  
As can be seen Figure 13B, spheroids were found to achieve a diameter and 
spheroid volume of 1,835.4±97.4µm and 3.3±0.5mm3 on an average after 7 days of culture 
i.e. day 0 for the treatments. After 15 days of treatment, A549 spheroids of single dose 
study had spheroid volumes of 16.8±5.1mm3 (Control), 13.9±2.5mm3 (AQ 10μM), 
7.7±0.67 mm3 (AQ NP 10μM), 11.9±5.2mm3 (AQ 25μM), and 8.7±1.2 mm3 (AQ NP 
25μM), thus demonstrating significant growth inhibition as compared to both drug free 
treatment and plain AQ (Control vs AQ NP 10μM: p<0.01; AQ 10μM vs AQ NP 10μM: 
p<0.01; Control vs AQ NP 25μM: p<0.01) (Figure  13C; Single dose). Multiple dosing 
(every 3rd day treatment) also resulted in significant spheroid growth inhibition after AQ 
NP treatment compared to AQ (10μM: p<0.001; 25μM: p<0.05) (Figure 13D; Multiple 
dose). Interestingly, no significant reduction in tumor volume was observed with plain AQ 
treatment compared to AQ NP treatment groups for both single and multiple dose studies. 
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Line graphs representing spheroid volume comparison after single and multiple dosing can 
be found in Figure 13C&D respectively. Bar graphs representing spheroid volume 
(normalized to control) comparison can be seen in Figures 11C & 11D confirming superior 
tumor growth inhibition by AQ NP compared to control and plain AQ treatments. 
From the observed efficacy in both spheroid models, it was confirmed that AQ NP 
could inhibit tumor growth in earlier as well as later stages.  
3.4.9. Live-Dead Cell Assay 
Figure. 14. A, B. Live dead cell assay Images of A549 spheroids of therapeutic model 
(Single and multiple dosing respectively). C, D. The graph represents comparison of 
green fluorescence intensity/mm2 (live cells) of A549 spheroids. 
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This study assists in determining viable and dead cells within a solid spheroid mass. One 
of the main objectives of developing a drug-loaded nanocarriers is to facilitate drug’s entry 
into the deep core of the tumor, otherwise inaccessible to the plain drug. However, a 2D 
tumor diameter or volume measurement may not reveal a nanoformulation’s efficacy in 
killing tumor cells within the tumor core, as the spheroid masses may consist of a dead cell 
core surrounded by a well-established structural periphery of live cells. 3D spheroid masses 
were reported to comprise of different regions where cells undergo proliferation, 
quiescence and necrosis (165). 
Therefore, it is necessary to quantify live-dead cell portions out of a spheroid mass. Figure 
14A (single dose) & 14B (multiple dose) are representing terminal spheroid images on day 
15th after treatment.  
Like regular xenograft tumor in mice, 3D spheroids are also grown over an extended 
period, with intratumoral core regions going through lack of O2, and nutrients, resulting in 
presence of necrotic and quiescent cells in the core regions (165). Due to this, even control 
spheroids are likely to exhibit red fluorescence due to the presence of necrotic cells. While 
AQ-NP treatments demonstrated significant reduction in tumor volume and cellular 
viability, a reduced red fluorescence (dead cells) were seen with all AQ/AQ-NP treatments 
in Figure 14A &14B. This observation can be explained on the basis of loss of tumor 
integrity with AQ/AQ-NP treatment, resulting in removal of dead cells during media 
changes. However, green fluorescence (live cells)/mm2 of tumor surface area has been 
quantified, which represented distinct reduction in presence of live cells with AQ-NP 
treatment at both doses, in both single- and multiple-dose treatment (Figure 14C & 14D). 
Green fluorescence intensity comparison on day 15th day of single dose (AQ NP) post 
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treatment period revealed presence of live cells, 1.4-3.2 folds lower as compared to control 
and also there observed a clear reduction in live cell population compared to plain AQ 
treated groups (Figure 14C).  
For multiple dose study, AQ NP of 10μM and 25μM were found to exhibit 4.5-9-fold 
reduction in live cell population compared to control group. In addition, live cell 
population observed for AQ NP treated groups was found to be less compared to that of 
plain AQ groups (Figure 14D). For both single and multiple dose studies, live cell 
proportion was found to be lowered in case of nanoparticle group compared to plain AQ 
or control treated groups, indicating ability of AQ NP in inhibiting tumor cell proliferation. 
3.5. Mechanism of Action 
3.5.1. Autophagy Inhibition Microplate Assay 
AQ NP (10µM) treated cells exhibit accumulation of green fluorescent vesicles with higher 
intensity compared to cells treated with plain amodiaquine or starved media, as seen in 
Figure 15A (blue fluorescence represents Hoechst 33342 nuclear stain). Following 
normalization of data to control as 100%, relative fluorescence intensities, representing co-
localization of LC3 protein and thus accumulation of autophagosomes, were found to be 
126.2±1.4% (AQ), and 173.9±28% (AQ NP) after treating A549 cells for 18 hours (Figure 
15B). Increased green signal indicated accumulation of autophagic vesicles further 
confirming autophagy inhibition which leads to tumor growth due to blockade of this 





3.5.2. Caspase 3 Assay 
To evaluate induced active caspase-3 enzyme, cleavage product of a fluorogenic caspase 
substrate, DEVD-AMC was measured. The EnzChek® Caspase-3 Assay Kit allows the 
detection of apoptosis by assaying for increases in caspase-3 and other DEVD-specific 
protease activities (e.g., caspase-7). As seen in Figure 15C, increased caspase-3 activity 
was observed in A549 cells with nanoparticle treatment compared to plain drug and control 
(fluorescence intensity measurements – Control: 5063.3±1093.8, AQ 10µM: 
5018.0±1715.1; AQ NP 10µM: 7408.7±2095.9; AQ 25µM: 5664.7±1161.6; AQ NP 25µM: 
7096.7±1694.0) as seen in Figure 15C. However, the results were not found to be 
statistically significant (p>0.05). This experiment may signal toward presence of an 
alternate apoptotic pathway responsible for AQ’s tumor inhibiting properties. 
 
Figure. 15. A. Autophagy Inhibition Microplate Assay on A549 cells. B. Graph 
represents the comparison of relative fluorescence units (RFU) after incubating 
with respective treatments. C. Detection of caspase-3 levels in A549 cells using 
the EnzChek® Caspase-3 Assay.  
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3.5.3. In-vitro Angiogenesis Study 
Angiogenesis i.e. formation of new blood vessels is a paramount mechanism for tumor 
growth, with its inhibition being a major anti-tumor mechanism. Endothelial tube 
formation and inhibition can easily be determined and quantified by analyzing microscopy 
images. While significant tube formation was observed in HUVEC endothelial cells 
mediated tube formation assay with drug free treatment (negative control), neither plain 
AQ nor AQ NP appeared to inhibit the tube formation in-vitro (Figure 16). It was found 
that there was no potential angiogenesis inhibition activity suggesting the requirement of 
altered doses to exert their anti-angiogenesis activity or further investigation. 
 
Figure 16. In-vitro angiogenesis assay: Fluorescence microscopy imaging of capillary 
tube formation by HUVEC cells after treating with AQ, AQ NP or control. Scale Bar 
100 μm.  
Figure 17. Inhibitory effects on A549 cells after treatments with amodiaquine (AQ), 
amodiaquine nanoparticle (AQ NP). B. Safety studies: Cytotoxicity studies on HEK 




Nanoparticle drug delivery systems are promising carriers for both hydrophilic and 
hydrophobic anticancer drugs. Tseng et al developed gelatin nanoparticles with 
biotinylated epidermal growth factor conjugation for targeting lung cancer (167). Through 
standard manufacturing approaches such as ultra-probe sonication, there exists a difficulty 
in scaling up to a large commercial scale. Moreover, payload capacities for hydrophilic 
drugs are low in those cases. Hence, there is great need to explore scalable approaches to 
develop nanoparticles at a laboratory scale. High pressure homogenization (HPH) has been 
utilized to formulate nanoparticles due to its scale-up feasibility and reproducible product 
quality (120). HPH has been widely used in industries for large scale production of 
nanoemulsions and solid lipid nanoparticles (120). However, formulation of nanoparticles 
using HPH involves multiple complex parameters to consider while obtaining an optimized 
system. Both process and formulation parameters can be studied to develop an optimized 
system. Application of design of experiments (DoE) assists in identifying the critical 
parameters and their respective levels (118). Critical formulation parameter such as PEI 
concentration in external aqueous medium and critical process parameter such as probe 
homogenization speed were studied in the present study. For this, we have utilized 
multifactorial design to identify optimal levels related to pre-emulsion quality and cationic 
polymer concentration in the formulation while keeping all other optimized variables 
constant. Cationic polymer such as PEI is capable of imparting positive surface charge to 
the nanoparticle formulations. As drug repurposing provides an excellent opportunity to 
find novel anti-cancer uses for previously FDA approved drugs, a vital approach to explore 
them where toxicity and safety data is already available in the public domain (2,105), AQ 
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(FDA approved anti-malarial) has been chosen to formulate NPs using scalable HPH 
approach. Qiao et al have reported the anti-cancer efficacy of AQ in melanoma. But, till 
now there were no studies reporting the efficacy of AQ or AQ nanoparticles in NSCLC. 
Moreover, development of efficacious NPs against NSCLC using a scalable approach is of 
significant translational value. Optimized nanoparticle formulation was identified through 
DoE and used further to assess the efficacy in treating NSCLC. As shown in Table 3, effect 
of PEI concentration on NP particle size prepared at lower homogenization speeds of 
6,000rpm, formulations A1, A4, and A7 is not distinctive. Increasing trend of particle 
size/polydispersity was observed at medium homogenization speed of 12,500rpm with an 
increase in PEI concentration. Preparation of pre-emulsion at high speed of 25,000rpm 
resulted in the reduction of coarse emulsion globule size and allowed formation of smaller 
uniform sized nanoparticles. Increase in encapsulation efficiency at higher speed of 
homogenization was found to be significant at 0.5% of PEI concentration. This may be due 
to the fact that a unidirectional and less turbulent flow in case of lower speed may have 
resulted in loss of drug from the organic phase as reported earlier by Sharma et al (168). 
No significant effect of the drug quantity was observed on the particles size. However, the 
PDI, % entrapment efficiency (%EE) and overall drug loading was greatly affected by the 
drug quantities. With an increase of drug quantity from 1 to 10 mg, %EE declined 
drastically from 47.5% to 22.6%. It seems that at higher drug quantity, %EE was less, 
resulting in lower actual:theoretical drug loading ratio. A possible explanation is that the 
higher drug loading resulted in increased drug concentration gradient between the polymer 
matrix and outer aqueous phase, which in turn led to more drug loss in the fabrication 
process. The polymer itself may have a limited capacity to encapsulate the specific drug. 
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Beyond its maximum capacity, more drug may be wasted during fabrication process and 
the EE thus decreased correspondingly (169). Moreover, C3 formulation was found to 
exhibit particle size of <250nm, and PDI of <0.1 along with highest % drug loading of 
4.02. Hence, C3 formulation was identified as the monodispersed nanoparticulate system 
with optimal characteristics with and used for further studies. 
STEM images represented in Figure 5C revealed that the nanoparticles were of 
spherical shape with smooth surface with little or no aggregations indicating that the 
vesicles were uniformly dispersed. XRD and DSC studies as seen in Figure  5D&E were 
found to be consistent with earlier reports (159,160), and also revealed AQ encapsulation 
inside nanoparticles while being amorphous. 
Presence of positive charge on AQ NP surface refers to the stability of nanoparticles 
through inhibiting aggregation. STEM studies revealed that the nanoparticles were 
spherical in shape. Cationic surface charge of nanoparticles associates with higher cellular 
uptake and greater cytotoxicity in cancer cells (170). Intracellular uptake shown in Figure 
8 reveals the same where coumarin nanoparticles were internalized by A549 cells 
efficiently within an hour compared to plain coumarin solution. Due to smaller particle 
size, there is a possibility of NP aggregation. Hence, stability studies were performed to 
determine stability of AQ nanoparticles at different temperatures. Results revealed that 
there was no significant difference in particle size (Figure 7A), zeta potential (Figure 7B) 
and drug entrapment over 4 weeks indicating formulation integrity.  
Pulmonary route of administration is well known for its ability to deliver 
therapeutics locally to site of action but is challenged by major obstacles like poor control 
over deposition rates and site of inhaled molecules for efficacious delivery at the same 
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time. NPs exhibiting optimal in-vitro aerosol lung deposition can be administered 
via inhalation, facilitating local delivery to the deep lungs, thus resulting in reduced 
exposure to other organs and reduced adverse events. Nebulizers can deliver the 
formulations as small droplets which will be deposited in the lung airways based on their 
MMAD (137). PLGA polymer was chosen to formulate NPs due to its ability to produce 
small size systems, excellent stability, high cytocompatibility and rapid cellular uptake 
(171). Moreover, it has been well documented about the distribution of PLGA NPs within 
alveolar cells (172). In current study, MMAD value was found to be 4.7±0.1µm with 
72.8±25.1% FPF, confirming the respirability of formulated AQ nanoparticles and 
efficient lung deposition. Developed amodiaquine nanoparticles are capable of providing 
a promising strategy to overcome the physiological barriers involved in respiratory tract, 
and ensuring their capability to reach the respirable regions of the lung (137). 
Extensive in-vitro cell culture studies were carried out to investigate the efficacy of 
AQ NP against different NSCLC cell lines. Even though each of the NSCLC cell line used 
in cytotoxicity study has its own characteristics, it was found that a significant reduction in 
IC50 values was observed for AQ after encapsulating into nanoparticles in all 6 NSCLC 
cell lines as seen in Table 6 and Figure  9. This reveals the significant anti-cancer efficacy 
of AQ NPs among wide range of NSCLC types. This could be a result of efficient cellular 
internalization of nanoparticles. Generally, cell migration is an important characteristic of 
any cancer which involves the movement of cells from one location to another, associated 
with cancer metastasis (173). In this study, results from scratch assays seen in Figure 10B 
and Figure 11A revealed that amodiaquine nanoparticles had greater ability to inhibit cell 
migration significantly compared to amodiaquine in NSCLC cell lines. Clonogenic assay 
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study revealed that AQ NPs can inhibit the ability of single cells to form colonies. Hence, 
it ensures the effectiveness of AQ NP on long term basis while preventing tumor 
recurrence. Altogether, AQ NP could be further evaluated for their establishment in 
NSCLC treatment explicitly. 
Development of 3D in-vitro models is of utmost necessity today to mimic in-vivo 
solid tumor conditions which could be achieved by using specific low attachment spheroid 
plates as reported by Vaidya et al (146). From results seen in Figure 13A-D, it can be 
understood that nanoparticles were able to deliver the drug to spheroids’ core efficiently in 
both prophylactic and therapeutic model ensuring their clinical use. Drug-loaded 
nanoparticles facilitated the entry of drug into deep tumor core, which would otherwise be 
inaccessible for plain drug. Thus, the physicochemical properties of nanoparticles such as 
small particle size, charge or surface modifications are crucial in imparting good 
penetration behavior to them (174). It has also been reported in the literature that smaller 
the nanoparticle size, more efficient will be their transport within the tumor (175). In 
addition, live dead cell assay results confirmed ability of AQ NP to inhibit tumor cell 
proliferation in solid mass of spheroids leading to the diminished live cell proportion. In 
accordance with earlier report by Qiao et al (139), AQ exhibited autophagy inhibition with 
AQ NP demonstrating significantly higher efficacy in autophagy inhibition, potentially due 
to higher cellular internalization of the treatment (105). Here, distinct accumulation of 
autophagosmes was found indicating the inhibition of autophagy process. AQ causes an 
increase in lysosomal pH, which inhibits lysosome function and blocks fusion of 
autophagosomes with the lysosomes (139), thus conserving LC-3 protein and producing a 
positive signal in the CYTO-ID® Autophagy detection assay as seen in Figure  15A&B.  
77 
 
Apoptosis is referred to a programmed cell death. Caspases are cysteine proteases, 
which play a key role in apoptosis. They will be activated in presence of death inducing 
stimuli (141). From the results, it was observed that AQ NP treatment induced caspase-3 
levels, demonstrating their ability to induce cell death through apoptosis as well. However, 
the results weren’t significant indicating toward presence of an alternate cell death 
pathway. The tube formation assay is a fast, reproducible method for in-vitro measurement 
of angiogenesis, a major event in tumorigenesis (176). No significant difference was 
observed between AQ and AQ NP in their ability to inhibit tube formation compared to 
control indicating toward an alternate mechanism. 
As the major challenge being scale-up issue with development of nanoparticulate 
systems, exploring a scalable approach of HPH is of special interest for successful 
translation of nanomedicines. Moreover, optimal respirable properties of the developed 
NPs enable a local delivery into the lungs. Repurposing of anti-malarial drugs for cancer 
treatment could be a promising approach to target predominant processes such as 
autophagy and proliferation involved in NSCLC progress. By utilizing the advantage of 
drug repurposing, AQ was found to be an efficacious molecule against NSCLC with 
enhanced efficacy in an optimized NP identified by DoE. Taken together, results from the 
current study including in-vitro cell culture studies as well as 3D spheroid models 
illustrating their pronounced efficiency in NSCLC treatment. Within this study, the 
potential of scalable HPH approach in formulating amodiaquine nanoparticles and the 
repurposing feasibility of an anti-malarial drug to treat NSCLC has been evaluated through 
a systematic approach, and optimal in vitro cell culture studies. Altogether, no research 
work has been reported until today, which accomplishes a comprehensive task of bridging 
78 
 
the gap between laboratory scale and industrial scale manufacturing of nanoparticles while 
reducing development costs due to repurposing feasibility of amodiaquine, achieved in the 
present project.  
3.7. Conclusion 
With the present investigations, it can be concluded that inhalable nanoparticles of 
amodiaquine were successfully formulated and optimized using systematic approach of 
design of experiments by a scalable high-pressure homogenization (HPH) approach. As 
HPH approach is feasible for scale-up while providing reproducible results, developed 
nanoparticles can be easily scaled-up with ensured product quality. Despite involvement 
of multiple factors, by using a 32-factorial design, it was possible to develop an optimized 
formulation with ease.  In addition to cellular uptake studies, cytotoxicity studies and 3D 
spheroid studies, assays exhibiting the autophagy inhibition or apoptosis inhibition 
capability of amodiaquine nanoparticles are promising them as a potential treatment 
strategy for NSCLC. While the preliminary results are promising, large animal preclinical 











4. Development and Characterization of Transferrin Functionalized 
Amodiaquine Loaded Nanoparticles-Efficacy in Non-small Cell Lung Cancer 
(NSCLC) Treatment 
                     
Non-small cell lung cancer (NSCLC) is a malignant tumor type leading to very high 
mortality. Transferrin receptors are overexpressed in many NSCLC, playing a crucial 
role in cellular proliferation. Targeting these receptors through specific targeting 
ligands (Transferrin: Tf) is advocated to achieve superior anti-cancer efficacy. Thus, 
simpler conjugation of Tf enables specific targeting of overexpressed transferrin 
receptors on NSCLC cells, further facilitating targeted delivery of therapeutics. As per 
the previous studies as reported in Chapter 1, AQ was found to exhibit anti-cancer 
efficacy which is improved after nanoparticulate encapsulation, we aim to develop 
inhalable and scalable transferrin conjugated AQ-loaded nanoparticles for targeted and 
efficient NSCLC treatment regimen, using an efficient scalable process of HPH. 
4.1. Introduction 
Nanoparticulate drug delivery systems are contributing greatly to the design and 
development of various therapeutics to overcome various limitations of plain drug 
administration without any carrier system while improving the therapeutic efficacy (177). 
Recently, there has been a prominent escalation in nanomedicine approval encouraging 
further nanotechnology based research (178). Reports from several recent research studies 
have been signifying the capability of nano-based systems to deliver higher payload 
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amounts of therapeutics to the target site and enhance therapeutic benefits while reducing 
the toxicity related to free drugs (179). As a result, noted growing attention towards nano-
based pharmaceutical products is considered to be appropriate (178). Especially, these 
delivery systems are evolving rapidly with great emphasis on understanding the 
complexities involved in certain lung disorders such as cystic fibrosis, idiopathic 
pulmonary fibrosis (IPF) and lung cancer (127,180,181). Due to their nanoscale size, 
nanoparticles (NPs) have demonstrated their ability to deliver drugs efficiently to the tumor 
site in lungs while outperforming their free drug counterparts (179,182). Lung cancer is the 
leading cause of all cancer -related deaths and is responsible for approximately 1.38 million 
annual mortalities worldwide number of deaths (183). Being a highly prevalent indication 
and representing approximately 85% diagnosed lung cancer cases, exploring further 
advancements in treatments for non-small cell lung cancer (NSCLC) is of highest attention 
to the researchers (184).  
Properties of NPs, such as nanoscale size, favorable drug release profiles and high 
flexibility are allowing modification of properties such as shape, size, and surface charge 
(185). In addition, surface of the NPs can be modified through conjugating with targeting 
ligands of specificity towards cancer cells. These ligands can include, peptides, nucleic 
aptamers, vitamins, proteins, small molecules and monoclonal antibodies (186). Cancer 
cells necessitate more iron for their uncontrolled growth and proliferation, resulting in 
overexpression of transferrin-receptors (TFR) in several malignant tumors including 
breast, brain, prostate cancers including NSCLC (187). Cellular iron uptake takes place 
through interaction of transferrin (Tf) with TFR which can be used as a targeting site for 
cancer-specific drug delivery to enhance therapeutic efficacy against various cancer cells 
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that overexpress transferrin receptors (188,189). Utilizing targeted NPs in drug delivery 
establishes a platform for an efficient, tumor-specific interactions by interacting with 
receptors on the surface of cancer cells (190). Altogether, NPs are presenting potential 
candidates for therapeutic applications because of their ability to specifically target cancer 
cells while minimizing side-effects. However, systemic administration of these systems 
has its own drawbacks demanding an alternative delivery route for an efficient local drug 
delivery to the lungs (127).   
In recent times, inhalation therapy has gained importance as it facilitates efficient 
delivery of therapeutics to target tissues in the lungs (191). Local pulmonary inhalational 
delivery of anti-cancer drug loaded nanoparticulate system offers substantial benefits in 
lung cancer treatment as the most current systemic treatments are not very effective or 
cause associated side-effects (191,192). Delivering nanocarriers to the lung through an 
inhalation therapy is potential enough to result in enhanced local drug accumulation, 
prolonged pulmonary residence time, improved cellular internalization while minimizing 
exposure of healthy cells to the drugs (193,194). Furthermore, inhalable therapy may also 
enhance drug penetration into the tumoral mass due to sustaining  significantly higher drug 
concentration at the lung tumor site compared to other non-target sites (133). Several 
studies have evaluated the accumulation of drug-loaded nanocarriers in the lungs after 
pulmonary delivery and have reported improved efficacy of inhalable carriers in NSCLC 
(21). Other therapeutic applications of inhalational therapy include treatment and 
management of chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, 
inflammation and cystic fibrosis (195,196). Hence, inhalational therapy remains the 
mainstay of clinical treatment in the care of pulmonary diseases; and sought after for lung 
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cancer therapeutics. The efficacy of inhalation therapy depends on suitable drug and carrier 
system while considering the physicochemical properties of drug, formulation 
characteristics and the inhalation device (133).  
In the current study, amodiaquine, 4-[(7-chloroquinolin-4-yl) amino]-2- 
[(diethylamino) methyl] phenol (AQ) has been chosen to formulate PLGA-based 
transferrin-conjugated NPs using a scalable, reproducible high-pressure homogenization 
approach and to evaluate their anti-cancer efficacy. Drug repurposing facilitates 
identification of novel anti-cancer uses for old drugs for which toxicity and safety data is 
already available in the public domain (2,105).While AQ have been explored for its 
repurposing potential against NSCLC by our research group where superior efficacy of AQ 
through nanoparticle encapsulation was reported. In another study repurposing potential of 
AQ was highlighted through a structure-based screening approach (105).   
In the present study, the anticancer activity of Tf conjugated amodiaquine loaded 
nanoparticles (Tf-AMQ NP) against Tf-receptors expressing human non-small cell lung 
cancer cells has been evaluated. Targeting ligand transferrin was chosen in this study as 
the overexpression of transferrin receptors in non-small cell lung cancer is evident from 
the patient data meta-analysis (197). Process of functionalization/conjugation refers to the 
chemical addition of targeting ligand transferrin to enhance the target nanoparticles to the 
lung tumor tissue. Targeted nanoparticles were evaluated to verify the hypothesis that 
transferrin decorated NPs are capable of demonstrating superior efficacy in NSCLC 




4.2. Materials and Methods 
4.2.1. Materials 
Poly (lactic-co-glycolic) (PLGA 50:50, 7-17 kDa, acid terminated), poly vinyl alcohol 
(PVA), and amodiaquine (AQ) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
A549 and H1299 NSCLC cell lines were obtained from ATCC (Manassas, VA, USA) and 
maintained in RPMI-1640 medium (Corning) supplemented with 10% FBS (Atlanta 
Biologicals, R&D Systems, Minneapolis, MN, USA), sodium pyruvate, penicillin-
streptomycin (Corning, NY, USA) at 5% CO2/37°C. Human embryonic kidney cell line 
(HEK-293) was obtained from ATCC and maintained in DMEM medium (Corning) 
supplemented with 10% FBS (Atlanta Biologicals) and penicillin- streptomycin (Corning, 
NY, USA) at 5% CO2/37 °C. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), dichloromethane (DCM), dimethyl sulfoxide (DMSO), coumarin-6, 
crystal violet dye, 16% paraformaldehyde (PFA) solution, Triton X100, HPLC grade 
methanol, acetonitrile (ACN) and water were purchased from Fisher Scientific (Hampton, 
NH, USA). Molecular biology kits, supplies, and antibodies were purchased from other 
commercial vendors which are listed at appropriate places throughout the manuscript. All 
other solvents including UPLC grade chemicals and solvents, unless it is otherwise 
specified, were purchased from Fisher Scientific (Hampton, NH, USA). 
4.2.2. Development of UPLC method for Determination of Amodiaquine (AQ) 
A reverse-phase liquid chromatography method was developed for quantifying AQ using 
Waters series Acquity UPLC (Waters, USA). Detailed description of method was reported 
in our recent publication (198). 
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4.2.3. Calibration curve for Texas Red-Transferrin 
Standard solutions of 0.4, 0.8, 1.6, 3.1, 6.3, 12.5, 25, 50 and 100 µg/ml were prepared by 
diluting with DMSO: water (1:2.5).  Fluorescence intensity was measured at 
excitation/emission 590/635nm using SPARK Tecan plate reader (Tecan Spark 10M; 
Tecan, Männedorf, Switzerland).  The calibration curve was constructed between 
concentration of Texas-Red Transferrin (Tf) and fluorescence intensity values. 
4.2.4. Synthesis of Transferrin conjugated PLGA 
Target-specific drug delivery coupling of Tf ligand to nanoparticle has been carried out by 
employing a surface-activation method as reported earlier with slight modifications (199). 
In brief, PLGA polymer (PLGA Resomer 502H; 10mg) Tf was activated by EDC-NHS 
chemistry (0.25 mL of EDC and NHS solutions in DMSO at 1mg/mL concentration) 
through stirring at room temperature for 4 hours. Activated PLGA will be recovered by 
addition of 4mL of water and centrifugation at 10,000 rpm for 10min. For Tf conjugation, 
activated PLGA was dissolved in DMSO followed by dropwise addition of 100 μl of Texas 
Red-Transferrin (Tf) (1 mg/ml), agitation for 2 hours, and then incubated overnight at 4°C. 
Excess of Tf will be removed the next day by centrifugation. Collected conjugated PLGA 
after centrifugation at 10,000 rpm for 30min was utilized in the formulation of 
nanoparticles. The supernatant obtained was analyzed for unconjugated Tf using the 
standard curve obtained. 
4.2.5. Formulation of Tf Conjugated AQ NPs (Tf-AMQ NPs) 
Non-targeted and transferrin conjugated amodiaquine nanoparticles were formulated 
through HPH process. In brief, nanoparticles were formulated through high pressure 
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homogenization using an established, recently published method from our research group 
(198) with slight modifications. Briefly, AQ-loaded nanoparticles were prepared by using 
organic solution of polymer PLGA 502H (20mg/1ml of DCM, aqueous solution of AQ 
(2.5mg/0.5ml), a stabilizer (20ml of 1% w/v polyvinyl alcohol solution in PBS). Tf-
conjugated NPs were formulated using both non-conjugated and Tf-conjugated PLGA at 
(5:1) ratio while other formulation components are the same as for non-targeted AQ-loaded 
NPs. A stable pre-emulsion was formed by use of a probe homogenizer at 25,000 RPM for 
10 minutes. Then, pre-emulsion was processed through high-pressure homogenizer (Nano 
DeBee®) at homogenization pressure of 30,000 psi and seven number of cycles to 
recirculate the formulation with reverse flow pattern. These process parameters have been 
chosen based on our previous investigations as reported in our recent publication (198). 
Later, formulations were subjected for overnight stirring for organic solvent removal 
followed by washing of nanoparticles for removal of excess PVA. 
 
4.2.6. Characterization of Tf-PLGA using Fourier Transform Infrared 
Spectroscopy (FT-IR) 
 FT-IR spectrum of PLGA, Tf and Tf-PLGA were obtained using FT-IR (Perkin Elmer, 
Inc., Branford, CT, USA). Organic solvent, DMSO (PLGA, Tf-PLGA) or milliQ water (for 
Tf) were used for background correction and 10 μL of samples were used for detection. 
Different peaks in plotted IR spectrum were then interpreted to detect the presence of 





4.2.7. Determination of Conjugation Efficiency 
Supernatants were analyzed for the florescence intensity measured at excitation/emission 
590/635nm using Tecan plate reader (Tecan Spark 10M; Tecan, Männedorf, Switzerland). 
Texas red Transferrin was conjugated to PLGA by formation of an amide bond between 
an amine and a hydroxyl group. The bond cleavage was carried out by using esterase 
enzymes from porcine liver (Esterase from porcine liver: E3019-20KU, Sigma Aldrich,) to 
analyze Texas red Transferrin present in the nanoparticles. Esterase of 40 U/ mL in PBS 
(pH 7.4) was used in this experiment using a previously reported method with slight 
modifications. Briefly, esterase enzyme (0.5ml) and Tf-AMQ NP formulation (diluted 10-
fold) were added to a tube in the ratio of and samples were shaken at 37°C for 72 hours. A 
control tube was maintained with AMQ NP formulation and enzyme at the same ratio in 
the same conditions. After 72 hours, samples were centrifuged (3000 x g, 5 min) using 
MWCO centrifugal filters and the collected supernatant was analyzed at Ex/Em 
590/635nm using Tecan plate reader (Tecan Spark 10M; Tecan, Männedorf, Switzerland). 
4.2.8. Physicochemical characterization: Particle size, PDI and Zeta potential 
Physicochemical properties such as size, polydispersity, and surface charge of AMQ NP 
and Tf-AMQ NPs were measured using Malvern® zeta-sizer. Drug loading efficiency was 
measured using Waters UPLC by quantifying AQ. 
4.2.9. Drug Content 
Encapsulated drug amount in nanoparticle formulation was determined using a direct 
vesicle lysis approach. To 20μL of formulation, 1,980 µL of ACN:water:DCM – 98:1.5:0.5 
was added followed by centrifugation for 45 min at 4°C at 21,000 x g to lyse nanoparticles 
87 
 
and to acquire loaded drug into the analyzing solution. Obtained supernatant was analyzed 
for the drug content using UPLC and % EE/%DL was calculated. 
% 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%𝐸𝐸) = [
𝐷𝑟𝑢𝑔 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦
] × 100        (Eq. 1) 
% 𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%𝐷𝐿) = [
𝐷𝑟𝑢𝑔 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑝𝑜𝑙𝑦𝑚𝑒𝑟+𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑
] × 100                          (Eq. 2) 
4.2.10. In-vitro Release Studies 
In-vitro release studies were performed for determining the drug release pattern from 
optimized AQ-loaded NPs using dialysis method as reported previously (53). Briefly, 
10,000 MWCO dialysis cassettes (Slide-A-Lyzer, 10,000 MWCO, 0.1–0.5 mL, Thermo-
Scientific, Waltham, MA) were preconditioned in PBS buffer (pH 7.4) for 10 min to allow 
them to get hydrated. Then, using syringe with 19G11/2 TW BD filter needle, 200µL of 
formulation was loaded into the cassettes’ membrane though one of the ports. The cassettes 
were immersed in a beaker with 100 mL of pH 5.5 buffer with 1% polysorbate 80 (37ºC) 
using a floater while stirring at a speed of 200 rpm. At regular time points of 0.5, 1, 2, 4, 
6, 8, 24 and 48 hours, samples were withdrawn with replenishing the dissolution medium 
with fresh pH 5.5 buffer with 1% polysorbate 80. The amount of drug released was 
estimated using UPLC. 
4.2.11. Morphological Analysis 
Imaging of unconjugated and conjugated amodiaquine nanoparticles was performed using 
transmission electron microscopy (TEM) for assessing nanoparticles’ morphology. The 
Formvar® carbon-coated copper grids 400-mesh (Electron Microscopy Sciences, PA, 
USA) were made hydrophilic using glow discharge plasma treatment for 60s. About 5µL 
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of diluted nanoparticles sample was added to the grid and allowed to adhere for 1 minute. 
The samples were negatively stained by adding 5 µL of uranyl acetate (1%) and excess 
was removed by using Whatman filter paper after 30s. This process was repeated twice and 
the sample was finally allowed to air dry. The grids were then imaged using Tecnai Spirit 
TWIN TEM operated at 120 kV voltage. 
4.2.12. Solid-state Characterization Studies 
Powder X-ray Diffraction (PXRD) Studies: The samples were first lyophilized into dry 
powders using Labconco FreeZone® freeze dryer system. X-ray diffraction spectroscopy 
was carried out using XRD-6000 (Shimadzu, Kyoto, Japan). The diffractometry was 
performed by using a graphite monochromator consisting of copper-Kα1 radiation of 
wavelength 1.5418 Å operating at 40 kV, 30 mA. The samples were spread uniformly on 
a glass micro sample holder and were analyzed in the range of 5 to 60° at the scanning 
speed of 2° (2θ)/minute. 
Differential Scanning Calorimetry (DSC) Studies: The thermograms for AQ, AMQ NP 
and Tf-AMQ NP were generated by closed pan technique using a DSC 6000 (PerkinElmer, 
Inc; CT, USA) equipped with an intra-cooler accessory. An accurately weighed sample 
(2mg) was sealed in an aluminum pan and analyzed against a sealed empty aluminum pan 
maintained as reference. Study was performed over a temperature range of 30°-210°C The 
heating rate was maintained at 10°C/min. 
4.2.13. Stability Studies 
Stability of Tf-AMQ NPs was evaluated while storing the triplicate samples at 
temperatures of 4ºC (storage temperature) and 25ºC (room temperature) for 4-week period 
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as reported previously (53). Aliquot of each sample was withdrawn at the end of week 1, 
2, 3 and 4; diluted with water (100-fold) and analyzed in terms of particle size, PDI and 
zeta potential using Malvern Zeta Sizer as described earlier. % entrapment efficiency was 
determined by lysing the samples using UPLC.  
4.2.14. In vitro Aerosol Performance Lung deposition test 
In-vitro aerosol lung deposition was assessed using Next Generation Impactor™ (M170 
NGI: MSP Corporation, Shoreview, MN, USA) according to previously published studies 
(198). NGI can categorize particles based on their size which is useful in predicting in-vivo 
deposition of particles (200). Briefly, prior to operation, NGI plates were placed in 
refrigerator (4°C; 90 min) for pre-conditioning NGI to minimize solvent evaporation 
during the process. 2 ml AMQ NP or Tf-AMQ NP formulation was then loaded into a 
PARI LC PLUS® nebulizer cup attached to a customized rubber mouth-piece connected to 
the NGI™. A Copley HCP5 vacuum pump (Copley Scientific, Nottingham, UK) was used 
to produce a flow rate (15 L/min; 4 min). After the run, samples were collected from every 
stage (1-8) as well as from throat and induction port by using ACN: water (75:25) for 
rinsing. Samples were centrifuged for 45 min at 21,000 x g, and lysed supernatant was then 
analyzed using previously established UPLC method.  
4.2.15. Determination of Targeting Capability 
4.2.15.1. Cellular Uptake Studies 
Cellular uptake studies were performed in order to determine the effect of NP loading and 
transferrin targeting on intracellular uptake of the drug encapsulated using a protocol 
reported earlier (201). NPs for cellular uptake were formulated by replacing AQ with 
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coumarin-6 (1mg), a fluorescent dye since it offers simple and sensitive detection for easier 
tracking while it has been frequently used in cellular uptake studies of PLGA nanoparticles. 
In brief, A549 or H1299 cells were plated in 8 chambered tissue culture (TC) treated cell 
imaging cover glass (Eppendorf, Hauppauge, NY, USA) at a seeding density of 10,000 
cells/chamber followed by overnight incubation. Next day, cells were incubated with 
coumarin-6, coumarin-6 loaded unconjugated and Tf conjugated nanoparticles at 1 µg/mL 
concentration in fresh culture medium for 3 and 24 hours. At each time point (3- and 24-
hours), cells were washed with ice cold PBS twice and fixed with 4% paraformaldehyde 
(PFA) for 10 min. Fixed cells were washed again with ice cold PBS twice. Then, the 
chamber was removed and 20µL of vectashield hardset mount with DAPI nuclear stain 
(H1500, Vector laboratories, Burlingame, CA, UAS) was placed on a glass slide dropwise 
followed by placing a cover glass. After hardening of mounting medium overnight at 4°C, 
slides were imaged using EVOS-FL microscope at 20X magnification (Thermo Scientific, 
Waltham, MA, USA).  
4.2.15.2. Quantification of Cellular uptake by Determining Fluorescence Intensity: 
A549 or H1299 cells were seeded into 24-well assay plates at 1 x 105 cells/well. Once, the 
cells reach confluency, incubated them with 1ml at 1μg/ml concentration of coumarin, 
coumarin-loaded NPs and transferrin conjugated coumarin nanoparticles at 5% CO2/37°C 
for 3 or 24 hr. At each time interval (3- and 24 hour), media was removed from the wells 
and washed three times with ice-cold PBS. Cells were harvested using trypsin and to the 
obtained cell pellets, 100 μl of 0.5% Triton X-100 was added for cell lysis. These samples 
were kept for sonication for one hour at 4°C. The fluorescence intensity of supernatants 
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from each sample was measured for coumarin quantification at Ex/Em 420/465nm (Tecan 
Spark 10M; Tecan, Männedorf, Switzerland). 
4.2.16. Cytotoxicity Studies 
AMQ NP, Tf-AMQ NPs along with plain AQ were evaluated for their cytotoxicity in two 
non-small cell lung cancer (NSCLC) cell lines: A549 and H1299 as reported earlier with 
slight modifications (59,202). Both of these immortalized NSCLC cell lines were reported 
to exhibit overexpression of transferrin receptors (107). In brief, cells were grown in FBS 
supplemented RPMI-1640 media as described in Materials section, and were seeded in TC 
treated 96-well plates (Eppendorf, Hauppauge, NY, USA) at a seeding density of 2,500 
cells/well (7,500 cells/cm2), incubated overnight for adherence at 37°C/5% CO2, and 
treatments were added next day at different AQ concentrations ranging from 0.39-50 µM. 
Corresponding volumes of AMQ NP and Tf-AMQ NPs were calculated based on the drug 
entrapment efficiency. Untreated cells were used as a control. After 72 hours of incubation, 
% cell viability was determined by performing MTT assay as described earlier (20), by 
reading the absorbance of dissolved formazan crystals at 570 nm (Tecan Spark 10M; 
Tecan, Männedorf, Switzerland). Further cytotoxicity studies were performed following 
same protocol to evaluate the safety of drug-free nanoparticles (A549 and HEK) using 
equivalent amounts of Blank NP at concentrations of 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25 






4.2.17. Clonogenic Assay 
Clonogenic assay is an in-vitro cell survival assay which is based on the single cell’s 
capability to grow into a colony. Using this assay, the effectiveness of the AQ, AMQ NP 
and Tf-AMQ NP toward colony inhibition was determined. The protocol reported 
previously (20,149) was briefly modified and followed in this study. A549 or H1299 cells 
were seeded into 6-well cell culture plates at seeding density of 5 x 102 cells per well for 
each cell line and incubated overnight at 37°C (5% CO2) Then, media was replaced, and 
cells were treated with AQ, AMQ NP and Tf-AMQ NP (10µM), or control for 48 hours 
followed by its replacement with fresh culture medium on alternative days for 7 days. On 
7th day, the colonies were stained with crystal violet as reported earlier (20). After staining 
cells were washed with distilled water. Colonies were photographed using digital camera 
and were counted by colony counter software Open CFU (150).  
4.3. Mechanism of Action 
4.3.1. Autophagy Inhibition Assay 
Autophagy enables cancer cells to survive under micro-environmental stress conditions 
and promotes tumorigenesis (151). While AQ is a known autophagy inhibitor, it is crucial 
to determine the capability of AMQ NP and Tf-AMQ NPs to inhibit autophagy. Autophagy 
inhibition microplate assay was performed using CYTO-ID® Autophagy Detection Kit 
(Enzo Life Sciences, Farmingdale, NY, USA) as reported earlier (60). In brief, A549 cells 
were plated at density of 1.0 x 104 cells/well in 96 well plate (Fisher scientific, Hampton, 
NH, USA)  and starved for 24 hours in serum free media, and were later incubated with 
25µM of AQ, AMQ NP and Tf-AMQ NP or drug-free control for 18 hours. Treatments 
were replaced with 100µL of 1X assay buffer followed by addition of 100µL of dual color 
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detection reagent (CYTO-ID® Green Detection Reagent + Hoechst 33342 nuclear stain in 
1X assay buffer). Plates were protected from light and incubated for 30 min at 37°C. Later, 
cells were washed with 200 µL of 1X assay buffer to remove excess dye. Then 100 µL of 
1X assay buffer was added to each well, and plates were read with a FITC filter (Ex ~480 
nm, Em ~530; green detection reagent), and with a DAPI filter set (Ex ~340 nm, Em ~480 
nm; Hoechst 33342 Nuclear Stain). Here, CYTO-ID® Green Detection Reagent serves as 
a bright fluorescent probe in vesicles produced during autophagy (152). 
4.3.2. Apoptotic Assay 
Apoptosis, or programmed cell death, plays a critical role in assessing the potency of drug 
delivery systems. Caspase-3 is one of the major markers of apoptotic cell death, which can 
be activated in apoptotic cells both by extrinsic and intrinsic pathways (153). Caspase-3 
enzymatic activity was measured using EnzChek™ Caspase-3 Assay Kit (Molecular 
Probes, Eugene, OR, USA) as reported earlier (203). Briefly, A549 or H1299 cells were 
seeded at a density of 1x106 cells per tissue culture dish (100 mm diameter) (Thermo 
Scientific, Rochester, NY, USA) followed by treatment with AQ, AMQ NP, Tf-AMQ 
NP (25µM) or control for 6 hours. Then, cells were harvested and cell pellets were 
washed with ice-cold PBS followed by cell lysis using 1X cell lysis buffer. Lysed pellets 
were centrifuged and supernatants obtained were transferred to 96 well plate to which 
50 µL of 2X substrate working solution (10mM Z-DEVD-AMC substrate + 2X reaction 
buffer) was added and incubated for 20 min. Fluorescence was measured at 
excitation/emission 360/460nm (154). Control without enzyme was used to estimate the 
background florescence of substrate in each assay. 
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4.4. 3D Spheroid Cell Culture Studies 
Tumor microenvironment plays an important role in its progression and development. This 
can be explored by developing 3D spheroids, which would simulate the 
microenvironmental tumor conditions and thus serve as a important tool for improving 
relevance to in vitro results. An effective NSCLC therapy is not only determined by 
enhanced cellular uptake or cytotoxic potential, but also improved penetrability of 
nanoparticles into solid tumors. 3D spheroid cell culture studies are capable of mimicking 
the in-vivo features of tumors as reported in our previous studies (20,42,147). Briefly, cells 
were seeded in in Corning® ultralow attachment spheroid 96-well plate (Corning, NY, 
USA) at a seeding density of 2 x 103 cells: A549, 2.5 x 103 cells: H1299 per well and were 
incubated overnight at 37°C/5% CO2. For later 3 days, spheroids were allowed to grow 
into solid tumor mass due to the shape of these ultra-low attachment cell culture plates as 
published in our studies (204). On day 3, all the wells were observed for spheroid formation 
with a rigid margin. In case of A549, images were captured using inverted microscope 
(Laxco, Mill Creek, WA, USA). Next day, media was replaced with either fresh media 
(control) or respective treatments of AQ, AMQ NP or Tf-AMQ NP. Briefly, spheroids were 
treated with 20 μM concentration of AQ, AMQ NP and Tf-AMQ NP (to maintain original 
concentrations of 10 μM employed in the beginning), and images were captured. Only half 
the volume of media (100µL) was replenished to avoid any chance of tumor aspiration of 
media was replaced with fresh media in a gentle manner to avoid the bubble formation and 
the aspiration of spheroid itself. on further days of imaging. Images were captured on day 
1, 3, 6 and 9 and 12 days following treatment. NIH ImageJ software (Version 1.44) was 
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used to measure diameter of all the spheroids and spheroid volumes were calculated. 
H1299 spheroids were imaged using live-dead cell staining on Day 15. 
4.4.1. CellTiter-Glo Luminescent Cell Viability Assay 
CellTiter-Glo cell viability assay was performed using a commercially available kit 
(CellTiter-Glo®, Promega, Madison, WI, USA) to determine viable cells in spheroids of 
day 12 as per the manufacturer’s protocol. On day 12, 100μL of medium was removed and 
replaced with 100μL of CellTiter-Glo® 3D reagent in each well (n=3 for each treatment 
group). The contents were mixed for 2 min, followed by incubation at room temperature 
for 30 min. The luminescence was measured using Spark 10 M plate reader (Tecan, 
Männedorf, Switzerland). 
4.4.2. Live-Dead Cell Assay 
Live-dead cell assay was performed on H1299 spheroids on day 15 according to 
manufacturer’s protocol. Briefly, 100 µL of 2µM calcein AM/4µM Ethidium homodimer 
III (EthD-III) staining solution was added to spheroids after complete removal of media 
from the respective wells. The plate was incubated for 45 min at room temperature. Green 
fluorescent staining represents viable cells. Images were captured using (EVOS-FL, 
Thermo Fisher Scientific). 
Data Analysis and Statistical Evaluation 
 All data were addressed as mean ± SD or SEM, with n=3 unless otherwise mentions. Three 
trials of cytotoxicity studies were performed for each control or treatment with n=6 for 
each trial data. Unpaired student’s t-test was used to compare two groups and one-way 
ANOVA followed by Tukey’s multiple comparisons test was used to compare more than 
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two groups using GraphPad Prism software (Version 7.04 for Windows, GraphPad 
Software, San Diego, California USA). A p value of<0.05 was considered statistically 
significant and was presented in data figures as a single asterisk (*). However, some studies 
have demonstrated a smaller p-value of 0.01 or less, which is included at respective places. 
4.5. Results 
4.5.1. Development of UPLC method for Determination of Amodiaquine (AQ) 
A rapid, UPLC method was developed for determination of AQ. Retention time was found 
to be 0.731 min with run time of 1.5 min. Peak was eluted with good resolution. The 
method provided excellent linearity between 0.05 to 6 µg/mL. Further details of this 
developed method have been reported in a recent publication from our group (198). 
4.5.2. Calibration curve for Texas Red-Transferrin 
Calibration curve for Texas Red-Transferrin has been plotted between fluorescence 
intensity and concentration of Tf. The linear regression data for the calibration curve 
showed good linear relationship over the concentration range 0.4-100 µg/ml for Tf. 
Standard plot was represented in Figure 18A. Linear regression equation was found to be 
Y=508.8*X + 20.45       
4.5.3. Synthesis of Tf-PLGA 
Generally, nanoparticles are chemically conjugated to different ligands for targeting 
purposes. For retaining maximum drug loading, instead of NPs, PLGA polymer was 
subjected for conjugation with Tf. Conjugation of PLGA with Tf was performed through 
very well-established EDC/NHS chemistry. Figure 18B outlines the synthesis procedure 
of Tf-PLGA. The underlying principles of the synthesis of Tf-PLGA are: activation of 
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carboxylic acid groups of PLGA using NHS/EDC and conjugation of an amine group 
(NH2) of transferrin with a activated PLGA. As evident from Figure 18B, the two-step 
EDC/NHS activation method enables the conjugation of Tf amino groups to the activated 
PLGA carboxyl groups through an amide bond formation. Tf-PLGA was collected through 
centrifugation after addition of water which facilitates precipitation of water insoluble Tf-
PLGA.  
4.5.4. FTIR 
Analysis by FTIR was used to characterize conjugation of Tf with the polymer after 
synthesis reaction. Figure 19 shows the FTIR spectra of Tf (A), PLGA (B) and Tf-PLGA 
(C). FTIR spectrum of PLGA has a peak at 1760 cm-1. Spectral analysis of PLGA-Tf 
showed characteristic band at 1660 cm-1 corresponding to C=O stretch of amide bond 
Figure. 18. A. Calibration curve for Texas-Red transferrin. B. Schematic 
representation of conjugation of PLGA polymer with Tf.  
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formed between carboxylic groups (PLGA) and amine groups (Tf). This shift is referred to 
the conjugation of Tf to PLGA polymer.  
4.5.5. Determination of Conjugation Efficiency 
Supernatant obtained after collecting Tf conjugated PLGA following subsequent 
conjugation reactions was analyzed for the florescence intensity using measured at 
excitation/emission 590/635nm using Tecan plate reader (Tecan Spark 10M; Tecan, 
Männedorf, Switzerland). The amount of unconjugated Texas Red-Transferrin is 
calculated by comparing the measured florescence intensity value with standard curve. It 
was found that 10±2.3µg of Tf was unconjugated to the PLGA polymer. Conjugation 
efficiency of Tf was also determined through a direct approach utilizing esterase enzyme 
as reported earlier (147). In brief, after completion of 72 hours of incubation of Tf-AMQ 
NP/AMQ NP, fluorescence intensity of the supernatant was quantified to determine the 
presence of Tf. This presents a more reliable way to assess conjugated Tf by measuring the 
amount of Tf present in Tf-AMQ NPs. Esterase enzymes were used to cleave the ester 
linkages binding Tf to the PLGA polymer in the nanoparticles. After cleavage, Tf was 
separated from the formulation sample using 30 kDa MWCO filters as the supernatant and 
then analyzed for fluorescence intensity using Tecan plate reader (Tecan Spark 10M; 
Tecan, Männedorf, Switzerland). The amount of Tf conjugated was found to be 
103.3 ± 9.0%, which is in correspondence with the results from supernatant analysis. No 
significant difference was observed between the supernatant analysis and esterase 




4.5.6. Physicochemical characterization: Particle size, PDI and Zeta potential 
Nanoparticle formulations AMQ NP and Tf-AMQ NPs were found to have average particle 
size and polydispersity index (PDI) of 222.3±41.7nm, 0.2±0.1; 244.1±10.5nm, 0.3±0.0 
respectively, suggesting uniform particle size distribution as represented in Fig 19D. The 
zeta potential of Tf-AMQ NPs was found to be positive (8.2±1.3mV) compared to AMQ 
NP (-11.1±5.6mV). The net surface charge of the Tf-AMQ NP may be affected due to the 
presence of Tf. It was assumed that presence of Tf molecules on the surface of 
nanoparticles is screening the surface of PLGA molecules thus reducing the exposed 
negative charges on the surface as reported earlier (205).  
4.5.7. Drug Content 
Amodiaquine was effectively encapsulated into nanoparticles, achieving % EE of 
31.8±1.5% (AMQ NP), 41.0±9.8% (Tf-AMQ NP) and high % DL of 1.2±0.1% (AMQ NP), 
1.6±0.4% (Tf-AMQ NP) as shown in Figure 19D. As Tf conjugated PLGA polymer and 
Figure 19. FTIR spectra of Texas Red-Transferrin (A), PLGA (B) and Tf-
PLGA (C). D. Characterization of non-targeted and targeted nanoparticles 
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plain PLGA (1:5) were used during the preparation of nanoparticles instead of conjugating 
Tf onto nanoparticles, possibility for drug leaching from conjugated NPs during the 
conjugation and incubation process was circumvented. 
4.5.8. In-vitro Release Studies 
The drug release pattern from Tf-AQ NP in pH 5.5 buffer was represented in Figure 20A. 
The cumulative percentage of drug release after 4 hours of release study was 80.0±17.6% 
for Tf-AMQ NP at pH 5.5. These results demonstrate that the Tf-AMQ NPs when 




Figure 20. A. In-vitro release studies:  % Cumulative in vitro drug release profile of 
Tf-AMQ NP.  B, C. Transmission electron microscopy (TEM) images of AMQ NP and 
tf-AMQ NPs. Magnification 20kX. C, D. Solid state characterization studies: (C) XRD 
and (D) DSC for AQ, AMQ NP and Tf-AMQ NPs 
101 
 
4.5.9. Morphological Analysis 
Representative TEM images of AMQ NP and Tf-AMQ NPs were presented in Figure 20B 
revealed that the nanoparticles had spherical appearance with a smooth surface. No 
aggregation of nanoparticles was observed during TEM analysis which gives an indication 
of the uniform dispersion of nanoparticles in formulation. The results were found to be in 
agreement with PDI and zeta potential measurements, shown in Figure 19D. 
4.5.10. Solid state Characterization 
Powder X-ray Diffraction (PXRD): Due to its crystalline nature, AQ showed distinct 
peaks at 2θ values of 19.66 and 25.60 in XRD spectra whereas there were no AQ peaks 
present in AMQ and Tf-AMQ NP indicating encapsulation of drug inside the nanoparticles 
as shown in Figure 20C. Results were found to be consistent with our earlier studies of 
amodiaquine nanoparticles (198).  
Differential Scanning Calorimetry (DSC): The DSC studies were performed to 
understand melting and crystallization behavior of AQ when present in NP formulation as 
compared to plain AQ. As can be seen in Figure 20D, thermogram of AQ showed a sharp 
endothermic peak at 166.8°C due to its melting transition. The absence of a sharp peak in 
AMQ NP and Tf-AMQ NP indicated complete drug encapsulation in the nanoparticle 
formulation core and suggested a consistent result with that of XRD as discussed above. 
Results found to be consistent with our earlier studies (198). 
4.5.11. Stability Studies 
Stability is a major concern while dealing with nanosized drug delivery systems due to 
emulsion instability and particle aggregation (53). As shown in Figure 21, stability 
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analysis data reveal that Tf-AMQ NP formulation was stable at 4⁰ and 25⁰C, with no 
significant changes in particle size, zeta potential or % entrapment efficiency (Figure 21A-
C). Although there observed a reduction in zeta potential after 4 weeks of storage at 25C, 
still the formulations were found to exhibit a positive surface charge which is very crucial 
in their superior cellular internalization. Here, the positive zeta potential of the Tf-AMQ 
NP prevents the particles from coalescing and aggregating. There was no detrimental effect 
of temperature and storage time on entrapment efficiency either. Altogether, the 
formulations were found to retain their physicochemical properties during their storage at 
different temperatures of 4°C and 25°C over a period of 4 weeks.  
Figure 21. Influence of storage temperature and length of storage on particle size 
(A), zeta potential (B) and % entrapment efficiency (C) of Tf-AMQ NPs. 
Formulations were stored at 4° and 25° over a period of 4 weeks. Data represent 
mean ± SD (n=3). 
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4.5.12. In vitro Aerosol Performance Lung Deposition test 
Pulmonary route of administration facilitates local therapeutic delivery in deep lungs (206). 
NPs exhibiting optimal in-vitro aerosol lung deposition can be administered via inhalation 
while reducing exposure to other organs and thus reducing adverse events. Nebulizers can 
deliver the formulations as small droplets which will be deposited in the lung airways based 
on their aerodynamic properties like median aerodynamic diameter (MMAD) and FPF 
(207). Particle size, surface morphology and MMAD of inhaled therapeutics determine 
their fate and the site of deposition in deep lungs (136). MMAD within the range of 2-5 
µm is essential for deep lung accumulation of particulate therapeutics, which is otherwise 
difficult to maintain due to inherent differences in particles’ physicochemical properties 
(137,138).  
Figure 22. In-vitro deposition profile of AMQ NP and Tf-AMQ NP. A. Aerosol 
dispersion performance as % deposited on each stage of the Next Generation Impactor™ 
(NGI™). B. Cumulative % deposition plot representing cumulative % of particles 
deposited at each stage. C. Aerosolization properties of AMQ NP and Tf-AMQ NP.  
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Aerosol deposition pattern is presented graphically in Figure  22A which refers to the % 
aerosol deposition at each stage of NGI which aids in determining the aerosol dispersion 
performance  Relation between recovered cumulative mass and effective cut-off diameter 
is shown in Figure  22B which represents the % cumulative particles deposition plot as a 
function of effective cut-off diameter. To assess the respirability of Tf-AQ NPs; dose 
recovered from nebulizer cup and NGI stages, fine particle fraction (FPF (%)), MMAD 
and GSD were calculated. FPF was found to be 87.7±1.2% and 83.2±3.0% for AMQ NP 
and Tf-AMQ NP respectively which suggests good aerosolization performance. Figure  
22C shows the MMAD and GSD values of 4.7±0.1 µm (AMQ NP), 4.4±0.1 µm (Tf-AMQ 
NP), and 1.3±0.0 (AMQ NP), 1.9±0.3 (Tf-AMQ NP) respectively, suggesting a high degree 
of aerosolization performance and thus NPs are capable of being delivered into targeted 
respirable region inside the lungs. A 92.5 ± 7.2% (AMQ NP) and 88.6 ± 3.5% (Tf-AMQ 
NP) recovery indicated that most of the loaded dose was recovered across all stages, 
demonstrating a near complete nebulization. From the results obtained, the efficacy of 
formulated AMQ NPs and Tf-AMQ NPs for inhalable drug delivery of AQ could be 
established and it can be ensured that developed nanoparticles would be able to provide a 
promising strategy to overcome the physiological barriers involved in respiratory delivery 
of anticancer therapeutics. 
4.5.13. Determination of Targeting Capability 
4.5.13.1. Cellular Uptake Studies 
Figure 23A & 24A represents intracellular uptake of nanoparticle formulations using A549 
and H1299 NSCLC cells with 3 hours (Figure 23) or 24 hours (Figure 24) of incubation. 
In this experiment, AQ was replaced with fluorescent coumarin to make it possible to 
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visualize the uptake and accumulation. Fluorescent images taken following 3 and 24 hour 
incubation with Tf conjugated coumarin loaded nanoparticles clearly demonstrated 
significant internalization compared to plain coumarin and non-targeted coumarin 
nanoparticles in A549 and H1299 cancer cells even after 3 hour incubation period. It can 
also be observed that there was higher accumulation of the Tf-Cou NP around the nucleus 
(DAPI stained), the most evident location for nanoparticle disruption and drug release 
inside the cells (163). Presence of Tf and positive surface charge on the Tf-Cou NP enables 
interaction of nanoparticles with cell surfaces (negatively charged), thus further resulting 
in efficient cellular internalization compared to that of Cou NP and plain coumarin. With 
increase in incubation period from 3- to 24 hours, even Cou NP treated cells were found to 
demonstrate higher fluorescence as Tf-Cou NP as can be seen from Figure 23A & 24A. 
Figure 23. In-vitro cellular uptake of coumarin-6 loaded non-targeted and Tf-targeted 
nanoparticles in A549 and H1299 cells at 3 hours. Coumarin-6 plain solution is used 
as control. Scale bar 100 μm. A. Fluorescence microscopy images. B. Quantitative 




4.5.13.2. Quantification of Cellular uptake by Determining Fluorescence Intensity 
The cellular uptake of Tf-Cou NP, Cou-NP and coumarin by A549 or H1299 cells was 
measured by fluorescence microscopy and cells were able to take up the respective 
treatments at various capacities as shown in Figure 23B & 24B. At 3hr time point, Tf-Cou 
NP uptake was ~6.7, 7.2: A549, ~2.8, 1.8: H1299, times higher compared with coumarin 
and Cou NP respectively. The fluorescence intensity of Tf-Cou NP (23928.3±3093.2: 
A549; 6527.6±784.3: H1299) treated cells was significantly higher when compared with 
Cou-NP (3291.0±2775.6: A549; 2330.0±722.0: H1299) and coumarin (3546.3±127.8: 
A549; 3165.6±1799.5: H1299) at 3hr time point (A549: Coumarin vs Tf-Cou NP: p<0.001, 
Cou-NP vs Tf-Cou NP: p<0.001; H1299: Cou-NP vs Tf-Cou NP: p<0.01).  
Figure 24. In-vitro cellular uptake of coumarin-6 loaded non-targeted and Tf-targeted 
nanoparticles in A549 and H1299 cells at 24 hours. Coumarin-6 plain solution is used as 
control. Scale bar 100 μm. A. Fluorescence microscopy images. B. Quantitative representation 




The quantitative results indicated analogous results to the fluorescence imaging shown 
in Figure  23A & 24A. Due to the presence of transferrin on the surface of nanoparticles, 
the uptake of the Tf-Cou NP into A549 cells is facilitated by the mutual interaction between 
Tf and the transferrin receptors on the cell membrane, resulting in an elevated uptake 
efficiency compared with Coumarin NP and plain coumarin. At 24hr time point, similar 
results of fluorescence intensities were obtained exhibiting highest uptake of Tf-Cou NP 
(39518.7±6937.2: A549; 29925.7±10056.7: H1299) compared to coumarin 
(16419.0±6676.1: A549; 7227.3±2237.0: H1299) and Cou-NP (27469.7±5907.3: A549; 
12128.7±1025.3: H1299) at 24hr time point (A549: Coumarin vs Tf-Cou NP: p<0.001; 
H1299: Cou-NP vs Tf-Cou NP: p<0.01).However, the difference was not significant at 
24hr time point. This might be because of saturation of all transferrin receptors. 
4.5.14. Cytotoxicity Studies 
Cell viability studies were performed using MTT assay to evaluate the cytotoxic potential 
of Tf-conjugated and non-conjugated AQ-loaded NPs versus plain drug. From this study, 
it was revealed that AQ cytotoxicity against NSCLC cell lines was significantly enhanced 
by nanoparticle encapsulation. Similar trend was found in both NSCLC cell lines: A549 
and H1299. Figures 25A & 25B illustrate the cytotoxic effects of AQ, AMQ NP and Tf-
AMQ NP in A549 and H1299 NSCLC cell lines respectively. The IC50 values for plain 
AQ, AMQ NP and Tf-AMQ NP were found to be 25.3±11.0µM, 3.0±1.7µM and 
3.0±2.1µM in A549 cell line; 42.2±3.0 µM, and 37.1±11.5µM and 18.0±5.0µM in H1299 
cell line respectively (Figure 25C). Smaller and consistent particle size and positive 
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surface charge and targeting capability of Tf-AMQ NP facilitates efficient internalization 
of nanoparticles resulting in more accumulation of nanoparticles inside the cells, thus 
leading to higher cytotoxic potential at the same dose.  The IC50 value of Tf-AMQ NP was 
lower than that of free AQ and AQ-loaded nanoparticle without Tf -conjugation in case of 
H1299 cell line which was reported to possess overexpression of transferrin receptors 
compared to their expression in A549 cells (107). However, to evaluate the anti-cancer 
efficiency of transferrin targeted nanoparticles further in vitro studies are performed. In-
vitro cytotoxicity studies of Blank NP and Blank Tf-NP were performed on A549 cell line. 
Both Blank NP and Blank Tf-NP were found be safe from % cell viability determinations 
after incubating A549 or HEK cell line for 72hours which has been represented in Figure 
26A & 26B respectively.  In none of the cases was cell viability below 70% using blank 
nanoparticles equivalent to concentrations ranging from 0.39 to 50µM, suggesting that 
formulation components were not toxic by themselves. To further determine the 
cytotoxicity of AQ, AMQ NP and Tf-AMQ NP toward normal cells, HEK cells were 
incubated with respective treatments. Free AQ reduced cell viability to a greater extent 
(34% viable; p<) whereas AMQ NP and Tf-AMQ NP treatments resulted in ~ 70% cell 
viability (Figure 26C) when compared with untreated control cells. Hence, AMQ NP and 
Tf-AMQ NPs demonstrated reduced cytotoxicity when compared with plain drug. These 
results demonstrate that developed targeted nano drug delivery formulation markedly 




Figure 25. Inhibitory effects on different NSCLC cell lines A. A549 and B. H1299. C. 
IC50 of AQ, AMQ NP and Tf-AMQ NP in A549 and H1299.  
Figure 26. Safety studies: A, B. Cytotoxicity studies on A549 and HEK cell line 
after treatment with Blank NP and Blank Tf-NP. C. Cytotoxicity studies on A549 
and HEK cell line after treatment with AQ, AMQ NP and Tf-AMQ NPs.  
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4.5.15. Clonogenic Assay 
Clonogenic assay is an in-vitro cell survival assay used to determine the colony formation 
capability of single cancer cells (164). AQ, AMQ NP and Tf-AMQ NP were evaluated for 
their long-term efficacy using clonogenic assay in A549 and H1299 cell lines. From Figure 
27A, it can be illustrated that colony growth was significantly inhibited by Tf-AMQ NP 
compared to AQ and AMQ NP in A549 and H1299 cell lines. After 48 hour treatment 
period and 7 day incubation, % of colonies survived after treatment with 10 µM AQ, AMQ 
NP and Tf-AQ NP were 38.2±5.4%, 28.8±2.1% and 2.0±1.0% (Figure  27B; AQ vs Tf-
AMQ NP: p<0.01, AMQ NP vs Tf-AMQ NP: p<0.05, Control vs Tf-AMQ NP: p<0.0001) 
considering number of colonies to be 100% in drug free treatment control wells. In case of 
Figure 27. A. Representative images showing distinct colonies after staining 
in A549 and H1299 cell lines. Three different experiments were performed. B 
& C. Quantitative representation of clonogenic assay as % colony growth 
with AQ, AMQ NP and Tf-AMQ NPs treatment as compared to control in 
A549 and H1299 cell lines respectively. 
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H1299 cell line, % of colony growth was found to be 38.0±7.7%, 36.7±1.1% and 0.6±0.4% 
AQ, AMQ NP and Tf-AMQ NP (Figure  27C; AQ vs Tf-AMQ NP: p<0.001, AMQ NP 
vs Tf-AMQ NP: p<0.001, Control vs Tf-AQ NP: p<0.0001). The data suggest an 
approximately 14.4, 19.1-fold (A549); 61.2, 63.3-fold (H1299) higher efficacy against 
cancer colony formation with Tf-AMQ NP as compared to AMQ NP and plain AQ 
respectively. This data may be considered a representative of Tf-AMQ NP’s efficacy in 
suppressing the possibility of metastasis or new tumor growth by reproduction inhibition; 
and can well be linked to enhanced intracellular (and intratumoral) drug accumulation with 
nanoparticles formulation.  
4.6. Mechanism of Action 
4.6.1. Apoptotic Assay 
To evaluate induced active caspase-3 enzyme, cleavage product of a fluorogenic caspase 
substrate, DEVD-AMC was measured. The EnzChek® Caspase-3 Assay Kit allows the 
detection of apoptosis by assaying for increases in µcaspase-3 and other DEVD-specific 
protease activities (e.g., caspase-7). As seen in Figures 28A & 28B, increased caspase-3 
activity was observed in A549 and H1299 cells with Tf conjugated nanoparticle treatment 
compared to plain drug, non-targeted nanoparticle and control (fluorescence intensity 
measurements: A549: 1250.0±254.1 (Control), 2284.0±226.2 (AQ 25 µM), 2625.0±348.5 
(AMQ NP 25 µM) and 3551.4±424.3 (Tf-AMQ NP: 25 µM); H1299: 9949.8±2395.6 
(Control), 12362.4±1799.0 (AQ 25 µM), 13816.0±1591.1 (AMQ NP 25 µM) and 
17227.4±1352.8 (Tf-AMQ NP 25 µM) as seen in Figure  28A & 28B. Treatment with Tf-
AMQ NP was found to exhibit significantly higher caspase-3 levels compared to rest of 
the treatments (A549: Control vs Tf-AMQ NP p<0.0001, AMQ NP vs Tf-AMQ NP p<0.01 
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and AQ vs Tf-AMQ NP p<0.001; H1299: Control vs Tf-AMQ NP p<0.001 and AMQ NP 
vs Tf-AMQ NP p<0.01). This experiment may signal toward presence of an alternate 
apoptotic pathway responsible for AQ’s tumor inhibiting properties. 
4.6.2. Autophagy Inhibition Assay 
Nanoparticles of AQ were found to cause autophagy inhibition significantly more 
compared to plain drug. This was confirmed from the results of fluorescence 
measurements. Nanoparticle (25µM) treated cells exhibit accumulation of green 
fluorescent vesicles with higher intensity compared to cells treated with plain amodiaquine 
or starved media, as seen in Figure 28C. (blue fluorescence represents Hoechst 33342 
nuclear stain). Following normalization of data to control as 100%, relative fluorescence 
intensities, representing co-localization of LC3 protein and thus accumulation of 
Figure 28. A, B. Detection of caspase-3 levels in H1299 and A549 cells 
respectively using the EnzChek® Caspase-3 Assay. C. Autophagy inhibition 
assay. Graph represents the comparison of relative fluorescence units (RFU) 
after incubating with respective treatments. 
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autophagosomes, were found to be 96.5±3.0% (AQ 25 µM), 125.0±8.8% (AMQ NP 25 
µM) and 154.4±5.8% (Tf-AMQ NP: 25 µM) after treating A549 cells for 18 hours (Control 
vs Tf-AMQ NP p<0.0001, AQ vs Tf-AMQ NP p<0.0001). Increased accumulation of 
autophagic vesicles is confirming autophagy inhibition which leads to tumor growth due 
to blockade of this crucial pathway required for the survival and proliferation of cancer 
cells (166).  
4.7. 3D Spheroid Cell Culture Studies 
As described in Methods section, 3D spheroid cell culture study was designed to better 
predict the physiological interaction of transferrin receptor targeted amodiaquine loaded 
NPs with tumors. In case of solid tumors, the monolayered cell cultures do not accurately 
mimic tumor structure, resistance to drugs and drugs’ poor penetrability due to tumor 
microenvironment (208). To bridge the gap between in-vitro and in-vivo studies, a 3D 
spheroid study was carried out according to previously published studies from our group 
(32,147,209). These cultures (tumor spheroids) combine the ability to mimic the 3D 
structure of malignant tissue accurately in addition to being relevant to cancer 
microenvironment to which the tumor cells are exposed (210,211). A 3D in-vitro model 
was developed successfully by using specific Corning ultra-low attachment spheroid plates 
as reported by Elbatanony and Parvathaneni et al (204) so that under favorable incubation 
conditions, cells grow into a spheroid mass.  
For this spheroid study, A549 cell line was chosen which forms spheroid masses from 
day 1 on culturing which were grown for 3 days. This study was performed using single 
dose regimen. Spheroid images were captured using inverted microscope (Laxco, Mill 
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Creek, WA, USA) on respective days and were analyzed using the ImageJ software 
Version 1.44 (National Institute of Health, USA). Spheroid images (Figure 29A), spheroid 
area (Figure 29B) and spheroid volume (Figure 29C) comparisons are represented in 
Figure 29. Control group of spheroids (blank media control) found to be growing in size 
over a period of 12 days, whereas the growth of treated spheroids was significantly 
inhibited. 
 In this single dose study with a single treatment given on day 1, control spheroids 
were found to have a diameters and volumes of 2731.7±325.2 µm, 11.1 ± 1.7 mm3 on day 
12 as compared to a spheroid diameters and volumes of 2813.1±277.0 µm, 11.9 ± 1.3 mm3 
(AQ: 10µM), 2948.7±193.6 µm (AMQ NP: 10µM), 13.6 ± 1.1 mm3 and 1101.5±830.2 µm,  
1.9± 1.3 mm3 (Tf-AMQ NP: 10µM). A significant reduction in spheroid volumes was 
Figure 29. 3D Spheroid study: A. Spheroid images of A549 cell line. B, 
C. Spheroid area and volume comparison plots. Data represent mean ± SEM (n = 6). 
D. Cell viability study was performed using CellTiter-Glo® Assay on A549 
Spheroids. E. H1299 spheroids were stained using the viability/cytotoxicity assay 
kit to differentiate between live and dead cell population in respective spheroids.  
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observed in case of Tf-AMQ NP treated spheroids on day 9 and 12. (Day 9: 10μM: Control 
vs Tf-AMQ NP p<0.001, AQ vs Tf-AQ NP p<0.01, AQ NP vs Tf-AQ NP p<0.001; Day 
12: Control vs Tf-AQ NP p<0.001, AQ vs Tf-AQ NP p<0.001, AQ NP vs Tf-AQ NP 
p<0.0001 (Figure  29C). Thus, underlining a more pronounced tumor reduction potential 
of Tf-AMQ NP. Treatment with Tf-AQ NP resulted in a significant difference in spheroid 
volumes as compared to AQ, AMQ NP and control treated groups. Tumor growth 
suppression was continually observed until the end of the treatment. 
4.7.1. CellTiter-Glo Luminescent Cell Viability Assay 
While volume determination provides valuable information about external size of the 
tumor/spheroid, it may not accurately predict the cytotoxicity of the treatment against cells 
inside the core of the tumor. CellTiter-Glo luminescent cell viability assay was performed 
to compare counts of viable cells in treated 3D single dose spheroids on day 12 after 
microscopic quantification. Once again, Tf-AQ NP treated spheroids exhibited 
significantly reduced proportion of viable cells compared to control and their 
corresponding AQ, AMQ NP concentration (10μM: Control vs Tf-AMQ NP p<0.0001, 
AQ vs Tf-AMQ NP p<0.0001, AMQ NP vs Tf-AMQ NP p<0.0001). % cell viability 
results (111.7 ± 9.8%, 92.7 ± 27.1% and 8.1 ±9.9% for AQ, AMQ NP and Tf-AMQ NP) 
were graphically represented in Figure 29D. These results support the previous findings 
of 3D spheroid studies, that demonstrated enhanced anti-cancer effectiveness of Tf-AMQ 





4.7.2. Live-Dead Cell Assay 
In case of H1299 spheroids, live cell population (green fluorescence) for Tf-AMQ NP 
treated groups was found to be less compared to that of plain AQ and AMQ NP groups 
on day 15. (Figure 29E). Reduction in live cell proportion in case of targeted nanoparticle 
group compared to other groups is indicating their ability of AQ NP in inhibiting tumor 
cell proliferation. 
4.8. Discussion 
Nanoparticle drug delivery systems are contributing greatly in the design and development 
of formulations to treat several lung disorders especially lung cancer (212). Moreover, 
application of targeted NPs promises immense potential owing to the recent advances in 
cancer therapeutics (213). Nanoparticles enable surface modifications, thus facilitate site-
specific delivery through active targeting to achieve an improved therapeutic strategy and 
reduced toxicity (213,214). As in case of non-small cell lung cancer (NSCLC), tumor cells 
exhibit overexpression of certain receptors like transferrin (215). Hence, nanocarriers 
functionalized with transferrin as targeting ligand are able to target those cancer cells and 
result in enhanced drug accumulation in tumor cells further demonstrating superior anti-
cancer efficacy. For instance, Upadhyay et al developed transferrin-decorated 
thymoquinone loaded nanoparticles and reported the their potential in targeting non-small 
cell lung cancer cells (215).  
As there is a great need to discover/develop new drugs with anti-cancer efficacy 
due to the toxic effects caused by chemotherapeutic agents, drug repurposing provides an 
excellent opportunity to find novel anti-cancer uses for previously FDA approved drugs 
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(2,105). Recently, nanoparticles of AQ (FDA approved anti-malarial) have been reported 
for their anti-cancer efficacy from our research group where cationic polymer loaded NPs 
were reported for their superior efficacy. Furthermore, to achieve a targeted drug delivery, 
a targeting ligand transferrin has been employed in the fabrication of nanoparticles in the 
current study. In this context, current study had explored the enhanced anti-cancer efficacy 
of surface functionalized amodiaquine-loaded polymeric NPs in NSCLC. Conjugation of 
the PLGA polymer with a targeting moiety, transferrin has been carried out successfully to 
address the payload to specific cancer. Schematic representation of the conjugation 
reactions is Further, results obtained from the conjugation efficiency determinations have 
assured the presence of Tf on the surface of nanoparticles. FTIR characterization have 
revealed the presence of an amide bond in transferrin conjugated PLGA polymer, thus 
confirming the formation of a covalent bond between Tf and PLGA as shown in Figure 
19. 
Physicochemical characterization of the drug loaded nanoparticles is important in 
the field of drug delivery, as it greatly influences the uptake and cellular interaction of the 
particulate system; thus, ultimately determining the fate of the entrapped drug under in 
vitro and in vivo conditions. Lower particle size of developed targeted NPs (244.1±10.5nm) 
with positive zeta potential (8.2±1.3 mV) (Figure 19D) enabled higher accumulation in 
cancer cells. Further, the nanoparticles exhibited desirable drug release kinetics under 
acidic pH (5.5) supporting their testing in biological systems as shown in Figure 20A. In 
addition, spherical surface with smooth morphology and narrow size distribution are 
evident by TEM analysis as represented in Figure 20B. From solid state characterization 
studies such as DSC and XRD, developed NPs were found to encapsulate drug inside their 
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polymeric core. No characteristic XRD or endothermic peaks were observed in case of both 
nanoparticle formulations (Figure 20C-D). Stability of the developed formulations has 
been evaluated in terms of physicochemical properties such as particle size, zeta potential 
and % entrapment efficiency. Results demonstrated that NPS possess long term stability 
(28 days) at both 4°C and room temperature (Figure 21), thus assuring the developed 
conjugated NPs as effective delivery carriers with desired stability.  
In achieving local delivery of therapeutics, pulmonary route of administration is of 
prime importance (191). As shown in Figure 22, developed both AQ-loaded nanoparticles 
have demonstrated excellent aerosolization properties confirming their superior deposition 
in the respirable region (bronchoalveolar) of the lungs. Hence, these nanoformulations can 
be administered via inhalation, facilitating local delivery to the deep lungs while reducing 
exposure to healthy tissues and further reducing adverse events. During in-vitro aerosol 
lung deposition test after nebulization, NPs were delivered as small droplets and deposited 
in the lung airways, confirming the respirability of formulated AQ nanoparticles and 
efficient lung deposition. Developed Tf conjugated and non-targeted amodiaquine 
nanoparticles are capable of providing a promising strategy to overcome the physiological 
barriers involved in respiratory tract, and ensuring their capability to reach the respirable 
regions of the lung (137).  
Intracellular uptake images shown in Figure 23A & 24A reveal the same where Tf 
conjugated coumarin nanoparticles were internalized by A549 or H1299 cells efficiently 
within 3 hours compared to plain coumarin solution or unconjugated nanoparticles. Figure  
23B & 24B clearly indicate that Tf-coumarin NP uptake was ~7.2 and 1.8 times higher 
compared with Cou NP in A549 and H1299 cells respectively after 3 hours. 
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Extensive in-vitro cell culture studies were carried out to investigate the efficacy of 
AQ NP against NSCLC. Presence of transferrin on nanoparticles associates with higher 
cellular uptake and greater cytotoxicity in cancer cells and explains the specificity of Tf-
mediated binding of conjugated NPs (170). Recently, research work conducted by Guo et 
al. has demonstrated that Tf-conjugated lipid-coated NPs were able to deliver doxorubicin 
to lung cancer cells both in-vitro and in-vivo (216). Cytotoxicity study results in the present 
study indicated differentiation in cell inhibition behavior between free amodiaquine and 
amodiaquine loaded nanoparticles either Tf conjugated or not, thus emphasizing the key 
role of targeted NPs internalization in enhancement of cytotoxic activity. As shown in 
Figure 25B, the cytotoxicity exhibited by transferrin conjugated amodiaquine NPs towards 
H1299 NSCLC cell line could be attributed to their targeting ability as respective cell line 
exhibits overexpression of transferrin receptors (107). To elaborate, targeted NPs exhibited 
a lower IC50 value than the plain drug and unconjugated NPs in case of AQ-loaded NPs 
were also evaluated for their effect of clonal expansion ability which is an important step 
of metastasis via clonogenic assay. Results from this study revealed that Tf-AMQ NPs  
have the ability to display a significant reduction in cell survival and a profound inhibition 
in the colony formation compared to AMQ NP or plain amodiaquine. the ability of single 
cells more efficiently to form colonies compared to non-targeted nanoparticles. Hence, it 
ensures the effectiveness of Tf-AMQ NP on long term basis while preventing tumor 
recurrence. Overall, Tf-AMQ NP could be further evaluated for their establishment in 
NSCLC treatment explicitly. 
Furthermore, the potential of AQ, AMQ NP and Tf-AMQ NP was investigated and 
compared through apoptosis assay as apoptosis is the main mechanism of growth inhibition 
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in many proliferative disorders, such as cancer. Caspases are cysteine proteases, activated 
in presence of death inducing stimuli (141). It was observed that Tf-AMQ NP treatment 
induced caspase-3 levels, demonstrating their ability to induce cell death through apoptosis 
as well via measurement of apoptotic marker (caspase-3). Thus, apoptotic induction could 
be a mechanism for its anti-cancer activity. In agreement with our earlier report on 
amodiaquine loaded NPs (198), amodiaquine exhibited autophagy inhibition with either 
targeted or non-targeted amodiaquine loaded nanoparticles demonstrating significantly 
higher autophagy inhibition efficiency, potentially due to higher cellular internalization of 
the treatment (105). This indicated the accumulation of autophagosmes which infers to the 
inhibition of autophagy process, essential for the further proliferation of cancer cells under 
stress conditions. In brief, AQ causes an increase in lysosomal pH, which inhibits lysosome 
function and blocks fusion of autophagosomes with the lysosomes (139), thus conserving 
LC-3 protein and producing a positive signal in the CYTO-ID® Autophagy detection assay 
as seen in Figure  28C.  
Development of 3D in-vitro models is of utmost necessity today to mimic in-vivo 
solid tumor conditions which could be achieved by using specific low attachment spheroid 
plates as reported in our previous publications (20,32). From results seen in Figure 29, it 
can be understood that nanoparticles were able to deliver the drug to spheroids’ core 
efficiently ensuring their clinical use. In addition, % cell viability assay results (Figure 
29D) on day 12 of spheroid study confirmed superior anti-cancer efficacy of Tf-AMQ NP. 
Hence, results from this spheroid study provide a strong evidence for capability of Tf 
conjugated nanoparticles to deliver the drug to spheroid’s core efficiently and their 
potential in-vivo efficiency, which could be extended to further preclinical studies. It can 
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be understood that through the addition of a ligand (Tf) at the NP surface, NPs are directed 
against receptors (transferrin) exposed at the outer cell surface, simultaneously improved 
uptake and distribution of NPs in the tumor mass despite of complicated tumor 
microenvironment (217). 
Taken together, we present the first report of transferrin conjugated nanoparticles 
for delivery of amodiaquine for the treatment of NSCLC. Different in-vitro cell culture 
studies as well as 3D spheroid models illustrated the pronounced efficiency of 
amodiaquine-loaded transferrin functionalized nanoparticles in NSCLC treatment. 
4.9. Conclusion 
From the present study, it can be concluded that inhalable transferrin conjugated 
nanoparticles of amodiaquine could be successfully formulated by a scalable high-pressure 
homogenization (HPH) approach. Formulated NPs were characterized for their 
physicochemical properties, found to have favorable particle size and surface charge 
facilitating efficient cellular internalization. Developed targeted AQ loaded NPs were 
compared with their counterpart (non-targeted AQ loaded nanoparticles) in their anti-
cancer efficacy against NSCLC. Several in-vitro cell culture studies including cytotoxicity 
studies and 3D spheroid studies, assays exhibiting the autophagy inhibition and colony 
formation where superior efficacy of transferrin conjugated NPs has been confirmed.  
Altogether along with apoptosis inhibition capability of Tf-AMQ NPs, results are 
promising them as a potential treatment strategy for NSCLC. Going forward, it would be 





5. Development and Characterization of Folic acid Conjugated Amodiaquine 
Loaded Nanoparticles-Efficacy in Cancer Treatment 
                            Non-small cell lung cancer (NSCLC) is a malignant tumor type with 
overexpression of certain receptors such as transferrin (Tf), folate etc. (FRα) etc. Hence 
targeting these receptors through specific ligands is of considerable interest. Especially, 
FRα regulates cellular uptake of folate molecules (FRα) (218). By targeting these 
receptors on cancer cells through specific targeting ligands is advocated to achieve 
superior anti-cancer efficacy. Hence, conjugation of receptor-specific ligand FA can 
specifically target multiple cancer cells facilitating targeted drug delivery of 
therapeutics. NSCLC cell lines such as A549, cervical cancer cell line (HeLa) and 
breast cancer cell line (MDAMV-231) were employed in the current study. We aim to 
develop scalable folic acid conjugated AQ-loaded nanoparticles (FA-AQ NPs) for 
targeted and efficient cancer treatment regimen. 
 
5.1. Introduction 
Cancer is the leading cause of deaths worldwide although there are several treatment 
regimens available for the treatment. Moreover, main limitations of the current therapies 
include resistance against chemotherapeutic agents and the adverse events/toxicity effects 
with majority of the current regimens. Thus, it raised attention of many researchers to 
explore new drugs or new therapies for an effective cancer therapy (219). While discovery 
or development of new drugs takes longer time periods, drug repurposing has become an 
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attractive strategy to discover new uses of old FDA approved drugs (2). Hence, utilization 
of old drugs against new indication is very crucial. 
All of the cancer types share majority of the features such as uncontrolled cell 
growth and probability for metastasis. When it comes to pathophysiology of cancer cells, 
majority of the cancer cells exhibit overexpression of certain receptors such as transferrin 
(Tf), folate (FRα) etc. which play a crucial role in iron homeostasis, cellular proliferation 
(Tf) and regulating cellular uptake of folate molecules (FRα). By targeting these receptors 
on cancer cells through specific targeting ligands is advocated to achieve superior anti-
cancer efficacy. Cancer cells necessitate more iron for their uncontrolled growth and 
proliferation, resulting in overexpression of folic acid-receptors (FA) in several malignant 
tumors including breast, cervical cancers including NSCLC. A 
glycosylphosphatidylinositol-anchored cell surface receptor (FRα) for folic acid has been 
known to be overexpressed in several human tumors such as non-small cell lung cancer, 
cervical, ovarian and breast cancers (220). Targeting FRα receptors through folic acid 
offers many potential advantages pertaining to its small size and promising 
pharmacokinetic properties of the folic acid conjugates. Moreover, this targeting ligand 
could reduce probability of immunogenicity, allowing for repeated administration; offers 
simple and well-defined conjugation chemistry enabling easier conjugation reactions 
(221). As the expression of folate receptors is highly restricted in normal tissues and 
presence of high receptor affinity of folic acid results in its high tumor tissue specificity. 
Further internalization of FA receptor–ligand complex takes place via endocytosis (221). 
While nanoparticles enable the delivery of therapeutics effectively, conjugation of 
targeting moieties would be of great importance in achieving a safer drug delivery. Several 
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nanocarrier systems such as liposomes and polymeric nanoparticles have been developed 
for the purpose of selective targeting against tumors. Utilizing targeted NPs in drug 
delivery establishes a platform for an efficient, tumor-specific interactions by interacting 
with receptors on the surface of cancer cells (190). Several other studies have investigated 
the targeting potential of drug-folic acid conjugates against different cancers as 
summarized by Lutz et al (222). 
Based on the previous investigations from our research group (198), amodiaquine 
(FDA approved anti-malarial drug) has been chosen for evaluating its superior efficacy 
through a combination of nanoparticle encapsulation and targeting. PLGA-based folic 
acid-conjugated NPs of amodiaquine, 4-[(7-chloroquinolin-4-yl) amino]-2- 
[(diethylamino) methyl] phenol (AQ) were formulated using a scalable, reproducible high-
pressure homogenization (HPH) approach and evaluated for their anti-cancer efficacy. 
Recently, superior anti-cancer efficacy of AQ-loaded nanoparticles against NSCLC has 
been reported in a research study published from our group. In the current project, we aim 
to achieve a further tumor targeting efficacy through folic acid decorated nanoparticles.  
In the present study, the anticancer activity of folic acid conjugated amodiaquine 
loaded nanoparticles (FA-AQ NP) against FA-receptors expressing cancer cells has been 
evaluated. Process of functionalization/conjugation refers to the chemical addition of 
targeting ligand folic acid to enhance the target nanoparticles to the lung tumor tissue. AQ-
loaded NPs with folic acid ligand conjugated were prepared and were then characterized 
by various analytical techniques such as for their physicochemical properties and also 
targeting capability. Thereafter several 2D and 3D cell culture studies were carried out to 
assess the specificity of the folate receptors and to determine whether nanoparticles are 
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exhibiting more anti-cancer efficacy than the plain drug. Targeted nanoparticles were 
evaluated to verify the hypothesis that folic acid decorated NPs are capable of 
demonstrating superior efficacy in treating multiple cancers.  
5.2.Materials and Methods 
5.2.1. Materials 
Poly (lactic-co-glycolic) (PLGA 50:50, 7-17 kDa, acid terminated), poly vinyl alcohol 
(PVA) and amodiaquine (AQ) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Folic acid was obtained from Fisher Scientific (Hampton, NH, USA). A549 (NSCLC) cell 
line was obtained from ATCC (Manassas, VA, USA) and maintained in RPMI-1640 
medium (Corning) supplemented with 10% FBS (Atlanta Biologicals, R&D Systems, 
Minneapolis, MN, USA), sodium pyruvate and penicillin-streptomycin (Corning, NY, 
USA) at 5% CO2/37°C. Human embryonic kidney (HEK-293), HeLa and MDAMB-231 
cell lines were obtained from ATCC and maintained in DMEM medium (Corning) 
supplemented with 10% FBS and penicillin- streptomycin at 5% CO2/37°C. 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dichloromethane (DCM), 
dimethyl sulfoxide (DMSO), coumarin-6, crystal violet dye, 16% paraformaldehyde (PFA) 
solution, Triton X100, diethyl ether, HPLC grade methanol, acetonitrile (ACN) and water 
were purchased from Fisher Scientific (Hampton, NH, USA). Molecular biology kits, 
supplies, and antibodies were purchased from other commercial vendors which are listed 
at appropriate places throughout the manuscript. All other solvents including UPLC grade 
chemicals and solvents, unless it is otherwise specified, were purchased from Fisher 




5.2.2. Development of UPLC method for Determination of Amodiaquine (AQ) 
A reverse-phase liquid chromatography method was developed for quantifying AQ using 
Waters series Acquity UPLC (Waters, USA). Detailed description of method was reported 
in our recent publication (198). 
5.2.3. Calibration Curve for Folic acid 
Standard solutions (15.6, 31.3, 125 and 250 µg/ml) of folic acid were prepared by diluting 
with DMSO. Absorbance was measured at 256nm using SPARK Tecan plate reader 
(Tecan Spark 10M; Tecan, Männedorf, Switzerland). The calibration curve was 
constructed between concentration of FA and absorbance values.  
5.2.4. Synthesis of PLGA–PEG–FA Conjugate 
Target-specific drug delivery through utilization of FA ligand has been carried out by 
employing a surface-activation method as reported earlier with slight modifications (223). 
A brief synthetic scheme for the PLGA–PEG–FOL conjugate preparation was prepared is 
represented in Figure 30B. Briefly, PLGA solution (1g/8mL DCM) was activated by 80 
mg EDCI and 57.5 mg NHS at room temperature for 24 hours under gentle stirring. 
Obtained solution was filtered and precipitated by dropping into ice-cold diethyl ether 
(50mL) and the resulting product of activated PLGA was completely dried under vacuum. 
Then organic solution of activated PLGA (0.5g/4mL DCM) was added slowly to PEG–bis-
amine solution (50 mg/1mL DCM) in a dropwise manner. This reaction was carried out for 
6 hours under room temperature, then the resultant solution was precipitated by the addition 
of ice-cold diethyl ether (25mL). The precipitated product, amine-terminated di-block 
copolymer, PLGA–PEG–NH2 was filtered and dried. FOL-conjugated di-block copolymer 
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was synthesized by coupling the PLGA–PEG–NH2 di-block copolymer with an activated 
folic acid. Briefly, 250 mg di-block copolymer dissolved in 2.5ml dimethyl sulfoxide 
(DMSO) was mixed with 6.5mg folic acid and 6.5 mg EDCI. The reaction was performed 
at room temperature for 7 hours and then mixed with 50 ml cold methanol and filtered 
through the paper filter. The precipitate on the filter was dried under vacuum, and then 
dissolved in 25mL DCM; in this way, free FOL was precipitated in DCM but conjugated 
FOL was dissolved, after centrifugation at 21,000 x g; the supernatant was dried under 
vacuum. Collected conjugated PLGA after centrifugation was analyzed for the conjugation 
efficiency and utilized in the formulation of nanoparticles.  
5.2.5. Determination of Conjugation Efficiency 
The conjugation percentage was calculated by determining the amount of folic acid 
conjugated in PLGA–PEG–FOL. A known amount (0.59-0.81mg) of dried PLGA–PEG–
FOL was dissolved in DMSO and an UV absorbance value at 256nm was measured to 
determine the concentration of conjugated folic acid.  
5.2.6. Formulation of FA Conjugated AQ NPs (FA-AQ NPs) 
Non-targeted and folic acid conjugated amodiaquine nanoparticles were formulated 
through HPH process. Nanoparticles were formulated through using an established high 
pressure homogenization technique which was recently published by our research group 
with slight modifications (198). Briefly, AQ-loaded nanoparticles were prepared by using 
organic solution of polymer PLGA 502H (20mg/1ml of DCM, aqueous solution of AQ 
(5mg/0.5ml), a stabilizer (20ml of 1% w/v polyvinyl alcohol solution in PBS). FA-
conjugated NPs were formulated using both PLGA and FA-conjugated PLGA i.e. PLGA-
128 
 
PEG-FA at 5:1 ratio while other formulation components are the same as for non-targeted 
AQ-loaded NPs. A stable pre-emulsion was formed through probe homogenization at 
25,000 RPM for 10 minutes. Obtained pre-emulsion was processed through high-pressure 
homogenizer (Nano DeBee®) at homogenization pressure of 30,000 psi and seven number 
of cycles to recirculate the formulation with reverse flow pattern. These process parameters 
have been chosen based on our previous investigations as reported in our recent publication 
(198). Later, formulations were subjected for rotary vacuum evaporation using rotary 
evaporator (Wilmad-LabGlass, Vineland, NJ, USA) for 10 min under reduced pressure of 
200 bar at room temperature for organic solvent removal followed by washing of 
nanoparticles for removal of excess PVA. Then, NPS were washed for removal of excess 
PVA and were re-dispersed in milliQ water. 
5.2.7. Physicochemical characterization: Particle size, PDI and Zeta potential 
Physicochemical properties such as size, polydispersity, and surface charge of AQ NP Rota 
and FA-AQ NPs were measured using Malvern® zeta-sizer. Drug loading efficiency was 
measured using Waters UPLC by quantifying AQ. 
5.2.8. Drug Content 
Encapsulated drug amount in nanoparticle formulation was determined using a direct 
vesicle lysis approach. To 20μL of formulation, 1,980µL of ACN:water:DCM – 98:1.5:0.5 
was added followed by centrifugation for 45 min at 4°C at 21,000 x g to lyse nanoparticles 
and to acquire loaded drug into the analyzing solution. Obtained supernatant was analyzed 
for the drug content using UPLC and % EE/%DL was calculated. 
% 𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%𝐸𝐸) = [
𝐷𝑟𝑢𝑔 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦
] × 100        (Eq. 1) 
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% 𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%𝐷𝐿) = [
𝐷𝑟𝑢𝑔 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑝𝑜𝑙𝑦𝑚𝑒𝑟+𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑
] × 100                          (Eq. 2) 
5.2.9. Morphological Analysis 
Imaging of unconjugated and conjugated amodiaquine nanoparticles was performed using 
transmission electron microscopy (TEM) for assessing nanoparticles’ morphology. The 
Formvar® carbon-coated copper grids 400-mesh (Electron Microscopy Sciences, PA, 
USA) were made hydrophilic using glow discharge plasma treatment for 60s. About 5 µL 
of diluted nanoparticles sample was added to the grid and allowed to adhere for 1 minute. 
The samples were negatively stained by adding 5 µL of uranyl acetate (1%) and excess 
was removed by using Whatman filter paper after 30s. This process was repeated twice and 
the sample was finally allowed to air dry. The grids were then imaged using Tecnai Spirit 
TWIN TEM operated at 120 kV voltage. 
5.2.10. Solid-state Characterization Studies 
Powder X-ray Diffraction (PXRD) Studies: The samples were first lyophilized into dry 
powders using Labconco FreeZone® freeze dryer system. X-ray diffraction spectroscopy 
was carried out using XRD-6000 (Shimadzu, Kyoto, Japan). The diffractometry was 
performed by using a graphite monochromator consisting of copper-Kα1 radiation of 
wavelength 1.5418 Å operating at 40 kV, 30 mA. The samples were spread uniformly on 
a glass micro sample holder and were analyzed in the range of 5 to 60° at the scanning 
speed of 2° (2θ)/minute. 
Differential Scanning Calorimetry (DSC) Studies: The thermograms for AQ, AQ NP 
Rota and FA-AQ NP were generated by closed pan technique using a DSC 6000 
(PerkinElmer, Inc; CT, USA) equipped with an intra-cooler accessory. An accurately 
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weighed sample (2mg) was sealed in an aluminum pan and analyzed against a sealed empty 
aluminum pan maintained as reference. Study was performed over a temperature range of 
30°- 300°C The heating rate was maintained at 10°C/min. 
5.2.11. Stability Studies 
Stability of FA-AQ NPs was evaluated while storing the triplicate samples at temperatures 
of 4ºC and 25ºC for 4-week period as reported previously (53). Aliquot of each sample was 
withdrawn at the end of week 1, 2, 3 and 4; diluted with water (100-fold) and analyzed for 
physicochemical characteristics such as particle size, PDI and zeta potential using Malvern 
Zeta Sizer as described earlier. Entrapment efficiency was determined by lysing the 
samples using UPLC.  
5.2.12. Determination of Targeting Capability 
5.2.12.1. Cellular Uptake Studies using Fluorescence Microscopy 
Cellular uptake studies were performed in order to determine the effect of NP loading and 
folic acid targeting on intracellular uptake of the drug encapsulated using a protocol 
reported earlier (201). NPs for cellular uptake were formulated by replacing AQ with 
coumarin-6 (1mg), a fluorescent dye since it offers simple and sensitive detection for easier 
tracking while it has been frequently used in cellular uptake studies of PLGA nanoparticles. 
In brief, A549 cells were plated in 8 chambered tissue culture (TC) treated cell imaging 
cover glass (Eppendorf, Hauppauge, NY, USA) at a seeding density of 10,000 
cells/chamber followed by overnight incubation. Next day, cells were incubated with 
coumarin-6, coumarin-6 loaded unconjugated and FA conjugated nanoparticles at 1 µg/mL 
concentration in fresh culture medium for 3 hours. After 3 hours, cells were washed with 
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ice cold PBS twice and fixed with 4% paraformaldehyde (PFA) for 10 min. Fixed cells 
were washed again with ice cold PBS twice. Then, the chamber was removed and 20µL of 
vectashield hardset mount with DAPI nuclear stain (H1500, Vector laboratories, 
Burlingame, CA, UAS) was placed on a glass slide dropwise followed by placing a cover 
glass. After hardening of mounting medium overnight at 4°C, slides were imaged using 
EVOS-FL microscope at 20X magnification (Thermo Scientific, Waltham, MA, USA).  
5.2.12.2. Quantification of Cellular Uptake by Determining Fluorescence Intensity 
A549, HeLa and MDAMB-231 cells were seeded into 24-well assay plates at 1 x 
105 cells/well. Next day, cells were incubated them with 1ml at 1μg/ml concentration of 
coumarin, coumarin-loaded NPs and folic acid conjugated coumarin nanoparticles at 5% 
CO2/37°C for 3 hours. After 3 hours, media was removed from the wells and washed three 
times with ice-cold PBS. Cells were harvested using trypsin and to the obtained cell pellets, 
100 μl of 0.5% Triton X-100 was added for cell lysis. These samples were kept for 
sonication for one hour at 4°C. The fluorescence intensity of supernatants from each 
sample was measured for coumarin quantification at Ex/Em of 420/465nm (Tecan Spark 
10M; Tecan, Männedorf, Switzerland). 
5.2.13. Cytotoxicity Studies 
AQ NP Rota, FA-AQ NPs along with plain AQ were evaluated for their cytotoxicity in 
multiple cancer cell lines: A549 (non-small cell lung cancer, NSCLC); HeLa (cervical 
cancer) and MDAMB-231 (breast cancer) as reported earlier with slight modifications 
(146,147). HeLa and MDAMB-231 cell lines were chosen because of their characteristic 
to exhibit overexpression of folic acid receptors (220). In brief, A549 cells were grown in 
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FBS supplemented RPMI-1640 media and HeLa, MDAMB-231 cells were grown in FBS 
supplemented DMEM media as described in Materials section, and were seeded in TC 
treated 96-well plates (Eppendorf, Hauppauge, NY, USA) at a seeding density of 2,500 
cells/well (7,500 cells/cm2), incubated overnight for adherence at 37°C/5% CO2, and 
treatments were added next day at different AQ concentrations ranging from 0.39-50 µM. 
Corresponding volumes of AQ NP Rota and FA-AQ NPs were calculated based on the 
drug entrapment efficiency. Blank culture media was added as control. After 72 hours of 
incubation, % cell viability was determined by performing MTT assay as described earlier 
(20), by reading the absorbance of dissolved formazan crystals at 570 nm (Tecan Spark 
10M; Tecan, Männedorf, Switzerland). Further cytotoxicity studies were performed 
following same protocol to evaluate the safety of drug-free nanoparticles (HEK) using 
equivalent amounts of Blank NP at concentrations of 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25 
and 50µM with 72 hours of incubation period. 
5.2.14. Clonogenic Assay 
Clonogenic assay is an in-vitro cell survival assay which is based on the single cell’s 
capability to grow into a colony. A colony forming assay was performed to evaluate long-
term cytotoxicity of AQ, AQ NP Rota and FA-AQ NP toward colony inhibition was 
determined. The protocol reported previously (149,201) was briefly modified and followed 
in this study. HeLa or MDAMB-231 cells were seeded in 6-well cell culture plates at 
seeding density of 500 cells/well for each cell line. After overnight incubation and 
adherence of cells, cells were subjected to AQ, AQ NP Rota and FA-AQ NP (10µM), or 
control treatments for 48 hours after which media was replaced with fresh culture medium 
on alternative days for 7 days. On 7th day, formed colonies were washed with ice-cold PBS 
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and stained with 0.01% (w/v) crystal violet followed by washing with distilled water as 
reported earlier. Colonies were photographed using digital camera and the mean number 
of colonies from three independent experiments were counted by colony counter software 
Open CFU (150).  
5.2.15. 3D Spheroid Cell Culture Studies 
An effective cancer therapy is not only determined by enhanced cellular uptake or cytotoxic 
potential, but also improved penetrability of nanoparticles into solid tumors. 3D spheroid 
cell culture studies are capable of mimicking the in-vivo features of tumors as reported in 
our previous studies (147). Briefly, 2,000 cells per well were seeded in Corning® ultralow 
attachment spheroid 96-well plate (Corning, NY, USA) and were incubated overnight at 
37°C/5% CO2. For later 3 days, spheroids were allowed to grow into solid tumor mass due 
to the shape of these ultra-low attachment cell culture plates. On day 3, all the wells were 
observed for spheroid formation with a rigid margin. Images were captured using inverted 
microscope (Laxco, Mill Creek, WA, USA). Next day, media was replaced with either 
fresh media (control) or respective treatments of AQ, AQ NP Rota or FA-AQ NP. Briefly, 
spheroids were treated with 20μM concentration of AQ, AQ NP Rota and FA-AQ NP (to 
maintain original concentrations of 10μM employed in the beginning), and images were 
captured. 100µL of media was replaced with fresh media on further days of imaging. 
Images were captured on day 1, 3, 6 and 9, 12 and 15 days following treatment. in a gentle 
manner to avoid the bubble formation and the aspiration of spheroid itself. NIH ImageJ 
software (Version 1.44) was used to measure diameter of all the spheroids and spheroid 
volumes were calculated. 
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5.2.16. Live-Dead cell assay 
Live-dead cell assay was performed on spheroids on day 15 of single dosing in therapeutic 
model according to manufacturer’s protocol. Briefly, 100µL of 2µM calcein AM/4µM 
Ethidium homodimer III (EthD-III) staining solution was added to spheroids after complete 
removal of media from the respective wells. The plate was incubated for 45 min at room 
temperature. This provides green/red fluorescent staining of viable and dead cells, 
respectively. Images were captured using (EVOS-FL, Thermo Fisher Scientific) and mean 
red fluorescence intensity/mm2 of spheroid was quantified using ImageJ software which 
signifies the presence of live cells in spheroid mass. 
Data Analysis and Statistical Evaluation 
 All data were addressed as mean ± SD or SEM, with n=3 unless otherwise mentions. Three 
trials of cytotoxicity studies were performed for each control or treatment with n=6 for 
each trial data. Unpaired student’s t-test was used to compare two groups and one-way 
ANOVA followed by Tukey’s multiple comparisons test was used to compare more than 
two groups using GraphPad Prism software (Version 7.04 for Windows, GraphPad 
Software, San Diego, California USA). A p value of<0.05 was considered statistically 
significant and was presented in data figures as a single asterisk (*). However, some studies 
have demonstrated a smaller p-value of 0.01 or less, which is included at respective places. 
5.3.Results 
5.3.1. Development of UPLC method for Determination of Amodiaquine (AQ) 
A rapid, UPLC method was developed for determination of AQ. Retention time was found 
to be 0.731 min with run time of 1.5 min. Peak was eluted with good resolution. The 
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method provided excellent linearity between 0.05 to 6 µg/mL. Further details of this 
developed method have been reported in a recent publication from our group (198). 
5.3.2. Calibration curve for Folic acid 
Calibration curve for folic acid has been plotted between absorbance and concentration of 
FA. The linear regression data for the calibration curve showed good linear relationship 
over the concentration range 15.6-250 µg/ml for FA. Standard plot was represented in 
Figure 30A. Linear regression equation was found to be 
Y=0.001039*X + 0.04648       
5.3.3. Synthesis of PLGA-PEG-FA 
Synthesized conjugate of PLGA-PEG-FA has been carried out via a set of reactions to 
activate PLGA first followed by subsequent conjugation reactions. presents more reactive 
γ-COOH group of folic acid which facilitates binding of folic acid with the folate receptor 
as reported earlier by Valencia et al (224). The chemistry presented here for the synthesis 
Figure 30. A. Calibration curve for Folic acid. B. Schematic representation of 
conjugation of PLGA polymer with Folic acid.  
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of PLGA-PEG-FA allowed for the conjugation of targeting ligand, folic acid. In brief, 
activated PLGA was conjugated with PEG moiety which is further conjugated with 
carboxyl group of FA via its amine group. Figure 30B outlines the synthesis procedure of 
PLGA-PEG-FA.  
5.3.4. Determination of Conjugation Efficiency 
Conjugate, PLGA-PEG-FA was analyzed for the amount of folic acid. Known amount of 
PLGA-PEG-FA was dissolved in DMSO and the resultant solution was analyzed for the 
absorbance at 256nm using Tecan plate reader (Tecan Spark 10M; Tecan, Männedorf, 
Switzerland). The amount of conjugated FA is calculated by comparing the measured 
absorbance value with standard curve. Amount of folic acid conjugated per 1 mg of PLGA-
PEG-FA was found to be 27.8±2.1µg. 
5.3.5. Physicochemical characterization: Particle size, PDI and Zeta potential 
Nanoparticle formulations AQ NP Rota and FA-AQ NPs were found to have average 
particle size and polydispersity index (PDI) of 197.5±1.7nm, 0.1±0.0; 203.4±8.8nm, 
0.2±0.1 respectively, suggesting uniform particle size distribution as represented in Fig 
31A. Negative zeta potential of both NPs was found to ~ -23mV. The high absolute value 
of zeta potential indicates a high electric charge on the surface of the drug-loaded NPs, 
which can cause strong repellent forces among particles to prevent aggregation of the NPs.  
5.3.6. Drug Content 
Amodiaquine was effectively encapsulated into nanoparticles, achieving % EE of 
20.8±1.6% (AQ NP Rota), 24.9.0±5.4% (FA-AQ NP) and high % DL of 1.6±0.1% (AQ 
NP Rota), 1.9±0.4% (FA-AQ NP) as shown in Figure 31A. As FA conjugated PLGA 
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polymer and plain PLGA (1:5) were used during the preparation of nanoparticles instead 
of conjugating FA onto nanoparticles, possibility for drug leaching from conjugated NPs 
during the conjugation and incubation process was circumvented. 
5.3.7. Morphological Studies 
Representative TEM images of AQ NP Rota and FA-AQ NPs were presented in Figures 
31B & 31C revealed that the nanoparticles had a spherical shape with a smooth surface. 
No aggregation of nanoparticles was observed during TEM analysis which gives an 
indication of the relatively monodispersed size distribution of nanoparticles in formulation. 
The results were found to be in agreement with PDI and zeta potential measurements, 
shown in Figure 31A.  
Figure 31. A. Characterization of non-targeted and targeted nanoparticles. B, 
C. Transmission electron microscopy (TEM) images of AQ NP Rota and FA-
AQ NPs. Magnification 20kX.  
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5.3.8. Solid state Characterization 
Powder X-ray Diffraction (PXRD): Due to its crystalline nature, AQ showed distinct 
peaks at 2θ values of 19.92 and 25.88 in XRD spectra whereas there were no AQ peaks 
present in AQ  and FA-AQ NP indicating encapsulation of drug inside the nanoparticles as 
shown in Figure  32A. Results were found to be consistent with our earlier studies of 
amodiaquine nanoparticles (198).  
Differential Scanning Calorimetry (DSC): The DSC studies were performed to 
understand melting and crystallization behavior of AQ when present in NP formulation as 
compared to plain AQ. As can be seen in Figure 32B, thermogram of AQ showed a sharp 
endothermic peak at 166.8°C due to its melting transition. The absence of a sharp peak in 
AQ NP Rota and FA-AQ NP indicated complete drug encapsulation in the nanoparticle 
formulation core and suggested a consistent result with that of XRD as discussed above. 
Results found to be consistent with our earlier studies (198). 
 
Figure 32. A, B. Solid state characterization studies: (A) XRD and (B) DSC for 
AQ, AQ NP Rota and FA-AQ NPs 
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5.3.9. Stability Studies 
Stability is a major concern while dealing with nanosized drug delivery systems due to 
emulsion instability and particle aggregation (53). As shown in Figure 33, stability 
analysis data reveal that FA-AQ NP formulation was stable at 4⁰ and 25⁰C, with no 
significant changes in particle size, zeta potential or % entrapment efficiency (Figure 33A-
C). Although there observed a reduction in zeta potential after 4 weeks of storage at 25C, 
still the formulations were found to exhibit a positive surface charge which is very crucial 
in their superior cellular internalization. Here, the positive zeta potential of the FA-AQ NP 
prevents the particles from coalescing and aggregating. There was no detrimental effect of 
temperature and storage time on entrapment efficiency either. Altogether, the formulations 
Figure 33. Influence of storage temperature and length of storage on particle size (A), 
zeta potential (B) and % entrapment efficiency (C) of FA-AQ NPs. Formulations were 
stored at 4° and 25° C over a period of 4 weeks. Data represent mean ± SD (n=3). 
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were found to retain their physicochemical properties during their storage at different 
temperatures of 4°C and 25°C over a period of 4 weeks.  
5.3.10. Determination of Targeting Capability 
5.3.10.1. Cellular Uptake Studies using Fluorescence Microscopy 
Figure 34A represents intracellular uptake of nanoparticle formulations using A549 cells 
with 3 hours of incubation. In this experiment, AQ was replaced with fluorescent coumarin 
to make it possible to visualize the uptake and accumulation. Fluorescent images taken 
following 3-hour incubation with FA conjugated coumarin loaded nanoparticles clearly 
demonstrated significant internalization compared to plain coumarin and non-targeted 
coumarin nanoparticles in A549 cells. It can also be observed that there was higher 
accumulation of the FA-C NP around the nucleus (DAPI stained), the most evident location 
for nanoparticle disruption and drug release inside the cells (163). Presence of FA on the 
FA-C NP enables interaction of nanoparticles with cell thus further resulting in efficient 
cellular internalization compared to that of C NP and plain coumarin.  
5.3.10.2. Quantification of Cellular uptake by Determining Fluorescence 
Intensity: 
The cellular uptake of FA-C NP, C NP and coumarin by A549, HeLa and MDAMB-231 
cells was measured by fluorescence microscopy and cells were able to take up the 
respective treatments at various capacities as shown in Figure 34B-D. At 3hr time point, 
FA-C NP uptake was ~7.6, 2.6: (A549), ~2.3, 1.6 (HeLa) and ~5.7, 1.8 (MDAMB-231) 
times higher compared to coumarin and C NP respectively. The fluorescence intensity of 
FA-C NP (23230.7±8927.8: A549; 37276.0±8773.1: HeLa; 42113.3±6115.8: MDAMB-
231) treated cells was significantly higher when compared with C NP (9042.6±5819.8: 
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A549; 23151.0±7241.0: HeLa; 23830.0±4587.6: MDAMB-231) and coumarin 
(2991.3±127.8: A549; 16300.0±3576.3: HeLa; 7434.0±4431.6: MDAMB-231) at 3hr time 
point (A549: Coumarin vs FA-C NP: p<0.05; HeLa: Coumarin vs FA-C NP: p<0.05; 
MDAMB-231: Coumarin vs FA-C NP: p<0.05). The quantitative results indicated 
analogous results to the fluorescence imaging shown in Fig 34A. Due to the presence of 
folic acid on the surface of nanoparticles, the uptake of the FA-C NP into cells is facilitated 
by the mutual interaction between FA and the folic acid receptors on the cell membrane, 
resulting in an elevated uptake efficiency compared with Coumarin NP and plain coumarin 
(A549) or plain coumarin (Hela, MDAMB-231). 
5.3.11. Cytotoxicity Studies 
Figure 34. In-vitro cellular uptake of coumarin-6 loaded non-targeted and FA-targeted 
nanoparticles. A. Fluorescence microscopy images in A549 at 3 hours. B, C and D. 
Quantitative representation of cellular uptake through fluorescence measurements in 
A549 (B), HeLa (C) and MDAMB-231 (D) cell lines. Coumarin-6 plain solution is used 
as control. Scale bar 100 μm.  
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Cell viability studies were performed using MTT assay to evaluate the cytotoxic potential 
of FA-conjugated and non-conjugated AQ-loaded NPs versus plain drug. From this study, 
it was revealed that AQ cytotoxicity against A459, HeLa and MDAMB-231 cell lines was 
significantly enhanced by nanoparticle encapsulation. Figure 35A-C illustrate the 
cytotoxic effects of AQ, AQ NP Rota and FA-AQ NP in A549, HeLa and MDAMB-231 
cell lines respectively. The IC50 values for plain AQ, AQ NP Rota and FA-AQ  NP were 
found to be 18.3±4.5µM, 11.5±11.8µM and 12.7±9.8µM in HeLa cell line; 17.5±6.6 µM, 
and 30.0±17.5µM and 11.5±8.3µM in MDAMB-231 cell line respectively (Figure 35E). 
The IC50 value of FA-AQ NP was lower than that of free AQ and AQ-loaded nanoparticle 
without FA-conjugation in case of MDAMB-231 cell line (AQ NP Rota vs FA-C NP: 
p<0.0001which was reported to possess overexpression of folic acid receptors compared 
to their expression in A549 cells (220). However, to evaluate the anti-cancer efficiency of 
folic acid targeted nanoparticles further in vitro studies are performed. In-vitro cytotoxicity 
Figure 35. Inhibitory effects on different cell lines A. A549, B. HeLa, C. MDAMB-
231 and D. HEK; after treatments with AQ, AQ NP Rota and FA-AQ NP. C. IC50 of 
AQ, AQ NP Rota and FA-AQ NP in HeLa and MDAMB-231. 
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studies of Blank NP and Blank FA-NP were performed on A549 cell line. Both Blank NP 
and Blank FA-NP were found be safe from % cell viability determinations after incubating 
HEK cell line for 72hours which has been represented in Figure 35D. In none of the cases 
was cell viability below 70% using blank nanoparticles equivalent to concentrations 
ranging from 0.39 to 50µM, suggesting that formulation components were not toxic by 
themselves.  
5.3.12. Clonogenic Assay 
Clonogenic assay is an in-vitro cell survival assay used to determine the colony formation 
capability of single cancer cells (164). AQ, AQ NP Rota and FA-AQ NP were evaluated 
Figure 36. A. Representative images showing distinct colonies after staining in HeLa and 
MDAMB-231 cell lines. Three different experiments were performed. B & 
C. Quantitative representation of clonogenic assay as % colony growth with AQ, AQ NP 
Rota and FA-AQ NPs treatment as compared to control in HeLa and MDAMB-231 cell 
lines respectively.  
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for their long-term efficacy using clonogenic assay in HeLa and MDAMB-231 cell lines. 
From Figure 36A, it can be illustrated that colony growth was significantly inhibited by 
FA-AQ NP compared to AQ and AQ NP Rota in HeLa and MDAMB-231 cell lines. After 
48 hour treatment period and 7 day incubation, % of colonies survived after treatment with 
10 µM AQ, AQ NP Rota and FA-AQ NP were 20.9±5.3%, 29.9±6.6% and 9.2±1.1% 
(HeLa, Figure  36B, AQ NP Rota vs FA-AQ NP: p<0.05, Control vs FA-AQ NP: p<0.05) 
considering number of colonies to be 100% in drug free treatment control wells. In case of 
MDAMB-231 cell line, % of colony growth was found to be 57.6±1.8%, 84.8±9.2% and 
43.2±9.9% with AQ, AQ NP Rota and FA-AQ NP (Figure  36C; AQ NP Rota vs FA-AQ  
NP: p<0.05, Control vs FA-AQ NP: p<0.05) The data suggest an approximately 2.3, 3.2-
fold (HeLa); 2-fold (MDAMB-231) stronger decrease in colony-forming ability with FA-
AQ NP as compared to AQ NP Rota, plain AQ;  AQ NP Rota respectively. This data may 
be considered a representative of FA-AQ NP’s efficacy in suppressing the possibility of 
metastasis or new tumor growth by reproduction inhibition; and can well be linked to 
enhanced intracellular (and intratumoral) drug accumulation with nanoparticles 
formulation.  
5.3.13. 3D Spheroid Cell Culture Studies 
As described in Methods section, 3D spheroid cell culture study was designed to better 
predict the physiological interaction of folic acid receptor targeted amodiaquine loaded 
NPs with tumors. In case of solid tumors, the monolayered cell cultures do not accurately 
mimic tumor structure, resistance to drugs and drugs’ poor penetrability due to tumor 
microenvironment (208). To bridge the gap between in-vitro and in-vivo studies, a 3D 
spheroid study was carried out according to previously published studies from our group. 
145 
 
These cultures (tumor spheroids) combine the ability to mimic the 3D structure of 
malignant tissue accurately in addition to being relevant to cancer microenvironment to 
which the tumor cells are exposed (210,211). A 3D in-vitro model was developed 
successfully by using specific Corning ultra-low attachment spheroid plates as reported by 
Vaidya et al (225) so that under favorable incubation conditions, cells grow into a spheroid 
mass.  
For this spheroid study, A549 cell line was chosen which forms spheroid masses from 
day 1 on culturing which were grown for 3 days. This study was performed using single 
dose regimen. Spheroid images were captured using inverted microscope (Laxco, Mill 
Creek, WA, USA) on respective days and were analyzed using the ImageJ software 
Version 1.44 (National Institute of Health, USA). Spheroid images (HeLa: Figure 37A, 
MDAMB-231: Figure 37B), and spheroid volume (Figures 38A & 38B) comparisons are 
represented. Control group of spheroids (blank media control) found to be growing in size 
over a period of 15 days, whereas the growth of treated spheroids was significantly 
inhibited. 
  
In this single dose study with a single treatment given on day 1, control spheroids of 
HeLa cell line were found to have volumes of 64.1 ± 2.7 mm3 on day 15 as compared to 
spheroid volumes of 51.8 ± 3.8 mm3 (AQ: 10µM); 53.3±7.0 mm3 (AQ  NP Rota: 10µM) 
and 39.3 ± 2.3 mm3 (FA-AQ  NP: 10µM). A significant reduction in spheroid volumes was 
observed in case of FA-AQ NP treated spheroids on day 15. (Control vs FA-AQ NP 
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p<0.0001, AQ vs FA-AQ NP p<0.05) (Figure 38A). While MDAMB-231 control 
spheroids of HeLa cell line were found to have volumes of 11.4 ± 0.7 mm3 on day 15 as 
compared to spheroid volumes of 14.2 ± 1.6 mm3 (AQ: 10µM); 13.0±1.3 mm3 (AQ  NP 
Rota: 10µM) and 8.8 ± 1.6 mm3 (FA-AQ  NP: 10µM). A significant reduction in spheroid 
volumes was observed in case of FA-AQ NP treated spheroids on day 15. (AQ vs FA-AQ 
NP, p<0.05) (Figure 38B). Thus, underlining a more pronounced tumor reduction 
potential of FA-AQ NP. Treatment with FA-AQ NP resulted in a significant difference in 
spheroid volumes as compared to AQ and control treated groups. Tumor growth 
suppression was continually observed until the end of the treatment. 
5.3.14. Live-Dead Cell Assay 
Determining viable and dead cells within a solid spheroid mass can be carried out by live-
dead cell assay. Developed drug-loaded nanocarriers facilitate drug’s entry into the inner 
core of the tumor while 2D tumor volume measurements may not reveal a 
Figure 37. 3D Spheroid study: A, B. Spheroid images of HeLa (A) and 
MDAMB-231 (B) cell lines after treating with control, AQ, AQ NP Rota and FA-
AQ NP. Images represent n=8 for each treatment. Scale bar is 400µM. 
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nanoformulation’s efficacy in penetrating tumor core, as the spheroid masses consist of 
dead cell core surrounded by a well-established structural periphery of live cells. 3D 
spheroids are also grown over an extended period, with intratumoral core regions being 
exposed to environmental conditions like lack of O2, and nutrients, resulting in presence of 
necrotic and quiescent cells in the core regions (165). Therefore, it is necessary to quantify 
actual dead cell portions out of a spheroid mass. Figures 38C & 38D are representing 
terminal spheroid images on day 15th after treatment and respective quantification plot of 
red fluorescence intensity respectively. While AQ NP Rota and FA-AQ NP treatments 
demonstrated reduction in tumor volume, higher red fluorescence (dead cells) was seen 
with FA-AQ NP treatment in case of HeLa spheroids as seen in Figure 38D. Red 
fluorescence intensity comparison on day 15th day of single dose (FA-AQ NP) post 
treatment period revealed presence of dead cells, 1.5, 1.3, 1.5 folds lower as compared to 
Figure 38. 3D Spheroid study: Spheroid volume comparison plots for HeLa (A) and 
MDAMB-231 (B) spheroids. Data represent mean ± SEM (n = 8). C. Live-Dead Cell 
assay: Red fluorescence Intensity demonstrated by HeLa Spheroids. D. Cell viability 
study was performed using CellTiter-Glo® Assay on HeLa Spheroids.  
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control, AQ NP Rota, FA-AQ NP (Control vs FA-AQ NP: p<0.05, AQ vs FA-AQ NP: 
p<0.05). 
5.4.Discussion 
The main aim of this study was to develop a strategy for increased delivery of amodiaquine 
to tumor cells while avoiding off-target effects through folic acid targeting. To accomplish 
this goal, folic acid decorated nanoparticles have been developed and evaluated for their 
anti-cancer efficacy in multiple cancer cell lines such as NSCLC, cervical and breast cancer 
types. As targeting specific tumor cells is relevant in the treatment of cancer therapies, it 
has become a very well-studied approach in delivering anticancer drugs which exert serious 
side effects due to their non-specific activity on non-cancerous cells. Folate receptors are 
generally overexpressed on the surface of several human cancer cells, including cervical, 
ovarian and breast cancer types. Thus, utilization of targeted drug delivery system imparts 
drug delivery systems the distinguishing feature between healthy and cancer cells. Folic 
acid presents an attractive targeting ligand for selective delivery, and thus is used for the 
surface conjugation to NPs. In the current study, highly monodisperse polymeric 
nanoparticles with high amodiaquine loading and folate decorated on the NP surface for 
site-specific targeting. The advantage of targeting folic acid receptors was exploited by the 
group of Rosenholm et al. (synthesized folate-conjugated porous hybrid silica 
nanoparticles for targeting to cancer cells) (226) and Liu et al (synthesis of folic acid 
conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core 
for targeted delivery of docetaxel) (227). Recently, Cheung et al have highlighted the 
importance of folic acid receptor targeting by summarizing the role of folic acid receptors 
with a special focus on treatment approaches (228). 
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Conjugation of the PLGA polymer with a targeting moiety have been carried out 
successfully to address the payload to specific cancer. Further, results obtained from the 
conjugation efficiency determinations have assured the presence of FA on the surface of 
nanoparticles. Physicochemical characterization of the drug loaded nanoparticles is of 
important in the field of drug delivery, as it greatly influences the uptake and cellular 
interaction of the particulate system; thus, ultimately determining the fate of the entrapped 
drug under in vitro and in vivo conditions. Lower particle size of developed targeted NPs 
(203.4±8.8nm) with high absolute zeta potential (~-20 mV) enabled higher accumulation 
in cancer cells. In addition, spherical surface with smooth morphology and narrow size 
distribution are evident by TEM analysis as represented in Figures 31B & 31C. Solid state 
characterization studies such as XRD and DSC revealed the encapsulation of AQ inside 
the nanoparticle formulations. Stability study results confirmed the capability of developed 
targeted NPs to retain their physicochemical properties even after a period of 4 weeks when 
stores under both refrigerated and room temperatures as shown in Figure 33. 
Intracellular uptake images shown in Figure 34 reveal that FA conjugated 
coumarin nanoparticles were internalized by A549 cells efficiently within 3 hours 
compared to plain coumarin solution or unconjugated nanoparticles. Figures 34B-D 
clearly indicates that FA-coumarin NP uptake was higher compared with coumarin in 
A549, HeLa and MDAMB-231 cells. 
Extensive in-vitro cell culture studies were carried out to investigate the efficacy of 
AQ NP against NSCLC. Presence of folic acid on nanoparticles associates with higher 
cellular uptake and greater cytotoxicity in cancer cells and explains the specificity of FA-
mediated binding of conjugated NPs (170). Recently, research work conducted by  
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Angelopoulou et al. has demonstrated that FA-conjugated pegylated magnetic NPs to 
deliver doxorubicin to cancer cells of solid tumors. (229). Cytotoxicity study results in the 
present study indicated differentiation in cell inhibition behavior between free amodiaquine 
and amodiaquine loaded nanoparticles either FA conjugated or not, thus emphasizing the 
key role of NPs internalization in enhancement of cytotoxic activity. As shown in Figure 
35, the cytotoxicity exhibited by folic acid conjugated amodiaquine NPs towards various 
cancer cell lines could be attributed to their targeting ability. Interestingly, targeted NPs 
exhibited a lower IC50 value than the plain drug and unconjugated NPs in case of MDAMB-
231 cell line which was reported to exhibit overexpression of folic acid receptors compared 
to A549 cells (220). Clonogenic assay study revealed that FA-AQ NPs can inhibit the 
ability of single cells more efficiently to form colonies compared to non-targeted 
nanoparticles. Hence, it ensures the effectiveness of FA-AQ NP on long term basis while 
preventing tumor recurrence. Overall, FA-AQ NP could be further evaluated for their 
establishment in cancer treatment explicitly. 
Development of 3D in-vitro models is of utmost necessity today to mimic in-vivo 
solid tumor conditions which could be achieved by using specific low attachment spheroid 
plates as reported in our previous publications (20,32). From results seen in Figures 38A 
& 9B, it can be understood that nanoparticles were able to deliver the drug to spheroids’ 
core efficiently ensuring their clinical use. Results from this spheroid study provide a 
strong evidence for capability of FA conjugated nanoparticles to deliver the drug to 
spheroid’s core efficiently and their potential in-vivo efficiency, which could be extended 
to further preclinical studies. It can be understood that through the addition of a ligand (FA) 
at the NP surface, NPs are directed against receptors (folic acid) exposed at the outer cell 
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surface, simultaneously improved uptake and distribution of NPs in the tumor mass despite 
of complicated tumor microenvironment (217). Furthermore, the potential of AQ NP Rota 
and FA-AQ NP was investigated and compared through different studies such as 
clonogenic assay and ex-vivo spheroid studies. In addition, increased red fluorescence 
intensities observed inside FA-AQ NP treated spheroid cores indicated the capability of 
targeted NPs in reaching the solid core of tumors in 3D environment as seen in Figure 38C 
& 38D. 
Taken together, results from the current study including in-vitro cell culture studies 
as well as 3D spheroid models illustrating the pronounced efficiency of amodiaquine-
loaded folic acid functionalized nanoparticles in NSCLC treatment.  
5.5.Conclusion 
In the present study, it can be concluded that folic acid conjugated nanoparticles of 
amodiaquine were successfully formulated by a scalable high-pressure homogenization 
(HPH) approach. Formulated NPs were characterized for their physicochemical properties, 
found to have favorable particle size and surface charge facilitating efficient cellular 
internalization. Developed targeted AQ loaded NPs were compared with their counterpart 
(non-targeted AQ loaded nanoparticles) in their anti-cancer efficacy against NSCLC. 
Several in-vitro cell culture studies including cytotoxicity studies and 3D spheroid studies, 
assays exhibiting colony formation inhibitory behavior where superior efficacy of folic 
acid conjugated NPs has been confirmed.  Altogether along with apoptosis inhibition 
capability of FA-AQ NPs, results are promising them as a potential treatment strategy for 




 In summary, nanotechnology-based drug repurposing of amodiaquine along with the 
feasibility towards a inhalable and targeted therapy presents a promising strategy in 
NSCLC treatment. Transferrin conjugated amodiaquine nanoparticles can be a potential 
inhalable treatment strategy for targeting NSCLC thus reducing the dose, side effects. 
While the in-vitro and ex-vivo results are promising, in-vivo studies are required to 
encompass the full spectrum of this approach’s feasibility. Moreover, folic-acid decorated 
amodiaquine-loaded nanoparticles have also demonstrated excellent anti-cancer efficacy 
in multiple cancer types suggesting further exploration of the developed systems in future 
studies. 
Future Directions: 
Repurposed, targeted nanomedicine presents a promising strategy for the treatment of non-
small cell lung cancer. Even though, the current study has demonstrated the efficacy of 
transferrin targeted nanoparticles, further exploration of anti-cancer mechanisms involved 
in their efficacy is highly encouraged. Especially, amodiaquine properties such as its ability 
to accumulate in the acidic environments and to disrupt lysosomal pH are further 
withdrawing attention of researchers by the scope available to study amodiaquine’s anti-
cancer properties. Understanding in-depth knowledge of the biological pathways involved 
in the anti-cancer efficacy of developed nanoparticles is recommended. Combination of 
drug repurposing and nanotechnology with targeting platform exhibits considerable 
therapeutic potential in treating lung cancer tumors. Altogether, we propose that our 
nanoparticles are capable for NSCLC treatment with a great potential for clinical 
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